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Abstract 
Prostate cancer preferentially metastasizes to the skeleton and abundant evidence exists 
that osteoblasts specifically support the metastatic process, including cancer stem cell niche 
formation. At early stages of bone metastasis, crosstalk of prostate cancer cells and 
osteoblasts through soluble molecules results in a decrease of cancer cell proliferation, 
accompanied by altered adhesive properties and increased expression of bone-specific genes, 
or osteomimicry.  
Osteoblasts synthesize a plethora of biologically active factors, which comprise the 
unique bone microenvironment. By means of quantitative real-time RT-PCR it was 
determined that exposure to the osteoblast secretome induced gene expression changes in 
prostate cancer cells, including the upregulation of osteomimetic genes such as BMP2, AP, 
COL1A1, OPG and RANKL. IL6 and TGFβ1 signaling pathway components also became 
upregulated at early time points. Moreover, osteoblast-released IL6 and TGFβ1 contributed to 
the upregulation of OPG mRNA in LNCaP. Thus, the earliest response of prostate cancer 
cells to osteoblast-released factors, which ultimately cause metastatic cells to assume an 
osteomimetic phenotype, involved activation of paracrine and autocrine IL6 and TGFβ 
signaling. On the other hand, a microarray analysis showed that osteoblasts exposed to the 
secretome of prostate cancer cells exhibited gene expression alterations suggestive of 
repressed proliferation, decreased matrix synthesis and inhibited immune response, which 
together indicate enhanced preosteocytic differentiation. TGFβ signaling, known to inhibit 
osteoblast maturation, was strongly suppressed, as shown by elevated expression of negative 
regulators, downregulation of pathway components and of numerous target genes. 
Transcriptional downregulation of osteoblast inhibitory molecules such as DKK1 and FST 
also occurred, with concomitant upregulation of the osteoinductive molecules ADM, STC1 
and BMP2, and of the transcription factors CBFA1 and HES1, which promote osteoblast 
differentiation. Finally, the mRNA encoding NPPB, the precursor of a molecule implicated in 
the inhibition of TGFβ effects, in bone formation and in stem cell maintenance, became 
upregulated after coculture both in osteoblasts and in prostate cancer cells. These results 
provide an insight into potential mechanisms of dysregulated bone formation in metastatic 
prostate cancer, as well as mechanisms by which osteoblasts might enhance the invasive, 
osteomimetic and stem cell-like properties of the tumor cells. In particular, the differential 
modulation of TGFβ signaling in prostate cancer cells and osteoblasts appears to merit further 
research. 
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Abbreviations: 
 
A - absorbance 
Ab - antibody 
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DMSO - dimethyl sulfoxide 
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dNTP - 2’-deoxynucleotide-5’-triphosphate 
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ECM - extracellular matrix 
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ERK - extracellular signal-regulated kinase 
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FCS - fetal calf serum 
FGF - fibroblast growth factor 
FGFR - fibroblast growth factor receptor 
Fig. - Figure 
g - gram 
·g - units of gravity (relative centrifugal force) 
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GTP - guanosine triphosphate 
h - hour 
HES - Hairy/Enhancer of split 
HRP - horseradish peroxidase 
HSC - hematopoietic stem cell 
HT - High Tris 
Ig - immunoglobulin 
IGF - insulin-like growth factor 
IL - interleukin 
IL6R - interleukin 6 receptor 
IL6 RE-BP - IL6 response element binding protein 
IRF 1/2 - interleukin-6 response factor 1/2  
                                                 
1
 In accordance with guidelines for gene nomenclature 
advocated by the HUGO Gene Nomenclature Committee 
(HGNC) [Wain et al. 2002], human gene symbols have been 
designated by upper-case letters and italicized, while protein 
symbols are represented in upper-case standard font. 
 
IVT - in vitro transcription 
JAK/STAT - Janus kinase/signal transducer and activator 
of transcription 
JNK - c-Jun N-terminal kinase 
k - kilo (103) 
l - liter 
LT - Low Tris 
m - meter 
m - milli (1/103) 
M - molar 
MAPK - mitogen-activated protein kinase 
MEM - Minimal Essential Medium 
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min. - minute 
mRNA - messenger RNA 
MTT - thiazolyl blue tetrazolium bromide 
n - nano (1/ 109) 
NEAA - non-essential amino acids 
NF-κB - nuclear factor kappa B 
NOG - noggin 
oC - degrees Celsius 
OC - osteocalcin 
OPG - osteoprotegerin 
OPN - osteopontin 
p - pico (1/1012) 
PAGE - polyacrylamide gel electrophoresis 
PBS - phosphate-buffered saline 
PCR - polymerase chain reaction 
pH - power of hydrogen 
PKC - protein kinase C 
PMSF - phenylmethylsulfonyl fluoride 
PPM1A - protein phosphatase 1A 
PSA - prostate-specific antigen 
PTHrP - parathyroid hormone-related protein 
PVDF - polivinylidene difluoride 
qRT-PCR - quantitative RT-PCR 
RANK(L) - receptor activator of nuclear factor kappa B 
(ligand) 
RNA - ribonucleic acid 
RNase - ribonuclease 
RPMI - Roswell Park Memorial Institute 
RT - reverse transcription 
s - second 
SCID - severe combined immunodeficient 
SD - standard deviation 
SDS - sodium dodecyl sulfate 
SNF1LK - sucrose nonfermented 1-like kinase 
Sp - specific protein 
STC1 - stanniocalcin 1 
Tab. - Table 
Taq - Thermus aquaticus 
TBS - Tris-buffered saline 
TEMED - N, N, N’, N’-tetramethylethylenediamine 
TESS - Transcription Element Search System 
TGFβ - transforming growth factor beta 
TGFBR - TGFβ receptor 
TRAIL - tumor necrosis factor-related apoptosis inducing 
ligand 
Tris - tris(hydroxymethyl)aminomethane 
U - units 
UDG - uracil-DNA glycosylase 
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V - volt 
v/v - volume/volume 
w/v - weight/volume 
x - times 
µ - micro (1/106) 
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1. Introduction  
 
1.1. Bone and bone remodeling 
1.1.1. Bone structure and functions 
Bone and cartilage constitute the skeletal system, which provides support and protection 
of vital internal organs, serves as the muscle attachment for locomotion and contains a reserve 
of calcium and phosphate necessary for the maintenance of serum homeostasis [Hadjidakis & 
Androulakis 2006, Datta et al. 2008]. Bone is a dynamic tissue which undergoes constant 
formation and resorption in response to changes in mechanical loading or altered serum 
calcium levels. Bone remodeling is also regulated by a wide range of secreted factors, both 
systemic and local [Sims & Gooi 2008]. 
There are two main histological types of mature bone: cortical bone, which has a dense, 
ordered structure, and trabecular bone, which is lighter, less compact and has an irregular 
structure. Although macroscopically and microscopically different, the two forms are 
identical in their chemical composition. Cortical bone, which comprises 80% of the skeleton, 
has a slow turnover rate and a high mechanical resistance, and constitutes the outer part of all 
skeletal structures. It is composed of bone matrix laid down concentrically in rings, so-called 
lamellae, around central spaces known as Haversian canals, which contain blood vessels, 
lymphatics, nerves and connective tissue. Trabecular bone, which forms the ends of long 
bones and the inner parts of flat bones, represents 20% of the skeletal mass and has a higher 
turnover rate than cortical bone. It is composed of interconnecting bars called trabeculae, 
aligned along lines of stress; the spaces contain bone marrow. Trabecular bone is ideally 
suited to withstanding compressive stress and hence is the predominant bone in vertebrae 
[Hadjidakis & Androulakis 2006, Datta et al. 2008]. 
Bone is a type of connective tissue, consisting of an extracellular matrix (largely 
mineralized) and cells. The mineralized bone matrix is made up of organic and inorganic 
components. Type I collagen constitutes 95% of the organic part, and the remaining 5% is 
composed of proteoglycans and noncollagenous proteins such as osteopontin (OPN), 
osteonectin (ON) and osteocalcin (OC). The inorganic component of bone consists of calcium 
hydroxyapatite crystals [Hadjidakis & Androulakis 2006]. 
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1.1.2. Bone cells 
Osteoblasts are located on inner bone surfaces and are cells of mesenchymal origin, 
responsible for bone formation. They secrete a characteristic mixture of extracellular matrix 
proteins called osteoid. Cells of the osteoblastic lineage also provide factors essential for the 
differentiation of osteoclasts, thus playing a central role in the regulation of skeletal 
architecture [Mackie 2003]. Furthermore, osteoblasts are a crucial element in hematopoiesis, 
constituting a niche for hematopoietic stem cells that home to the bone marrow [Wilson & 
Trumpp 2006, Zhu & Emerson 2004, Neiva et al. 2005]. 
Some osteoblasts ultimately become encased in mineralized bone matrix and turn into 
osteocytes. These cells reside in spaces called lacunae and form a network throughout bone 
tissue, communicating with each other and with surface osteoblasts through long cellular 
extensions located within so-called canaliculi in the mineralized bone matrix. Osteocytes are 
the most common cell type found in bone, comprising 90% of adult bone cells, and their half-
life has been estimated at 25 years, whereas the average lifespan of active osteoblasts is only 
about three months. Osteocytes are believed to act as mechanosensory cells and participate in 
the control of bone turnover [Franz-Odendaal et al. 2005, Datta et al. 2008, Noble 2008]. 
Osteoclasts are multinucleated cells of monocyte/macrophage lineage which carry out 
the unique function of resorbing mineralized bone matrix. They are formed by the attraction 
of hemopoietic myelomonocytic precursors to the resorption site, followed by their fusion and 
attachment of the resultant multinucleated cell to the bone surface. Osteoclasts break down 
bone by acidification and proteolysis of the bone matrix and undergo apoptosis when 
resorption has been completed [Hadjidakis & Androulakis 2006, Sims & Gooi 2008]. 
Bone development can occur through two distinct pathways: intramembranous and 
endochondral ossification. In intramembranous ossification, mesenchymal cells condense and 
directly differentiate into osteoblasts. In contrast, in endochondral ossification, mesenchymal 
cells condense and then become chondrocytes. This cartilage mold then directs the formation 
of osteoblasts, which form mature bone [Kobayashi & Kronenberg 2005].  
 
 
1.1.3. Osteoblast differentiation and function 
1.1.3.1. Stages of osteoblast differentiation and the central role of CBFA1/RUNX2 
Osteogenic differentiation is controlled by a range of hormonal and local factors 
converging onto a finite number of transcriptional regulators that ultimately determine the fate 
of cells committing to the osteogenic lineage [Karsenty & Wagner 2002]. In the course of 
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osteoblast differentiation, peak levels of expressed genes reflect a sequence characterized by 
three principal periods: proliferation, extracellular matrix maturation and mineralization [Lian 
& Stein 1995] (Fig. 1). 
Osteoprogenitors develop from bone marrow-derived multipotent mesenchymal stem 
cells that also give rise to fibroblasts, myoblasts, adipocytes and chondrocytes. They undergo 
further differentiation to preosteoblasts that still proliferate, and these cells then develop into 
osteoblasts that no longer divide, but instead lay down bone matrix. Osteoblasts can 
ultimately undergo one of three fates: they can become osteocytes upon entrapment within the 
mineralized matrix; they can evolve into inactive lining cells that protect the bone matrix from 
osteoclasts; or they can undergo apoptosis, which appears to be the fate of up to 80% of the 
cells. Some of the key proteins expressed by osteoblasts are type I collagen, alkaline 
phosphatase (AP), bone sialoprotein (BSP) and OC [Lian & Stein 1995].  
 
 
 
Fig. 1 Stages of osteoblast differentiation. [Lian et al. 2006] 
 
 
Osteoblastic differentiation is orchestrated by multiple signaling pathways converging 
on the transcription factor core binding factor 1/ runt-related transcription factor 2 
(CBFA1/RUNX2), which controls the expression of all major genes responsible for the 
osteoblast phenotype [Ducy 2000]. CBFA1 overexpression in nonosteogenic cells such as 
skin fibroblasts induced them to express genes characteristic for osteoblasts [Ducy et al. 
1997] and introduction of CBFA1 into mesenchymal stem cells stimulated differentiation 
along the osteoblast lineage [Byers & Garcia 2004], whereas its targeted disruption resulted in 
a complete arrest of osteoblast maturation and lack of bone formation [Ducy et al. 1997].  
The role of CBFA1 extends beyond development and differentiation, as this 
transcription factor also regulates the rate of bone matrix deposition by osteoblasts. Thus, 
CBFA1 is a critical gene not only for osteoblast differentiation but also for osteoblast function 
[Ducy 2000, Schroeder et al. 2005]. Significantly, CBFA1 overexpression inhibits osteoblast 
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maturation, matrix deposition and mineralization [Liu et al. 2001], indicating that CBFA1 
levels in lineage-restricted osseous cells must be tightly regulated. 
CBFA1 cooperates with numerous proteins, is posttranslationally modified, and 
associates with the nuclear matrix to integrate a variety of signals. The pathways regulating its 
activity are just beginning to be understood. CBFA1 can be phosphorylated and activated by 
the mitogen-activated protein kinase (MAPK) pathway, which is stimulated by multiple 
signals, including those initiated by mechanical loading, contact with the extracellular matrix 
and by osteogenic growth factors. Furthermore, CBFA1 activity is enhanced by interaction 
with other transcription factors, resulting in the assembly of higher-order transactivation 
complexes. In sum, CBFA1 appears to play a central role in coordinating myriad signals 
involved in osteoblast differentiation [Franceschi & Xiao 2003, Schroeder et al. 2005]. 
Two other transcription factors crucial for osteoblast differentiation are osterix, which 
acts downstream of CBFA1, and β-catenin [Kobayashi & Kronenberg 2005]. 
 
1.1.3.2. Main pathways regulating osteoblast biology 
Factors that directly regulate osteoblast differentiation and function include, among 
others, the bone morphogenetic proteins (BMPs), transforming growth factor β 1 (TGFβ1), 
fibroblast growth factors (FGFs) and WNTs. The four main signal transduction pathways 
involved in bone formation are depicted in Fig. 2. 
BMPs, which belong to the TGFβ superfamily, induce the differentiation of 
mesenchymal cells towards the osteoblastic lineage and also enhance osteoblast function. 
These molecules initiate signaling from the cell surface by interacting with two distinct 
serine/threonine kinase receptors. The binding of BMP ligands to preformed heteromeric 
receptor complexes leads to phosphorylation of the SMAD1 and SMAD5 proteins, which 
translocate to the nucleus and regulate transcription, whereas BMP-induced formation of 
heteromeric receptor complexes results in activation of the MAPK pathway. CBFA1 and 
osterix are both downstream targets of BMP signaling. The effects of BMPs can be blocked 
by extracellular antagonists such as noggin (NOG), which inhibits bone formation [Canalis et 
al.  2003, Logothetis & Lin 2005, Wan & Cao 2005]. 
TGFβ1, the prototypic member of the TGFβ superfamily, is one of the most important 
factors in the bone microenvironment, helping to maintain the balance between the dynamic 
processes of bone resorption and bone formation  [Janssens et al. 2005, Kanaan & Kanaan 
2006]. TGFβ signals through type I and type II transmembrane serine/threonine receptor 
___________________________________________________1. Introduction 
 
 13 
kinases. Ligand binding to the TGFβ receptor type II initiates phosphorylation of the TGFβ 
receptor type I, which then propagates the signal downstream via phosphorylation of receptor-
activated SMAD2/3 - the so-called canonical pathway, and via noncanonical routes such as 
the MAPK pathway [Shi & Massague 2003, Derynck & Zhang 2003]. 
 
 
 
Fig. 2 Major signal transduction pathways that regulate osteoblast function.  For details see text. 
[based on: Logothetis & Lin 2005] 
 
 
FGFs signal through a group of high-affinity transmembrane receptors (FGFRs) which 
have intrinsic tyrosine kinase activities. In osteoblasts, the interaction of FGFs like FGF2 with 
their FGFRs induces receptor dimerization and autophosphorylation, which in turn activates 
downstream kinase cascades. FGF signaling promotes bone formation by regulating 
osteoprogenitor proliferation, as well as osteoblast differentiation and survival. E.g. FGF2 
acting via protein kinase C (PKC) and via p42/44 MAPK enhances the expression and activity 
of CBFA1, stimulating the expression of osteoblast-specific genes [Marie 2003, Franceschi & 
Xiao 2003, Logothetis & Lin 2005].  
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The WNT ligands interact with WNT receptor Frizzled and a coreceptor, the low 
density lipoprotein receptor-related protein 5 or 6 (LRP5/6) to activate a signaling pathway 
that stabilizes cytoplasmic β-catenin. Stabilized β-catenin is then translocated to the nucleus 
to regulate genes that promote bone formation. WNT/β-catenin signaling represses alternative 
mesenchymal differentiation pathways and promotes osteoblast proliferation, differentiation, 
and mineralization activity [Krishnan et al. 2006, Yavropoulou & Yovos 2007, Milat & Ng 
2009]. Canonical WNT signaling promotes bone formation directly, e.g. by elevating CBFA1 
expression in osteoblasts, which contributes to their maturation [Gaur et al. 2005] and by 
preventing osteoblast apoptosis [Almeida et al. 2005], as well as indirectly by decreasing 
bone resorption, since OPG, which inhibits osteoclast formation, is a WNT target gene [Glass 
et al.  2005]. 
The soluble antagonist dickkopf 1 (DKK1), which blocks WNT signaling by binding to 
LRP5/6 receptors and promoting their internalization and degradation, is an inhibitor of 
osteoblast differentiation and bone formation [Pinzone et al. 2008]. 
Osteoblast differentiation can also be promoted by other factors, e.g. by interleukin 6 
(IL6), which stimulates maturation of committed osteoprogenitors and the expression of 
osteoblast-specific genes [Bellido et al. 1997, Erices et al. 2002, Li et al. 2008]. 
 
1.1.3.3. Bone remodeling by the basic multicellular unit 
Bone remodeling, a complex process wherein old bone is constantly replaced, occurs 
continuously at discrete sites within the skeleton. It requires interaction between different cell 
types and is regulated by a plethora of biochemical and mechanical cues. The remodeling 
cycle consists of three consecutive phases: resorption, during which osteoclasts digest old 
bone; reversal, when mononuclear cells appear on the bone surface; and formation, when 
osteoblasts lay down new bone until the resorbed bone is completely replaced. Bone 
remodeling serves to adjust bone architecture to meet changing mechanical needs. It also 
helps to repair microdamages in bone matrix, and plays an important role in maintaining 
plasma calcium homeostasis [Hadjidakis & Androulakis 2006, Sims & Gooi 2008]. 
The basic multicellular unit (BMU) responsible for coordinated bone remodeling 
consists of osteocytes, osteoclasts and osteoblasts (Fig. 3). Its activation is at least partly 
regulated by the osteocytes, which detect mechanical stress and respond to biochemical 
stimuli. The lining cells of the endosteal surface then become retracted and release matrix 
metalloproteinases, which digest the endosteal collagenous membrane. Osteoclasts become 
recruited and, after activation, resorb the underlying bone. Subsequently, osteoblasts are 
___________________________________________________1. Introduction 
 
 15 
recruited to the resorption cavity and lay down new osteoid, which eventually becomes 
calcified; this process is completed in approximately 3-6 months. The rate of bone turnover 
varies according to the type of bone, being highest in sites where trabecular bone 
predominates [Hadjidakis & Androulakis 2006, Datta et al. 2008, Sims & Gooi 2008]. 
 
 
 
 
Fig. 3 The basic multicellular unit (BMU). These temporary anatomic structures resorb bone and subsequently 
induce bone formation. In the resorption phase, multinucleated osteoclasts (OCL) resorb the calcified matrix. 
Preosteoblasts then migrate to the region and differentiate into osteoblasts (OB). In the formation phase, these 
lay down new, uncalcified bone matrix, referred to as osteoid. Subsequently, the osteoid becomes mineralized. In 
the end or resting phase of bone remodeling, osteoblasts trapped in the matrix become osteocytes (OCY); others 
die or transform into lining cells (LC) found on the bone surface and characterized by low/absent bone-forming 
activity. The number of BMUs can be modulated by mechanical loading, hormones and cytokines, marrow 
hematopoiesis and drugs, e.g. bisphosphonates. [Buijs & van der Pluijm 2009] 
 
 
1.1.3.4. The RANKL/RANK/OPG axis 
Under normal conditions, a dynamic balance is maintained within the skeleton between 
the activities of osteoblasts and osteoclasts. The processes of bone formation and resorption 
are tightly regulated, and any shift in their balance leads either to osteoporosis (loss of bone 
density) or osteosclerosis (abnormal bone thickening) [Sims & Gooi 2008]. 
Recently, a novel cytokine system responsible for the regulation of bone resorption has 
been identified and extensively characterized. This cytokine system is comprised of a ligand, 
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receptor activator of nuclear factor-κB ligand (RANKL), its specific receptor - receptor 
activator of nuclear factor-κB (RANK), and its decoy receptor osteoprotegerin (OPG). 
RANKL, RANK, and OPG constitute an axis that is capable of regulating all aspects of 
osteoclast function, including proliferation, differentiation, fusion, activation and apoptosis 
[Hofbauer & Heufelder 2001, Hofbauer et al. 2001, Boyce & Xing 2007]. 
 
 
 
 
 
Fig. 4 The network of factors that regulate bone remodeling.  Blue - factors promoting bone resorption; 
yellow - factors promoting bone formation; green - factors that influence both processes. Arrows - induction; T 
signs - repression. 
[Kozawa et al. 1997; Hofbauer et al. 1998; Franchimont et al. 2000; Lindemann et al. 2001; Thirunavukkarasu 
et al. 2001; Palmqvist et al. 2002; Canalis et al. 2003; Marie 2003; Fakhry et al. 2004; Guillen et al. 2004; 
Farhadi et al. 2005; Glass et al. 2005; Janssens et al. 2005; Logothetis & Lin 2005; Krishnan et al. 2006; 
Pinzone et al. 2008] 
 
 
RANKL is expressed by activated T cells, bone marrow stromal cells and osteoblasts. 
Alternative splicing of RANKL mRNA allows its expression as a transmembrane 
glycoprotein or a soluble ligand; soluble RANKL can also be released from its membrane-
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bound state by metalloproteinases. It binds to its receptor, RANK, which is expressed by 
osteoclast precursors and mature osteoclasts. The binding of RANKL to RANK promotes 
osteoclast maturation and activation. OPG, mainly secreted by bone marrow stromal cells and 
osteoblasts, is a soluble decoy receptor for RANKL which blocks the RANKL-RANK 
interaction and thus inhibits osteoclast differentiation and function [Hofbauer & Heufelder 
2001, Hofbauer et al. 2001].   
OPG and RANKL mediate the stimulatory or inhibitory effects of a variety of systemic 
hormones, growth factors, and cytokines on osteoclastogenesis. The so-called “convergence 
hypothesis” proposes that the activity of many resorptive and antiresorptive agents 
“converges” at the level of these two mediators, whose final ratio controls the degree of 
osteoclast differentiation, activation, and apoptosis [Hofbauer et al. 2001]. The RANKL/OPG 
ratio becomes deregulated in many conditions characterized by pathological rates of bone 
resorption, including osteoporosis and cancer metastasis to bone [Wittrant et al. 2004, Blair et 
al.  2005].  
Osteoblasts, which not only lay down new bone matrix, but also indirectly regulate bone 
resorption by expressing both RANKL and OPG, act as the “central switch” in the skeleton 
that regulates bone turnover in response to local or systemic cues [Mackie 2003]. Some of the 
local factors involved in the regulation of bone remodeling are presented in Fig. 4. 
  
 
1.1.4. Osteoblasts as the hematopoietic stem cell niche in bone 
All blood cell production comes from hematopoietic stem cells (HSCs), the great 
majority of which are contained in the bone marrow. To maintain their pluripotency, stem 
cells require a niche, or spatial structure where they are housed and can undergo self-renewal 
in the absence of differentiation. In the bone marrow, HSCs stay in close proximity to 
endosteal bone surfaces, and recent publications suggest that osteoblasts are a major, defining 
component of the HSC niche, responsible for regulating HSC proliferation and survival. The 
functions of the HSC niche depend on the expression of a broad array of adhesion molecules 
and cytokines [Wilson & Trumpp 2006, Zhu & Emerson 2004, Neiva et al. 2005, Suda et al. 
2005]. Osteoblasts and HSCs stay in direct contact through homotypic N-cadherin 
interactions, and specialized spindle-shaped N-cadherin-expressing osteoblasts located in the 
endosteum have been postulated to function as essential niche cells, helping to maintain HSC 
quiescence [Zhang et al. 2003]. Suppression of N-cadherin expression by oxidative stress 
causes HSCs to detach from the osteoblastic niche [Hosokawa et al. 2007]. OPN expressed by 
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osteoblasts also mediates HSC attachment to the niche and negatively regulates their 
proliferation, limiting the size of the stem cell pool [Nilsson et al. 2005, Stier et al. 2005]. 
Finally, osteoblasts secrete chemokine (C-X-C motif) ligand 12 (CXCL12), also known as 
stromal derived factor 1 (SDF1), a chemokine which acts as a potent chemoattractant for 
immature and mature hematopoietic cells. CXCL12 plays an important role in the homing of 
HSCs, which express its receptor CXCR4, to the bone marrow [Juarez & Bendall 2004].  
 
 
1.2. Bone metastasis of prostate cancer 
Prostate cancer is the most commonly diagnosed cancer in males and the second leading 
cause of cancer-related death among men [Jemal et al. 2008]. It frequently metastasizes to the 
skeleton, and bone metastasis is usually associated with the development of hormone-
refractory disease with poor prognosis. The skeletal lesions typically cause severe pain, as 
well as complications such as anemia, pathological fractures and spinal cord compression, and 
thus pose a significant clinical problem. Bone metastases of prostate cancer are characterized 
by increased osteoblastic activity, and accumulating evidence suggests that the crosstalk of 
prostate cancer cells and osteoblasts is an important step in the metastatic process  [Keller et 
al.  2001, Mundy 2002, Edlund et al. 2004, Logothetis & Lin 2005, Yin et al. 2005, Choueiri 
et al. 2006 and others]. 
 
 
1.2.1. The origins of prostate cancer  
The prostate is a complex tubulo-alveolar gland composed of an epithelial parenchyma 
embedded within a connective tissue matrix. The epithelial cells are organized in glands that 
branch out from the urethra and terminate in secretory acini. The main cell types present 
within normal prostatic epithelium are luminal, basal and neuroendocrine cells [Lang et al. 
2009].  
The luminal cells, which constitute the exocrine compartment of the prostate, are 
terminally differentiated and represent the major cell type in normal epithelium. They express 
high levels of the androgen receptor (AR) and are dependent on androgens for their survival. 
In contrast, basal cells are relatively undifferentiated and lack secretory activity. They rest on 
the basement membrane, express low/undetectable levels of AR and are independent of 
androgens for their survival. Significant populations of neuroendocrine cells, which are 
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terminally differentiated, post-mitotic and androgen insensitive, also reside amongst the basal 
cell compartment [Lang et al. 2009]. 
Prostate stem cells are thought to reside in the basal cell compartment. Studies have 
shown that basal cells preferentially survive androgen ablation, whereas most of the luminal 
epithelial cells are lost through apoptosis. Androgen treatment restores the secretory glandular 
structure, suggesting that the basal compartment contains stem cells which undergo 
amplification to repopulate the luminal epithelium [Kasper 2008, Lang et al. 2009]. 
Several lines of evidence suggest that prostate cancer arises as a result of mutations in 
normal prostate stem cells. Tumor-initiating cells are present within prostate tumors, in line 
with the cancer stem cell theory [Kasper 2008, Lang et al. 2009]. According to this theory, 
solid tumors originate as a result of the transformation of stem or progenitor cells. Normal 
stem cells give rise to all tissues during embryonic development and control tissue 
homeostasis in the adult. They have the ability to perpetuate themselves through self-renewal 
and to generate other, differentiated cell types [Reya et al. 2001]. Undifferentiated cells 
capable of self-renewal remain present within a heterogeneous tumor mass, and these “cancer 
stem cells” (CSCs) fuel tumor growth and initiate metastases. The CSC is defined as a cell 
within a tumor that possesses the capacity to self-renew and differentiate into the 
heterogeneous lineages of malignant cells that comprise a tumor. Current treatments target the 
bulk of differentiated cells which are not tumor-initiating, while the CSCs survive, so that 
tumors recur after therapy. In order to achieve long-term success, anti-cancer treatment needs 
to be aimed at the CSCs, which enter the cell cycle infrequently and thus are refractory to 
standard therapies [Reya et al. 2001, Clarke et al. 2006, Lobo et al.  2007].  
A CSC population possessing a significant capability for self-renewal and 
differentiation into phenotypically mixed populations has been isolated from human prostate 
tumors. These cells share surface antigens with normal prostate stem cells [Collins 2005]. The 
prostate cancer cell line PC3 also contains a subpopulation of self-renewing, tumor-initiating 
cells [Li 2008]. Cocciadiferro et al. (2009) have recently reported that both androgen-
responsive and androgen-independent prostate tumor cell lines contain a presumptive CSC 
population that can be identified using a panel of selected gene markers, while Klarmann et 
al. (2008) found that prostate cancer cell subpopulations with strongly invasive properties are 
also tumor-initiating and possess a stem cell-like genomic signature. 
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1.2.2. Androgen independence 
The AR is pivotal not only to the initiation and growth of prostate cancers, but also in 
their responses to therapy. Localized prostate cancer can be effectively treated by surgery or 
radiation. Like normal prostate tissue, most prostate cancers initially require the presence of 
androgens for growth and survival, and the majority of patients with advanced disease 
respond at first to androgen ablation therapy, aimed at blocking signaling through the AR. 
Unfortunately, aggressive androgen-independent cancers refractory to conventional hormonal 
therapies eventually develop, and subsequently widespread metastasis occurs [Devlin & 
Mudryj 2009, Lang et al. 2009]. 
Androgen independence is a state where prostate cancer cells can survive and proliferate 
even in the presence of very low androgen levels. The molecular events that drive the 
transition from an androgen-dependent to androgen-independent state remain unclear, but 
several mechanisms have been proposed, including overexpression of the AR, AR mutations 
or AR activation by non-steroid ligands such as growth factors and cytokines. It has been 
suggested that androgen ablation therapy might actually promote disease progression by 
activating normally quiescent CSCs to repopulate the tumour with androgen-independent cells 
[Devlin & Mudryj 2009, Lang et al. 2009]. 
 
 
1.2.3. The metastatic cascade 
Metastasis requires that cancer cells escape from the primary tumor, become dispersed 
through the circulation, seed at distant sites and grow. This extremely inefficient process 
involves several distinct steps: cell detachment from the tumor mass, intravasation, survival 
within the blood or lymphatic systems, extravasation and homing to a new location, where the 
microenvironment must permit the cancer cell to adhere, survive and propagate to establish a 
secondary lesion (Fig. 5) [Chambers et al. 2002]. 
Certain cancers preferentially metastasize to some organs, but rarely to others. The 
organ specificity of metastasis is determined by blood flow patterns, but also by intrinsic 
properties of the cancer cells and the target organ. In 1889, Stephen Paget proposed that 
certain tumors, compared to ‘‘seeds’’, have a special affinity for particular organs, the ‘‘soil’’, 
and the seed-soil interaction determines whether tumors survive and grow at a distant site. 
Paget’s premise still holds true today, and the modern seed-and-soil hypothesis has been 
defined by Fidler (2003) as consisting of three principles. First, cancerous tissues contain 
heterogeneous subpopulations of cells with different angiogenic, invasive, and metastatic 
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properties. Second, the metastatic process is selective for the small subpopulation of cells that 
have survived the journey to a distant site. Third, the survival and growth of those metastatic 
cells depends on their ability to interact with their new milieu [Arya et al. 2006, Chambers et 
al.  2002, Fidler 2003].  
 
 
 
 
Fig. 5 Main steps in tumor progression and metastasis. The small probability of successfully completing all 
steps of this cascade explains the low likelihood that any single cancer cell leaving a primary tumor will succeed 
in becoming the founder of a distant, macroscopic metastasis. [Buijs & van der Pluijm 2009] 
 
 
Metastases can occur many years after primary cancer treatment. Tumor dormancy 
might be due to pre-angiogenic micrometastases that subsequently acquire the ability to 
become vascularized, or to solitary cells that persist for an extended period of time without 
division in a secondary site. These cells would be resistant to current cancer therapies that 
target actively dividing cells. Treatments aimed at the specific “seed-soil” compatibility that 
results in organ-specific metastatic growth could prove especially useful [Chambers et al. 
2002]. 
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1.2.4. Bone metastasis - phenotypes and mechanisms 
Bone, particularly trabecular bone, is one of the most preferential metastatic target sites 
for malignancies such as breast, prostate and lung cancers. Skeletal metastasis frequently 
leads to pain, fractures and other complications. Crosstalk between tumor cells and bone cells, 
both through direct cell-cell contact and through soluble factors, is considered critical for the 
development and progression of bone metastases [Keller et al. 2001, Mundy 2002, Edlund et 
al. 2004, Logothetis & Lin 2005, Yin et al. 2005 and others]. 
Depending on their radiographic appearance, bone metastases can be predominantly 
osteolytic, involving bone destruction, or osteoblastic (osteoinductive, osteosclerotic), 
characterized by increased deposition of new bone. The lesion phenotype reflects the local 
interaction between tumor cells and the bone remodeling system [Virk & Lieberman 2007]. 
Prostate cancer metastases are typically osteoblastic [Logothetis & Lin 2005], whereas breast 
cancer metastases are usually osteolytic [Kozlow & Guise 2005]. More precisely, recent 
observations suggest that bone metastases represent a spectrum. At one end, osteolytic lesions 
are associated with increased bone resorption and reduced osteoblast activity, but an attempt 
at bone repair is often also present, whereas bone metastases that are predominantly 
osteoblastic also show enhanced bone resorption. Dysregulated bone resorption by osteoclasts 
is necessary for the establishment of metastases, since it releases growth factors from the bone 
matrix, fueling tumor growth [Keller et al. 2001, Chirgwin et al. 2004, Keller & Brown 2004, 
Kozlow & Guise 2005, Guise et al. 2006]. 
Tumor cells produce chemokine receptors, cell adhesion molecules and cell surface 
receptors which enable them to home to bone and attach to the endosteal surfaces [Yin et al.. 
2005]. Although tumor cells secrete proteolytic enzymes and can directly destroy bone matrix 
in vitro, the main mediators of bone destruction within a metastatic lesion are the osteoclasts 
[Kozlow & Guise 2005]. The bone matrix is a rich deposit of growth factors which become 
released into the tumor microenvironment as a result of osteolysis. These factors stimulate the 
growth of tumor cells and alter their phenotype, thus promoting a vicious cycle of metastasis 
and bone pathology. Physical factors within the bone microenvironment, including low 
oxygen levels, acidic pH, and high extracellular calcium concentrations, may also enhance 
tumor growth [Kingsley et al. 2007, Virk & Lieberman 2007].  
A simplified model of the molecular mechanisms involved in osteolytic and osteoblastic 
metastasis is presented in Figs. 6 and 7. 
Tumor-produced parathyroid hormone-related protein (PTHrP) is one of the important 
mediators of the osteolytic process occurring in metastatic breast carcinoma. TGFβ, which is 
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abundant in bone matrix and becomes released as a result of osteoclastic bone resorption, 
promotes osteolysis by stimulating PTHrP production by tumor cells. PTHrP then stimulates 
osteoclastic bone resorption by increasing osteoblast production of RANKL and decreasing 
their production of OPG (Fig. 6) [Guise 2000, Kozlow & Guise 2005]. Cancer cells can also 
secrete multiple other cytokines that stimulate osteoclastogenesis [Virk & Lieberman 2007]. 
Furthermore, there is evidence that osteolytic lesions are linked with impaired osteoblast 
differentiation and activity [Mercer et al. 2004, Hall et al. 2005, Hall et al. 2006, Bu et al. 
2008] and elevated osteoblast apoptosis [Mastro et al. 2004].  
 
 
 
 
 
Fig. 6 Pathophysiology of osteolytic bone metastasis. Release of osteolytic factors by metastatic breast cancer 
cells causes nearby osteoblasts to increase RANKL synthesis. RANKL induces osteoclast precursors to mature 
into functional osteoclasts. The latter undertake osteolysis, which causes bone demineralization and liberation of 
growth factors such as TGFβ and insulin-like growth factors (IGFs) which stimulate cancer cell proliferation and 
survival. Additionally, TGFβ released from the bone matrix stimulates production of PTHrP by the cancer cell, 
resulting in a self-sustaining positive feedback loop that has been termed the “vicious cycle” of osteolytic 
metastasis. [Buijs & van der Pluijm 2009] 
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Fig. 7 Pathophysiology of osteoblastic bone metastasis. Release of ET1 and of different BMPs and WNTs by 
metastatic prostate cancer cells causes nearby osteoblast progenitors to differentiate into osteoblasts. These 
secrete growth factors which can stimulate cancer cell growth. Therefore, a ‘vicious cycle’ is also considered to 
occur in osteoblastic metastasis. [Buijs & van der Pluijm 2009] 
 
 
On the other hand, in the case of osteoblastic metastasis, osteoblast proliferation and 
matrix deposition become increased [Yang et al. 2001, Logothetis & Lin 2005, Hall et al. 
2005, Hall et al. 2006]. Prostate cancer cells alter bone homeostasis by secreting factors such 
as BMPs, WNTs and endothelin 1 (ET1) that directly affect osteoblast function, as well as 
PSA and other proteases which influence bone formation indirectly, e.g. by releasing and 
activating growth factors present in the bone microenvironment (Tab. 1) [Logothesis & Lin 
2005, Yin et al. 2005, Rentsch et al. 2009]. The net result is increased osteoblast proliferation 
and differentiation, leading to increased deposition of abnormal, woven bone. Osteoblast-
secreted factors in turn promote tumor cell survival and growth, enforcing the cycle (Fig. 7) 
[Mundy 2002, Logothetis & Lin 2005, Yin et al.  2005, Choueiri et al. 2006]. Prostate cancer 
cells also produce factors that stimulate osteoclast activity [Keller & Brown 2004]. 
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Tab. 1 Factors produced by prostate cancer cells that induce bone formation [Logothetis & Lin 2005] 
 
Factor Target Effect on osteoblasts 
BMP2, 6 Osteoblasts Induced differentiation 
TGFβ Osteoblasts Increased proliferation 
PDGF Osteoblasts Increased proliferation 
FGF Osteoblasts Increased proliferation and differentiation 
VEGF Osteoblasts Increased proliferation 
WNT Osteoblasts Increased proliferation and differentiation 
ET1 Osteoblasts Increased proliferation and differentiation 
PSA PTHrP (cleaves) Increased proliferation 
uPA IGFBP3 (cleaves) Increased proliferation 
 
IGFBP3, IGF-binding protein 3; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.  
For other abbreviations, see Abbreviations. 
 
 
Different prostate cancer cell lines are capable of causing either osteolytic or 
osteoblastic bone metastases in immunocompromised mouse models [Nemeth et al. 1999, 
Thalmann et al. 2000, Fisher et al. 2002]. The degree of osteolytic or osteoblastic capability 
can be linked to differences in the cancer cell secretome, more specifically - to the secreted 
factors that affect the bone microenvironment. In particular, recent studies show that cancer 
cell-secreted DKK1 and NOG, which suppress bone formation by inhibiting - respectively - 
WNT and BMP signaling in osteoblasts, are crucial determinants of osteolytic metastasis 
[Hall et al. 2005, Hall et al. 2006, Schwaninger et al. 2007, Dai et al. 2008, Rentsch et al. 
2009]. 
 
 
1.2.5. Current perspectives for bone metastasis therapy. 
The number of skeletal metastatic foci is the most powerful independent prognostic 
factor of poor survival in advanced prostate cancer. Disease progression frequently occurs in 
the metastases, even though androgen ablation therapy still provides adequate control of 
disease at the primary site. The in vivo response of malignant cells to anticancer therapies is 
directly influenced by the local milieu. For example, in the case of prostate cancer cells, 
cytokines such as IL6 can transactivate the AR even in the absence of androgen, thereby 
inhibiting apoptosis. This can explain the long-term failure of androgen ablation therapy in 
prostate cancer [Bogdanos et al. 2003, Culig et al. 2002, Culig et al. 2005].  
At present, despite advances in the diagnosis and management of prostate carcinoma, 
advanced disease with skeletal metastasis remains incurable. Current therapeutic options - 
mostly palliative - include hormonal therapy, pharmacological management of bone pain, 
radiotherapy for pain and spinal cord compression, various chemotherapy regimens, and the 
___________________________________________________1. Introduction 
 
 26 
use of bisphosphonates to inhibit osteoclast activity. Various targeted therapies, e.g. aimed at 
ET1 signaling or at normalizing the RANKL/OPG axis, are being developed. The complex 
nature of tumor-bone microenvironment interactions and the presence of multiple pathways 
that lead to bone metastasis suggests that simultaneous targeting of these pathways in the 
metastatic cascade is required for effective treatment [Mundy 2002, Logothetis & Lin 2005, 
Virk & Lieberman 2007]. 
Importantly, bone cells such as osteoblasts are thought to be involved in the 
establishment, maintenance and regulation of CSC niches. A novel concept suggests that 
prostate CSCs are required to initiate bone metastases and that bone provides a niche which 
enables their long-term survival. The presence of disseminated cancer cells in the bone 
marrow of prostate cancer patients is an early event; it has been suggested that the bone 
microenvironment enables them to remain viable and quiescent (i.e. non-dividing) for long 
periods, a situation known as minimal residual disease [Pantel & Brakenhoff 2004, Buijs & 
van der Pluijm 2009]. Changes in osteoblast physiology and function may, therefore, alter 
niche characteristics which mediate the dormancy and survival of CSCs in bone. Therapies 
targeted at the dormant CSCs and/or at the niche that supports them are an important future 
possibility. 
Disseminated cancer cells within the bone marrow can remain quiescent, and thus 
invulnerable to chemotherapy, for years before a clinically evident lesion develops [Pinski et 
al. 2001, Buijs & van der Pluijm 2009]. There is evidence from in vitro models that crosstalk 
with osteoblasts induces gene expression changes in prostate cancer cells involving 
suppressed proliferation and enhanced adhesion, which favor the bone colonization process. 
Large-scale transcript profiling and quantitative RT-PCR have shown that osteoblast-released 
soluble factors cause the repression of various G1 and S phase promoting genes, accompanied 
by an elevation of cell cycle inhibitory genes. This enhanced G0-G1 checkpoint control 
diminishes tumor cell chemosensitivity. Genes encoding anchoring junction components are 
also elevated, presumably facilitating tumor cell adherence to inner bone surfaces  [Pinski et 
al. 2001, Knerr et al. 2004]. Interactions such as these, if studied in vivo, might provide 
further options for therapy aimed at the prevention of skeletal metastasis. 
 
 
1.2.6. Osteomimicry 
Koeneman et al. (1999) have formulated the hypothesis that prostate cancer cells 
metastasizing to bone must become osteomimetic, i.e. express genes characteristic for the 
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osteoblast phenotype, in order to survive and grow within the skeleton. This hypothesis is 
substantiated by autopsy findings. The ability of prostate cancer cells to mimic bone could aid 
prostate cancer bone colonization. Osteomimicry appears to be facilitated by common growth 
factor tropisms between bone stromal cells, osteoblasts and prostate cancer cells, wherein a 
number of growth factors and their receptors are involved. 
A model of prostate cancer progression and osteomimicry exists and has been 
extensively characterized. The sublines C4, C4-2, and C4-2B, which demonstrate increasing 
proliferative capability, invasiveness and capability to metastasize, were derived from the 
LNCaP prostate cancer cell line by co-culturing with human bone fibroblasts and growing in 
castrated athymic male mice [Thalmann et al. 2000]. C4-2B, derived from a bone metastasis 
of the androgen-independent and highly invasive C4-2, exhibited osteomimetic properties and 
showed the most potent ability to metastasize to bone in vivo. Unlike LNCaP cells, which are 
androgen-dependent, capable of growth in immunocompromised mice only when co-
inoculated with supporting stromal cells and do not spontaneously generate metastases, the 
C4-2B subline has a high growth potential, is androgen-independent and osteotropic, i.e. 
capable of spontaneous metastasis to bone. It has an osteoblast-like phenotype, characterized 
by the expression of specific markers such as AP, BSP, OC, OPG and RANKL. Most 
importantly, C4-2B cells produce mineralized nodules in culture. These data demonstrate a 
novel mechanism through which prostate cancer cells may directly contribute to the formation 
of osteoblastic lesions [Thalmann et al. 2000, Lin et al. 2001]. In another study, C4-2B also 
induced approximately 80% more osteoclastogenesis than the parental LNCaP line, with 
strong evidence that this effect is linked to RANKL expression by the cancer cells [Zhang et 
al. 2001]. Thus, metastatic prostate cancer cells within bone appear to usurp some of the 
functions of osteoblasts. The LNCaP progression model is thought to accurately reflect the 
stages of prostate cancer progression in vivo [Thalmann et al. 2000]. 
The mechanisms of osteomimicry remain unclear. The expression of bone-specific 
proteins by prostate cancer cells might be mediated by the same transcription factors which 
are active in osteoblasts [Koeneman et al. 1999, Lin et al. 2001]. C4-2B cells acquire 
osteoblastic properties in part through the activation of Notch and ERK signaling pathways, 
which are essential for CBFA1 DNA binding activity and OC gene expression [Zayzafoon et 
al. 2004]. Curcumin, a non-toxic tyrosine kinase inhibitor, reverses osteomimicry in C4-2B 
cells by interfering with growth factor receptor pathways [Dorai et al. 2004]. Finally, it has 
been reported that β2-microglobulin, secreted by osteoblasts and by prostate cancer cell lines, 
enhances BSP and OC expression in human prostate cancer cells by activating a cyclic AMP-
___________________________________________________1. Introduction 
 
 28 
dependent protein kinase A signaling pathway [Huang et al. 2005, Huang et al. 2006]. The 
mechanisms regulating the expression of other osteomimetic genes have yet to be elucidated.  
 
To summarize, the establishment of skeletal metastatic lesions in prostate cancer is 
fueled by a synergistic paracrine loop existing between the cancer cells and osteoblasts. 
Investigating the molecular mechanisms of their crosstalk may prove the key to effective 
therapy or prevention of prostate cancer bone metastases.  
 
 
1.3. Aims 
 
The aims of the here presented dissertation were as follows: 
• Investigating the mechanisms of the crosstalk between prostate cancer cells and 
osteoblasts, known to affect the transcriptomes of both cell types. Identifying the 
secreted proteins that contribute to this crosstalk, with a focus on osteomimicry and 
bone remodeling.   
• Identifying genes and pathways affected in osteoblasts by crosstalk with prostate cancer 
cells, creating a picture of the early-stage events ultimately leading to bone colonization 
by prostate cancer cells and dysregulated bone formation within metastatic lesions. 
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2. Materials and methods 
Frequently-used chemicals were obtained from Carl Roth GmbH, Fluka, Merck or 
Sigma-Aldrich and are not listed separately. In the case of reagents, materials and equipment 
used for multiple applications, the source is listed only once.  
 
2.1. Cell culture 
Cells that are cultured directly from a subject are known as primary cells and usually 
have a limited lifespan, whereas an established or immortalized cell line has acquired the 
ability to proliferate indefinitely. Numerous cell lines have been established by researchers. 
They can be used as an in vitro model for the living organism, since they retain the 
characteristic qualities of their ontogenetic origin.  
Cells are grown and maintained in sterile, controlled conditions. Culture conditions may 
vary widely depending on the cell type, and their variation for a particular cell type can result 
in different phenotypes being expressed. 
Cells can be grown in suspension or as adherent cultures, attached to a surface such as 
the bottom of a plastic culture flask. Most cells derived from solid tissues are adherent. 
 
Media and supplements 
RPMI 1640 + GlutaMAX (Gibco BRL) 
Dulbecco’s Minimal Essential Medium (DMEM) + 4500 mg/ml glucose + GlutaMAX (Gibco BRL) 
DMEM/F12 + GlutaMAX (Gibco BRL) 
Fetal calf serum (FCS) (Biochrom AG) 
Geneticin (50 mg/ml) (Gibco BRL) 
MEM Non-essential amino acids (NEAA), 100x (Gibco BRL) 
 
Reagents 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) 
Hydrochloric acid (HCl) 37% w/v (Prolabo) 
Sodium dodecylosulfate (SDS) (GERBU Biotechnik GmbH) 
Thiazolyl blue tetrazolium bromide (MTT) (Sigma-Aldrich) 
Trypsin 2,5% w/v (Gibco BRL)  
 
Materials 
Cell culture flasks, plastic (75 cm2) (Greiner Bio-One) 
Cell culture plates, 6-well, FalconTM (Becton Dickinson Labware) 
Cell culture plates, 6-well (Greiner Bio-One) 
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Cell culture plates, 12-well, FalconTM (Becton Dickinson Labware) 
Cell scrapers (“rubber policeman”) (Corning Incorporated) 
Cryo-tubes (Nalgene) 
ELISA strips (Greiner Bio-One) 
15 ml plastic tubes (Greiner Bio-One) 
50 ml plastic tubes (Greiner Bio-One) 
Inserts for 6-well cell culture plates, 1 µm pore size (Becton Dickinson Labware) 
 
Equipment 
Automatic pipetting help, neoAccupette 3-9905 (NeoLab Migge Laborbedarf-Vertriebs GmbH) 
Centrifuge with cooling, Megafuge 1.0 R (Heraeus); rotors #3041, #3360 
Centrifuge with cooling, Sorvall RC 5C Plus (GMI); rotor #SS-34 
Freezer (-20oC) (Liebherr) 
Freezer (-80oC) (Sanyo) 
Incubator, Steri-Cult 200 (Labotect) 
Incubator, B5060 EK/CO2 (Heraeus) 
Light microscope, Telaval 3 (Zeiss) 
Microplate reader, Multiskan MS (Labsystems) 
Neubauer chamber for counting cells (Brand) 
Laminar flow cabinet, Bio Gard Hood (Baker Company) 
Water bath, SW-20 (Julabo) 
 
 
Tab. 2 Prostate cancer cell lines used. 
 
Cell line LNCaP C4-2B4 PC3 
Description Human prostate 
adenocarcinoma  
 
Human prostate 
adenocarcinoma - 
subline of LNCaP  
Human prostate 
adenocarcinoma 
 
Morphology Epithelial Epithelial Epithelial 
Derived from Supraclavicular lymph 
node metastasis in 50-
year-old Caucasian male 
[Horoszewicz et al. 1983] 
Bone metastasis of 
androgen-independent 
LNCaP subline C4-2 
 
Bone metastasis of a grade 
IV prostatic 
adenocarcinoma from a 62-
year-old male Caucasian 
[Kaighn et al. 1979] 
Lesions produced 
in nude mice 
Mixed osteoblastic-
osteolytic 
[Nemeth et al. 1999] 
Osteoblastic 
[Thalmann et al. 2000] 
Osteolytic 
[Nemeth et al. 1999] 
Androgen 
independency 
No Yes Yes 
Metastatic potential Low High High 
Source Dr. G. Thalmann, 
University of Bern, Bern, 
Switzerland 
Dr. G. Thalmann, 
University of Bern, 
Bern, Switzerland 
Dr. H. Corban-Wilhelm, 
DKFZ, Clinical Cooperation 
Unit, Radiation Therapy 
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Tab. 3  Non-prostate cell lines used. 
 
Cell line HeLa IMR-90 hfOB 1.19 
Description Human cervical 
adenocarcinoma 
 
Lung fibroblasts Human fetal osteoblasts, 
conditionally 
immortalized by stable 
transfection with SV40 
large T antigen  
Derived from Cervical lesion in 31-
year-old black female 
Lungs of a 16-week female fetus Bone biopsies from a 
spontaneous miscarriage 
Morphology Epithelial Fibroblast Osteoblast 
Properties Malignant cells with high 
proliferative capacity 
[Gey et al. 1952] 
Standard diploid fibroblast 
strain; undergo senescence after 
a certain number of population 
doublings. 
[Nichols et al. 1977] 
Able to differentiate into 
mature osteoblasts 
expressing typical bone 
formation markers. 
[Harris et al. 1995] 
Source J. Richards; Division of 
Pathochemistry (B0100), 
DKFZ Heidelberg, 
Germany 
American Type Culture 
Collection (ATCC), CCL186 
Dr N. Schuetze and Dr T. 
Spelsberg, Endocrine 
Research, Mayo Clinic, 
Rochester, Minnesota, 
USA 
 
The cells were tested and found free of Mycoplasma spp. contamination. 
 
 
2.1.1. Cell cultivation, passaging and harvest 
As they divide, adherent cells fill the available surface and undergo growth inhibition 
upon reaching confluence. It is necessary to dislodge them, dilute the cell suspension and seed 
a smaller number out. This is known as passaging or splitting cells. During passaging, cells 
are commonly detached from the flask by the action of the endopeptidase trypsin, which 
hydrolizes the peptide bonds between lysine and arginine in protein chains. 
LNCaP, C4-2B4, PC3 and HeLa were cultured at 37oC in RPMI-1640 containing 10% 
FCS and 1% nonessential amino acids. IMR-90 were cultured at 37oC in DMEM containing 
4500 mg/ml glucose and 10% FCS, and cells between passages 10 and 20 were used. hfOB 
were cultured at 33.5°C in DMEM-F12 containing 10% FCS and 30 µg/ml geneticin, and 
cells between passages 16 and 24 were used. All cell lines were cultured in an atmosphere 
containing 95% air and 5% CO2, with 4% humidity. 
When passaging was necessary, the medium was aspirated. Cells were washed with 5 
ml PBS (128 mM NaCl; 2 mM KCl; 8 mM Na2HPO4; 2 mM KH2PO4; pH 7.2-7.4), then 
treated with 2 ml trypsin-EDTA solution (0.25% w/v trypsin; 0.5 mM EDTA; pH 7.2) and 
incubated briefly at 37oC. The trypsinized cells were resuspended in medium and a small 
number was seeded out again. 
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2.1.2. Freezing and thawing cells 
The phenotype of a cell line may change as a result of prolonged culturing in vitro. To 
maintain the original characteristics of a cell line over many years, it is necessary to 
permanently store aliquots with a low passage number frozen in liquid nitrogen. These 
aliquots can then periodically be used to replace the cells in culture. To protect the cells from 
ice crystal damage during freezing, the cryoprotectant DMSO must be added to medium. 
Before freezing, cells were trypsinized, resuspended in medium and counted. 1·106 cells 
were transferred to a cryo-tube and DMSO was added in drops to a final concentration of 
10%. Cells were initially frozen at -80oC and transferred to liquid nitrogen (-196oC) after 
several hours. 
Cells taken out from liquid nitrogen were thawed in a water bath at 37oC and seeded out 
in 15 ml fresh medium. The medium was changed after 24 h to remove traces of DMSO. 
 
 
2.1.3. In vitro metastasis model 
Cell crosstalk can be mediated either by direct physical contact via adhesion molecules 
or by released factors. An in vitro bicompartment coculture system has been characterized in 
literature as a model for paracrine interactions in the early stages of bone metastasis [Knerr et 
al. 2004, Pinski et al. 2001, Yang et al. 2001]. Prostate cancer cells and bone cells are seeded, 
respectively, in culture plates and transwell inserts with a porous membrane bottom. Inserts 
are subsequently placed into wells and the cells are cocultured in shared media (Fig. 8). This 
model limits cell crosstalk to soluble factors. Cells from inserts and wells can then be 
harvested separately and assayed for changes in transcript and protein levels. Paracrine 
interactions without direct cell-cell contact have been proved to induce significant changes in 
gene expression in both prostate cancer cells and osteoblasts [Yang et al. 2001, Pinski et al. 
2001, Knerr et al. 2004, Zayzafoon et al. 2004].  
For coculture experiments described in section 3.1, 6·105 LNCaP, C4-2B4 or PC3 cells 
were seeded in 6-well FalconTM culture plates and 6·105 hfOB cells were seeded into inserts 
possessing 1 µm porous membrane bottoms. After allowing cells to grow overnight, hfOB-
containing inserts were placed into wells lined with either LNCaP, C4-2B4 or PC3 and 
cocultured in a 1:1 mixture of respective media (6 ml/well) at 37°C for the designated times. 
Cells were harvested by scraping in PBS and pelleted by centrifugation for 4 min. at 1431·g, 
4oC. After removing the supernatant, pellets were stored frozen at -80oC until analysis. 
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For coculture experiments described in section 3.2, hfOB (6·105)  were seeded in 6-well 
FalconTM culture plates. 4·105 cells from either LNCaP, C4-2B4, PC3, HeLa or IMR-90 were 
seeded into inserts possessing 1 µm porous membrane bottoms. After allowing cells to grow 
overnight, the inserts were placed into wells lined with hfOB. Cells were cocultured in a 1:1 
mixture of respective media at 37°C for 48 h. 
 
 
 
Fig. 8 In vitro metastasis model. 
 
 
2.1.4. Preparation of conditioned medium 
Conditioned medium (CM) was prepared by culturing cells in the flask to 90% 
confluence, washing twice with 10 ml PBS, then incubating with 12 ml serum-free RPMI-
1640 + 1% nonessential amino acids (LNCaP, C4-2B4, PC3) or DMEM-F12 + 30 µg/ml 
geneticin (hfOB) at 37oC. Supernatants containing secreted proteins were collected after 24 h 
and centrifuged (5000·g, 30 min, 4oC) to pellet debris. Conditioned medium was either used 
fresh in cell culture experiments or frozen at -20oC for later analysis. 
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2.1.5. Cell treatment with conditioned medium, antibody neutralization assays and 
recombinant protein stimulation 
For experiments described in section 3.1.2, cells (LNCaP, C4-2B4 or PC3) were seeded 
in 6-well culture plates and grown to 80% confluence, then washed twice with PBS and 
switched to serum-free 1:1 RPMI 1640+DMEM-F12 (control) or 1:1 RPMI 1640 + hfOB CM 
(see above) for the designated times. For antibody neutralization experiments, 400 ng/ml of 
anti-IL6 (sc-7920), anti-TGFβ1 (sc-146) or anti-FGF2 (sc-7911) antibodies (all rabbit, 
polyclonal) were added to the medium. All antibodies were from Santa Cruz Biotechnology. 
For stimulation with recombinant proteins, 80% confluent LNCaP cells were washed 
twice with PBS and incubated in serum-free RPMI1640 for 24 h, then incubated with 10 
ng/ml human IL6 (ImmunoTools) or 10 ng/ml human TGFβ1 (Santa Cruz Biotechnology) for 
24 h. 
In the experiments described in sections 3.2.3 and 3.2.5, hfOB were seeded in 6-well 
culture plates and grown to 90% confluence, then washed twice with PBS and switched to 
serum-free 1:1 RPMI 1640+DMEM-F12 (control) or 1:1 DMEM-F12 + LNCaP CM or PC3 
CM (see above) for the designated times. 
Serum-free media, whenever mentioned, contained all other necessary supplements 
except FCS. 
 
 
2.1.6. MTT cell proliferation assay 
The reduction of tetrazolium salts is widely accepted as a reliable way to examine cell 
proliferation. The yellow tetrazolium compound MTT (3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) is reduced by metabolically active cells to crystals of insoluble 
purple formazan, which can be solubilized and quantified by spectrophotometric means. 
Absorbance at 570 nm is directly proportional to the number of viable cells. 
To investigate the influence of prostate cancer cell-relased factors on osteoblast 
proliferation, hfOB cells (2·105/well) were seeded out on 12-well plates and allowed to grow 
overnight, reaching a confluence of ca. 10%. Cells were then switched to 1:1 RPMI 1640 + 
DMEM-F12 + 5% FCS (control) or 1:1 DMEM-F12 + CM + 5% FCS and left to grow at 
33.5oC (the permissive temperature for hfOB proliferation). After 72 h, MTT solution (5 
mg/ml MTT in PBS) was added to the wells to a final working concentration of 0.45 mg/ml. 
A cell-free well with control medium and MTT served as the blank. After 3 h of further 
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incubation at 33.5oC, the newly formed formazan crystals were dissolved by adding 1 ml/well 
acidified SDS solution (20% w/v SDS, 20 mM HCl). Plates were incubated overnight at room 
temperature in the dark. Then, the contents of each well were mixed and 100 µl were 
transferred in triplicate to wells on an ELISA microplate strip. Absorbance was read at 570 
nm. 
 
 
2.2. RNA and DNA  
According to the central dogma of molecular biology, the main carrier of genetic 
information in the cell is double-stranded DNA, which is transcribed into complementary 
copies of RNA. Messenger RNA (mRNA) then in turn serves as the template for protein 
synthesis, known as translation. Gene expression is subject to many levels of regulation, both 
at the stages of transcription and translation. However, mRNA transcript levels, which can 
change dynamically in response to signaling input from many different pathways, can offer 
important clues as to the events occurring in the cell. 
RNA is sensitive to degradation by ubiquitous RNase enzymes, present e.g. in dust and 
on the skin surface. Therefore all procedures involving RNA must be performed on ice, and 
RNase contamination of the sample must be avoided by clean working conditions and 
wearing gloves. All solutions must be prepared using water treated with diethyl pyrocarbonate 
(DEPC), which inactivates RNAses. 
 
Reagents 
Biozym LE Agarose (Biozym Scientific GmbH) 
Chloroform (Sigma-Aldrich) 
DEPC (Sigma-Aldrich) 
DEPC-treated H2O (ultrapure H2O treated with 0,1% DEPC for several hours, then autoclaved) 
EDTA (Acros Organics) 
Ethidium bromide 1% w/v (Carl Roth GmbH) 
50 kB DNA ladder (New England Biolabs) 
Isopropanol (Fluka) 
Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) 
SuperScript III First-Strand Synthesis System (Invitrogen) 
Taq DNA polymerase (Invitrogen) 
TriFast (Peqlab) 
Tris(hydroxymethyl)aminomethane (Tris) (Sigma-Aldrich) 
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Materials 
MicroAmp Optical 8-Cap Strips (Applied Biosystems) 
MicroAmp Optical 96-Well Reaction Plates (Applied Biosystems) 
 
Equipment 
Agarose gel running chambers (LMS GmbH Labortechnik) 
Gradient PCR machine, Mastercycler gradient (Eppendorf) 
Microcentrifuge, Biofuge Pico (Heraeus) 
Electrophoresis power supply, model 200/2.0 (Bio-Rad) 
Electrophoresis power supply, PowerPac 300 (Bio-Rad) 
MultiImageTM Light Cabinet - camera and imaging system for gel visualisation (Alpha Innotech 
Corporation) 
Mx3000P light cycler (Stratagene) 
Spectrophotometer, LS 500 (Dr Lange) 
Thermal blocks, Thermostat 5320 (Eppendorf) 
Vacuum concentrator (Bachofer) 
Vacuum pump (KNF-Neuberger) 
Vortex mixer (NeoLab) 
 
Software 
AlphaImagerTM 4.1.0 (gel visualisation) 
Primer Designer 2.0  
MxPro 3.20 (quantitative real-time PCR) 
 
 
2.2.1. RNA isolation 
Popular methods for isolating nucleic acids are based on a common principle. First, the 
cells are lysed with a reagent such as phenol, and extraction with a solvent is performed to 
separate the mixture into an aqueous phase and a phenol-solvent phase. Nucleic acids stay in 
the aqueous phase and can be precipitated with ethanol or isopropanol. 
TriFast reagent is a variation of the single-step method reported by Chomczynski and 
Sacchi (1987) for total RNA isolation. Composed of guanidine isothiocyanate and phenol in a 
mono-phase solution, it effectively dissolves DNA, RNA, and protein. After adding 
chloroform and centrifuging, the mixture separates into 3 phases: an aqueous phase containing 
the RNA, the interphase containing DNA and an organic phase containing proteins. Each 
component can then be isolated after separating the phases.  
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Total RNA was extracted from frozen cell pellets using TriFast solution according to 
the manufacturer’s instructions. Cells were lysed for 5 min. at room temperature with 1 ml of 
TriFast reagent per pellet. 0.2 ml chloform was added to each tube, the mixture was agitated 
for 15 s, incubated for 3 min. at room temperature and centrifuged for 15 min. at 20 124·g at 
4oC, resulting in separation into a lower (phenolic) und upper, colourless (water) phase. The 
water phase was removed to a fresh tube. 0.5 ml isopropanol/tube was added and the mixture 
was agitated, then incubated for 10 min. at room temperature. After centrifugation for 10 min. 
at 20 124·g, 4oC the supernatant was removed and each pellet was washed twice with 1 ml 
70% ethanol, with 5 min. centrifugation at 20 124·g, 4oC between washes. After the second 
wash step, the supernatant was removed using a water pump. The pellets were then dried for 
1-2 min in a vacuum concentrator and dissolved in an appropriate volume of DEPC-treated 
H2O (25-60 µl, depending on pellet size). 
 
 
2.2.2. RNA quantification and quality control 
RNA quantification was performed spectrophotometrically by measuring absorbance 
(A) at 260 nm (wavelength absorbed by DNA, RNA and proteins) and 280 nm (wavelength 
absorbed by proteins alone). For the measurements, 1 µl of RNA was diluted in 100 µl water 
and diluted further if necessary.  
The RNA concentration was determined from the following formula: 
 
(A260 x 40 x dilution) / 1000 = RNA concentration [µg/ µl] 
 
A260 / A280 is an estimate of RNA purity (degree of protein contamination). It was 
ascertained that the purity quotient values for the RNA samples were always in the required 
range between 1.5 and 2.2. 
RNA quality was verified by running 1 µg RNA/well on a 1% agarose gel. Before 
loading, samples were mixed with 5x RNA loading dye (50% v/v glycerol; 1 mM EDTA pH 
8.0; 0.25% w/v bromophenol blue; 0.25% w/v xylene cyanol FF). Bands were visualised by 
staining the gel in ethidium bromide solution, then rinsing with H2O and photographing under 
UV light. Strong, distinct bands of ribosomal RNA indicate good RNA quality. 
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2.2.3. Reverse transcription 
Reverse transcription is the process of making a DNA (deoxyribonucleic acid) molecule 
from a single-stranded RNA (ribonucleic acid) template. This reaction, catalyzed by the 
enzyme reverse transcriptase, is commonly used in research for mRNA profiling. The 
classical PCR technique can be applied only to DNA strands, but, with the help of reverse 
transcriptase, RNA can be transcribed into DNA, making PCR analysis of RNA molecules 
possible. 
In a two-step RT-PCR approach, a cDNA template was synthesized using the 
SuperScript III First-Strand Synthesis System. 5 µg total RNA were combined with 1 µl 
oligo(dT)20 primer (50 µM), 1 µl dNTPs (10 mM) and DEPC-treated H2O to 10 µl. After 
incubation for 5 min. at 65oC and 1 min. on ice, 2 µl 10x RT-buffer, 2 µl DTT (100 mM), 4 µl 
MgCl2 (25 mM), 1 µl RNaseOUT (40 U/µl) and 1 µl SuperScript III reverse transcriptase 
(200 U/µl) were added, bringing the reaction volume up to 20 µl. Reverse transcription was 
carried out at 55oC for 50 min, followed by enzyme deactivation at 85oC for 5 min, after 
which the RNA strand was digested by 1 µl E. coli RNAse H  (2 U/µl ) at 37oC for 20 min. At 
the end, reactions were diluted with sterile H2O to a final volume of 50 µl. 
 
 
2.2.4. Quantitative real-time RT-PCR 
The polymerase chain reaction (PCR) is one of the best-known techniques in molecular 
biology. It is used to amplify DNA in vitro with the use of two oligonucleotide primers, each 
of them complementary to one end of the target sequence. The primers are elongated by a 
thermostable DNA polymerase in repeated cycles of DNA denaturation, primer annealing and 
polymerisation, each of these steps occurring at a different temperature. A thermostable DNA 
polymerase such as Taq is used, since it can withstand repeated exposures to the high 
temperature required for DNA denaturation. 
PCR technology is widely used for quantifying DNA because of its high sensitivity. In 
an optimized reaction, the target quantity will approximately double during each amplification 
cycle. In quantitative real-time PCR, a fluorescent reporter molecule such as the SYBR Green 
I dye, which binds to double-stranded DNA, is used to monitor the progress of the 
amplification reaction. The fluorescence intensity increases proportionally with each 
amplification cycle in response to the increased amplicon concentration. The first cycle in 
which the amplification-generated fluorescence rises above the ambient background signal is 
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called the threshold cycle, or Ct. This Ct value can be directly correlated to the initial target 
concentration in the sample.  
cDNA was quantitatively PCR-amplified on 96-well microplates by combining 10 µl 2x 
Platinum SYBR Green qPCR SuperMix-UDG, 1 µl each of appropriate sense and antisense 
primers (20 pmol/µl) and 1 µl RT sample (to minimize the pipetting error, 8 µl were taken 
after diluting the samples 1:8 with H2O) in a 20 µl reaction. Samples were assayed in 
duplicate. Thermal cycling was performed using the Mx3000P light cycler. The following 
program was used for all runs: 
 
Segment 1 
95oC   10 min. (initial denaturation) 
 
Segment 2  (30-45 cycles)  
95oC    30 sec. (denaturation) 
XoC     1 min. (annealing) 
72oC    30 sec. (elongation) 
 
Segment 3  (dissociation curve) 
95oC 1 min. (denaturation) 
XoC 30 sec. (annealing) 
95oC 30 sec. (denaturation) 
 
X = annealing temperature 
 
 
Amplification rates were measured automatically using MxPro 3.20 software. Results 
were normalized to casein kinase II, beta subunit (CK2B), a housekeeping gene [Pyerin & 
Ackermann 2003]. A dissociation curve was included in every PCR program to verify that 
each reaction yields a single product. Additionally, the specificity of all PCR reactions was 
verified by electrophoresis on 2% agarose gels. Before separation, samples were mixed with 
6x DNA loading dye (0.25% w/v bromophenol blue; 0.25% xylene cyanol FF; 30% glycerol) 
and a 50 kB DNA ladder was always separated in parallel. 
For primer sequences and cycling conditions, see Tab. 4 (pages 53-54). 
 
 
2.2.5. Primer design and optimization of annealing temperatures 
Primers were designed using Primer Designer 2.0 against mRNA sequences from the 
database Entrez Gene (for link see Materials and methods 2.3.4). Primer specificity was 
verified in each case by a Blast search against the complete human genome. With the 
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exception of FOXO3, all primers were exon-exon spanning to exclude the amplification of 
contaminating genomic DNA. 
To determine optimal cycling conditions, 1 µl cDNA was PCR-amplified in a 25 µl 
reaction, comprising 2.5 µl 10x PCR buffer (100 mM Tris-HCl pH 8.8; 50 mM KCl; 1% 
Triton X-100), 1 µl dNTP mix (10 mM), 1 µl MgCl2 (50 mM), 1 µl each sense and antisense 
primers (20 pmol/µl), 0.5 µl Taq DNA polymerase (5 U/µl) and sterile H2O.  
The following amplification program was used: 
1. 94oC 3 min. (initial denaturation) 
2. 94oC 30 s (denaturation) 
3. XoC 1 min. (annealing) 
4. 72oC 30 s (elongation) 
(steps 2-4 repeated 39 x) 
5. 72oC 3 min. (end polymerization). 
A gradient PCR cycler was used, allowing different annealing temperatures to be tested 
in parallel. Reaction products were separated on a 2% agarose gel. 
 
 
2.3. OligoDNA chip technology 
A DNA microarray consists of thousands of microscopic spots of DNA 
oligonucleotides, called probes, chemically bonded to the surface of a glass or silicon chip. 
Each probe type is located in a specific area on the array called a probe cell, containing 
millions of copies of a given probe. A cDNA or cRNA sample, known as the target, is 
hybridized to the array under high-stringency conditions. Probe-target hybridization is usually 
detected and quantified by fluorescence-based detection of fluorophore-labeled targets to 
determine the relative abundance of nucleic acid sequences in the target. Gene expression 
profiling via microarrays makes it possible to simultaneously monitor the expression of 
thousands of genes. 
In the Affymetrix oligoDNA array system (GeneChip), a biotin-labeled cRNA target is 
hybridized to chips containing 25 bp-long cDNA sequences complementary to different areas 
of mRNA transcripts. The chips are then stained with streptoavidin-phycoerythrin and 
scanned (Fig. 9). The Human Genome U133A 2.0 array contains more than 22,000 probe sets 
corresponding to 14,500 well-characterized genes. 
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Fig. 9 Flow chart of Affymetrix GeneChip array protocol. 
 
 
Reagents 
Control Oligo B2, 3 nM (Affymetrix) 
DNA ligase (Invitrogen) 
DNA polymerase I (Invitrogen) 
Enzo BioArray HighYield RNA Transcript Labeling Kit (Affymetrix)  
GeneChip Eukaryotic Hybridization Control Kit (Affymetrix) 
GeneChip Hybridization, Wash and Stain Kit (Affymetrix) 
Herring sperm DNA (Promega) 
MES (Sigma-Aldrich) 
Phenol:chloroform:isoamyl alcohol 25:24:1 (saturated with 10 mM Tris-HCl pH 8.0/1 mM EDTA) (Carl 
Roth GmbH) 
RNeasy Mini Kit (Qiagen) 
SuperScript II reverse transcriptase (Invitrogen) 
T4 DNA polymerase (Invitrogen) 
 
Materials 
Human Genome U133A Array (Affymetrix) 
Tough-SpotsTM, Label Dots (USA Scientific) 
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Equipment 
GeneChip Scanner 3000 (Affymetrix) 
Fluidics Station 450 (Affymetrix) 
Hybridization Oven 640 (Affymetrix) 
Media bottles and pre-drilled bottle caps (Affymetrix) 
Tygon Tubing, 0,04’’ inner diameter (Cole-Parmer) 
Refrigerated water bath (MGW Lauda) 
 
Software 
GeneChip Operating Software (GCOS) 1.4 
 
 
2.3.1. GeneChip array target preparation (one-cycle target labeling) 
In the Affymetrix one-cycle labeling protocol, double-stranded cDNA is synthesized 
from total RNA isolated from cells. An in vitro transcription (IVT) reaction is then performed 
to produce biotin-labeled cRNA from the cDNA. This step serves to amplify the target. The 
cRNA is fragmented before hybridization to the chip. 
Two individual biological replicate samples were assayed per coculture set. Target 
labeling, hybridization, staining and scanning of the chips was performed according to the 
manufacturer's instructions. 
 
2.3.1.1. RNA purification 
Total RNA isolated using TriFast was subjected to an additional column-based cleanup 
using silica-based columns from the RNeasy Mini Kit, according to the manufacturer’s 
instructions. Nucleic acids precipitated by ethanol bind selectively to a silica membrane and 
can be eluted with H2O. 
The sample was adjusted up to 100 µl with DEPC-treated H2O and mixed with 350 µl 
of buffer RLT. Then, 250 µl ethanol were added. After mixing, the sample was transferred to 
an RNeasy Mini Kit spin column placed in a 2 ml collection tube. After centrifuging for 15 s 
at 16 060·g in a microcentrifuge, the flow-through was discarded and the column was washed 
twice with 500 µl buffer RPE with 15 s, 16 060·g centrifugation after the first wash and 2 
min, 16 060·g after the second. The flow-through was discarded. The spin column was placed 
in a fresh collection tube and centrifuged for another 1 min at 16 060·g to completely dry the 
silica membrane. The spin column was placed again in a fresh collection tube and 30µl 
DEPC-treated H2O were added directly to the membrane. After 1 min incubation at room 
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temperature, RNA was eluted by centrifuging for 1 min at 16 060·g. The elution was repeated 
with another 30 µl DEPC-treated H2O. Samples were dried completely in a vacuum 
concentrator, then the RNA was resuspended in a smaller volume of H2O depending on the 
expected yield. The RNA yield and purity were assessed spectrophotometrically and RNA 
quality was verified by agarose gel electrophoresis as described in section 2.2.2. 
 
2.3.1.2. Synthesis and purification of double-stranded cDNA 
For first strand cDNA synthesis, 12 µg total RNA were combined with 1 µl T7-(dT)24 
primer (100 pmol/µl; described below) and DEPC-treated H2O to 11 µl. After incubation for 
10 min at 70oC and 1 min on ice, 4 µl 5x first strand cDNA buffer (250 mM Tris-HCl pH 8.3;  
375 mM KCl; 15 mM MgCl2), 2 µl DTT (100 mM), 1 µl dNTP mix (10 mM) and 2 µl 
SuperScript II reverse transcriptase (200 U/µl) were added to a final volume of 20 µl. After 
temperature adjustment (2 min, 42oC), the reaction mixture was incubated at 42oC for a 
further 1 h. 
 
T7-(dT)24 oligomer: 
5’-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3’ 
 
Second strand synthesis was performed in a reaction volume of 150 µl, containing 91 µl 
DEPC-treated H2O, 30 µl 5x second strand reaction buffer (94 mM Tris-HCl pH 7.0; 453 mM 
KCl; 23 mM MgCl2; 0.75 mM NAD+; 50 mM (NH4)2SO4), 3 µl dNTP mix (10 µM), 1 µl 
DNA ligase (10 U/µl), 4 ml DNA polymerase I (10 U/µl) and 1 ml RNase H (2 U/µl). 
Reactions were incubated at 16oC for 2 h in a cooling water bath. Afterwards, 2 µl T4 DNA 
polymerase (5U/µl) were added and, after incubation for 5 min at 16oC, 10 µl EDTA (0.5 M). 
The cDNA was purified by phenol-chloroform extraction. 162 µl (an equal volume) of 
25:24:1 phenol:chloroform:isoamyl alcohol was added to the final cDNA synthesis 
preparation, to a final volume of 324 µl. After vortexing, the mixture was centrifuged at 
16 060·g for 2 minutes at room temperature. The aqueous upper phase was transferred to a 
fresh tube. The cDNA was precipitated by adding 0.5 volumes of 7.5 M ammonium acetate 
and 2.5 volumes of absolute ethanol (stored at -20oC). After vortexing and centrifugation at 
16 060·g for 20 minutes at room temperature, the supernatant was removed and the pellet 
washed twice with 0.5 ml of 80% ethanol (stored at -20oC), with 5 min centrifugation 
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(16 060·g, room temperature) between washes. Pellets were allowed to air dry, then 
resuspended in 12 µl DEPC-treated H2O. 
 
 
2.3.1.3. In vitro transcription (IVT) and purification of biotin-labeled cRNA 
Biotin-labeled cRNA was synthesized using the Enzo BioArray HighYield RNA 
Transcript Labeling Kit according to the manufacturer’s instructions. 5 µl of cDNA solution 
were mixed with 4 µl 10x HY reaction buffer, 4 µl 10x biotin-labeled ribonucleotides, 4 µl 
10x DTT, 4 µl RNase inhibitor mix, 2 µl 20x T7 RNA polymerase and 17 µl DEPC-treated 
H2O to a final volume of 40 µl. The reactions were incubated for 5 h at 37oC with gentle 
mixing every 30-45 minutes. Labeled cRNA was stored at -20oC until purification. 
Cleanup of labeled cRNA was performed using RNeasy Mini Kit columns, as described 
in section 2.3.1.1. Ethanol precipitation was performed as described in section 2.3.1.2, but 
with overnight incubation of the cRNA-ethanol-ammonium acetate mixture at -20oC before 
centrifuging. cRNA quantity and purity were determined spectrophotometrically (see section 
2.2.2). 
The adjusted cRNA yield was calculated from the following formula: 
 
adjusted cRNA yield = RNAm - (total RNAi)(y) 
 
RNAm = amount of cRNA measured after IVT (µg) 
total RNAi = starting amount of total RNA (µg) 
y = fraction of cDNA reaction used in IVT 
 
2.3.1.4. Target fragmentation 
The fragmentation mix, with a final unadjusted concentration of cRNA between 0.5 
µg/ml and 2 µg/ml, was prepared by combining 2 µl of 5x fragmentation buffer (200 mM Tris 
acetate pH 8.1, set with glacial acetic acid; 500 mM potassium acetate; 150 mM magnesium 
acetate in DEPC-treated H2O) for every 8 ml cRNA plus H2O. The mixture was incubated at 
94oC for 35 min., then put on ice. This procedure produces a distribution of RNA fragment 
sizes from ca. 35 to 200 bases. 1 µg aliquots of unfragmented and fragmented cRNA were run 
on a 1% agarose gel to verify that fragmentation was complete. 
The undiluted, fragmented cRNA was stored at -20oC until hybridization. 
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2.3.2. Target hybridization 
The following hybridization mix was prepared for each target: 15 µg cRNA (adjusted 
concentration); 50 pM control oligonucleotide B2; 100x control cRNA cocktail (1.5 pM bioB; 
5 pM bioC; 25 pM bioD; 100 pM cre); 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated 
BSA; 2x MES hybridization buffer (final 1x concentration: 100 mM MES, 1M [Na+], 20 mM 
EDTA, 0.01% Tween-20). The final volume for the standard array format is 300 µl. 
Immediately before use, the probe array was equilibrated to room temperature, then 
filled with 1x MES hybridization buffer and incubated at 45oC for 10 min. with rotation. The 
hybridization cocktail was heated at 99oC for 5 min. in a heat block, then transferred to 45oC 
for 5 min. and spun for 5 min. at 16 060·g to remove insoluble material. The probe array 
cartridge was emptied and refilled with 250 µl of the clarified hybridization cocktail. The 
hybridization was conducted at 45oC for 16 h in a rotisserie box with 60 rpm rotation. 
 
 
2.3.3. Washing, staining and scanning the array 
The washing and staining procedure was performed according to the manufacturer’s 
instructions, using a fluidics station and reagents from the GeneChip Hybridization, Wash and 
Stain Kit. After hybridization was complete, the array was emptied, then refilled with Wash 
Buffer A. The fluidics protocol was as follows:  
Post Hyb Wash #1: 10 cycles of 2 mixes/cycle with Wash Buffer A at 25°C 
Post Hyb Wash #2: 4 cycles of 15 mixes/cycle with Wash Buffer B at 50°C 
1st stain for 10 minutes with Stain Cocktail 1 at 25°C 
Post Stain Wash: 10 cycles of 4 mixes/cycle with Wash Buffer A at 25°C 
2nd stain for 10 minutes with Stain Cocktail 2 at 25°C 
3rd stain for 10 minutes with Stain Cocktail 3 at 25°C 
Final Wash: 15 cycles of 4 mixes/cycle with Wash Buffer A at 30°C.  
After the procedure was completed, the array was filled with array holding buffer at 
25°C, inspected for air bubbles, then scanned with the GeneChip Scanner 3000. Tough-
Spots™ were applied to each of the two septa on the probe array cartridge to prevent leakage 
of fluids from the cartridge during scanning.  
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2.3.4. Data analysis 
Initial analysis of the array data was performed using the GCOS 1.4 software package. 
Scanned images of the arrays were converted to numerical data by GCOS. To normalize for 
variations in signal intensity between arrays (caused by differences in staining, washing etc.), 
global scaling was carried out to a target intensity of 500. The signals for the eukaryotic 
hybridization controls (bioB, bioC, bioD, cre) were assessed and always found to be present 
with increasing signal values, reflecting their relative concentrations. BioB, bioC and bioD 
represent genes in the biotin synthesis pathway of E. coli, while cre is the recombinase gene 
from P1 bacteriophage. They are spiked into the hybridization cocktail independent of RNA 
sample preparation, and are used to evaluate sample hybridization efficiency. The good target 
quality of the samples (RNA integrity and quality of labeling) was confirmed by the signal 
value ratio of the 3’ and 5’ probe sets of internal control genes (ACTB and GAPDH). 
After log transformation of the data, comparison analysis between the baseline (control) 
and experimental (coculture) arrays was performed in GCOS. Each transcript was assigned a 
Present or Absent call, and an Increase or Decrease call (with the corresponding Signal Log 
Ratio) in the experimental sample as compared to the baseline. The expression data was 
exported to Excel files and analyzed further in Microsoft Excel. Probe sets listed twice as 
Increase, with an average increase in signal of 2-fold or more (Signal Log Ratio ≥ 1), were 
listed as significant increases, and those with an average increase of at least 1.5-fold (Signal 
Log Ratio ≥ 0.6) as tendentious increases. Probe sets listed twice as Decrease, with an 
average decrease in signal of 2-fold or more (Signal Log Ratio ≤ -1) were listed as significant 
decreases, and those with an average decrease of at least 1.5 fold (Signal Log Ratio ≤ -0.6) as 
tendentious decreases. “Absent-Present” increases and “Present-Absent” decreases were 
considered significant, whereas “Absent-Absent” changes were excluded from the analysis. 
The genes showing expression alterations were divided into functional groups using 
information from the databanks Entrez Gene and PubMed (NCBI, 
http://www.ncbi.nlm.nih.gov/). The expression changes of selected genes were subsequently 
verified using quantitative real-time RT-PCR with multiple biological replicates. 
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2.4. Protein analysis 
An overwhelming part of the structural and enzymatic machinery of the cell is made up 
of proteins, polymers composed of amino acid building blocks joined by peptide bonds. 
Compared to the transcriptome, or mRNA levels, the proteome (intracellular proteins) and 
secretome (secreted proteins) are a more direct reflection of the events that are actually 
occurring in the cell at a given time. 
Proteins are large, labile molecules. Biological material usually contains large amounts 
of protein-degrading enzymes, or proteases, which can be present within the cell or secreted. 
To prevent protease degradation of the sample, it is necessary to work on ice and use protease 
inhibitors, such as phenylmethylsulfonyl fluoride (PMSF). 
 
Reagents 
AmershamTM LMW Calibration Kit for SDS Electrophoresis (GE Healthcare) 
AmershamTM ECL Western Blotting detection reagents, product code RPN2108 (GE Healthcare) 
Ammonium persulfate (APS) (Sigma-Aldrich) 
Bio-Rad Dc Protein Assay (Bio-Rad) 
Non-fat milk powder, blotting grade (Carl Roth GmbH) 
PMSF (Roche Diagnostics) 
Ponceau S (Sigma-Aldrich) 
RotiphoreseR Gel 30 (37.5:1 acrylamide-bisacrylamide) (Carl Roth GmbH) 
Secondary HRP-conjugated goat IgG (Dianova) 
N, N, N’, N’-tetramethylenethylenediamine (TEMED) (Sigma-Aldrich) 
 
Materials 
AmershamTM Hyperfilm ECL - high performance chemiluminescence film (GE Healthcare) 
Centriplus filter devices, membrane cutoff 10 kDa (Millipore Corporation) 
ImmobilonTM membrane, polivinylidene difluoride (PVDF) (Millipore Corporation) 
Whatman blotting paper 
 
Equipment 
Gel dryer (Drystar) 
Metal film cassette 24x30 cm (Dr. Goos Suprema) 
Mini Protean II SDS-PAGE apparatus - electrophoresis chambers, frames, glass plates, combs, spacers 
etc. (Bio-Rad) 
Sonicator, Ultrasonic Processor XL (Heat Systems) 
TransBlot SD Semi-Dry Transfer Cell (Bio-Rad) 
USB Scanner (Plustek Technology GmbH) 
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Software 
Action Manager 32 (scanner software) 
TINA 2.09 
 
 
2.4.1. Protein sample preparation: whole-cell lysates and conditioned medium 
Cells were seeded on 6-well culture plates and grown to 80% confluence, washed twice 
with PBS, then lysed in lysis buffer (50 mM Tris pH 7.5; 1 M NaCl; 5 mM EDTA pH 8.0; 1% 
v/v Triton X-100) with 1 µl/ml protease inhibitor mix (1 mM pepstatin A, 1 mM leupeptin, 
0.1 mM aprotinin in H2O) and 1µl/ml PMSF (100 mM stock in methanol) added just prior to 
use. Lysates were sonicated on ice (4x 1 s) and cleared by centrifugation (20 124·g, 10 min, 
4oC), after which the supernatant was removed to a fresh tube. Protein quantitation was 
performed using the Lowry method (see section 2.3.2). Samples were mixed with 5x SDS 
sample buffer (200 mM Tris pH 6.8; 20% v/v glycerol; 10% w/v SDS; 10 mM DTT; 0.05% 
w/v bromophenol blue) and denatured for 5 min at 95oC.  
Conditioned medium was concentrated 60x at 4oC by ultrafiltration (rotating at 3000·g, 
4oC) on Centriplus filter devices. The protein content was determined by the Lowry method 
and proteins were precipitated from the medium by 4 volumes of cold acetone at -20oC 
overnight. The precipitates were pelleted by centrifugation (20 124·g, 10 min, 4oC) and the 
supernatant removed. After drying, the pellets were resuspended in an appropriate volume of 
1x SDS sample buffer and denatured for 5 min at 95oC. 
 
 
2.4.2. Lowry protein assay 
The Lowry colorimetric assay is the most commonly referenced procedure for protein 
determination. It relies on two different reactions.  The first is the formation of a copper ion 
complex with peptide bonds under alkaline conditions (a "biuret" chromophore). The second 
is the reduction of Folin-Ciocalteu reagent (phosphotungstate and phosphomolybdate) by the 
Cu2+-treated protein. Color development is mainly dependent on the number of tyrosine and 
tryptophan residues. The resulting blue color is quantifiable with a spectrophotometer at 650-
750 nm [Lowry et al. 1951].  
The Bio-Rad DC Protein Assay utilizes an improved version of the Lowry method, 
allowing reliable protein detection in the presence of interfering substances such as detergents 
(e.g. 1% Triton X-100 present in lysis buffer). 
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To perform the assay, 5 µl of the samples were pipetted into microplate wells, with 
either lysis buffer (cell lysates) or PBS (conditioned medium) serving as the blank. First 25 µl 
of reagent A, then 200 µl of reagent B were added to each well. After 15 min, the well 
contents were mixed and absorbances were read at 690 nm. If samples contained detergent, 
reagent S was added to reagent A before the assay (20 µl reagent S per 1 ml required 
solution). Protein concentration in the samples was determined from a standard curve 
prepared with serial dilutions of bovine serum albumin in a buffer either containing 1% Triton 
X-100 or not. 
 
 
2.4.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot 
The underlying principle of electrophoresis is the migration property of charged species 
within an electric field. Polyacrylamide gels are neutral, hydrophilic, three-dimensional 
networks of long hydrocarbons crosslinked by methylene groups. Polymerisation is initiated 
by APS (source of free radicals) and catalysed by TEMED (a free radical donor and acceptor). 
The separation of molecules within the gel is determined by the relative size of the pores 
formed within the gel. The greater the acrylamide percentage, the slower the migration rate. 
 
 
Tab. 5 Composition of SDS-PAGE gels. 
 
2 Bio-Rad Mini-Gels  
Separating gel Stacking gel 
Acrylamide content 12% 15% 4.5% 
Acrylamide/bisacrylamide 
(30%/0.8%) 8 ml 10 ml 1.5 ml 
1 M Tris-HCl pH 6.8 --- --- 1.25 ml 
1 M Tris-HCl pH 8.9 8 ml 8 ml --- 
H2O 4 ml 2 ml 7 ml 
10% w/v SDS 216 µl 216 µl 100 µl 
10% w/v APS 160 µl 160 µl 100 µl 
TEMED 20 µl 20 µl 10 µl 
 
 
In denaturing SDS-PAGE, sample preparation involves heating the protein in the 
presence of SDS to fully unfold the protein and permit binding of negatively-charged SDS 
molecules throughout the length of the polypeptide. The SDS binds to proteins, via 
hydrophobic interactions, in a stoichiometry approximately proportional to the size of the 
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protein. Due to this, the charge to mass ratio of all the proteins in the mixture becomes 
constant and proteins migrate through the gel at a rate proportional to their molecular mass.  
The resolution and focus of the protein bands is increased by using discontinuous gels 
(Laemmli system). The lower pH and acrylamide concentration of the stacking gel causes 
samples to enter the separating gel as a concentrated, narrow line [Laemmli 1970].  
The popular Western blot technique allows the immunodetection of specific proteins. 
Proteins resolved on a polyacrylamide gel are transferred in an electric field to a membrane, 
to which they permanently bind. After blocking nonspecific binding sites on the membrane 
with an agent such as non-fat milk, proteins of interest can be detected using antibodies. A 
secondary antibody, directed against the first, is coupled with an enzyme such as horseradish 
peroxidase (HRP). After substrate addition, either the precipitation of a colored product or 
light emission (chemiluminescence detection) occurs in places where the antigen-antibody 
complex is present. 
Samples of lysate and conditioned medium containing 30 µg total protein were re-
denatured for 5 min at 95oC prior to loading and separated on 12% or 15% SDS-PAGE gels 
(100 V stacking, 200 V separation). The gel running buffer contained 25 mM Tris-HCl, 200 
mM glycine, 0.1% w/v SDS. A protein standard with band molecular weights of 14.4, 20.1, 
30, 43 and 67 kDa was always run in parallel to the samples.  
When protein separation was complete, the separating gel was equilibrated for ca. 20 
min. in 6-aminocaproic acid-containing buffer (25 mM Tris; 40 mM 6-aminocaproic acid; 
20% v/v isopropanol; pH 9.4) to wash out SDS. A PVDF membrane was moistened with 
isopropanol and equilibrated for ca. 20 min. in Low Tris (LT) buffer (25 mM Tris; 20% v/v 
isopropanol; pH 10.4). 
A semi-dry transfer apparatus was used. The transfer sandwich was assembled as 
follows (from the bottom): 
- 4 rectangles of blotting paper soaked in High Tris (HT) buffer (300 mM Tris; 
20% v/v isopropanol; pH 10.4) 
- 5 rectangles of blotting paper soaked in LT buffer 
- membrane 
- gel 
- 5 rectangles of blotting paper soaked in LT buffer 
- 4 rectangles of blotting paper soaked in HT buffer. 
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Electrotransfer was carried out for 60 min. at 25 V. To verify that protein transfer was 
successful, membranes were briefly stained with Ponceau S (0.2% w/v Ponceau S; 3% w/v 
trichloroacetic acid), then destained in H2O and dried. 
Prior to immunodetection, membranes were moistened with isopropanol and washed for 
2x 5 min. in Tris-buffered saline + Tween-20 (TBST) (50 mM Tris-HCl pH 7.4; 150 mM 
NaCl; 0.1% v/v Tween-20), then blocked with 5% w/v milk in TBST. Detection of IL6, 
TGFβ1 and FGF2 was performed with the same primary antibodies, diluted 1:2000 in TBST, 
that were used for neutralization experiments (see section 2.1.5). CKIIβ, the loading control, 
was detected by a rabbit polyclonal antibody diluted 1:4000 in TBST. Secondary HRP-
conjugated goat IgG was used at a 1:10 000 dilution in TBST.  
The following basic protocol was followed for all blots: 
1. Blocking - 1 h 
2. Brief rinse in TBST 
3. Primary antibody - 2 h 
4. 3 x 10 min. washes in TBST 
5. Secondary antibody - 1 h 
6. 4 x 10 min. washes in TBST 
The procedure was carried out at room temperature, on a shaker.  
Bands were visualised using enhanced chemiluminescence (AmershamTM ECL Western 
Blotting detection reagents) according to the manufacturer’s instructions. Equal amounts of 
reagent 1 and 2 (luminol and hydrogen peroxide solutions) were mixed and the membrane 
was incubated for 1 min. in the mixture, then packed in foil. The image was captured on 
photographic film in a cassette and developed. Exposure times ranged from 20 s to 30 min. 
depending on signal strength. 
After immunodetection with antibodies against IL6, TGFβ1 or FGF2, blots were 
promptly stripped for 2 h at room temperature in stripping buffer (25 mM glycine; 1% w/v 
SDS, pH 2.0 set with HCl 37%), rinsed twice for 10 min. in TBST, reblocked and reblotted 
with the antibody against CKIIβ. 
Blots were scanned and band density was quantified using TINA 2.09 software. 
In the experiment shown in section 3.2.3, Fig. 26C, to revisualise all protein bands after 
immunodetection, the membrane was stained briefly with Coomassie blue solution (50% v/v 
isopropanol; 10% v/v acetic acid; 0.1% w/v Coomassie R250) and destained with ethanol. 
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2.4.4. Silver staining of proteins 
Colloidal silver staining is a highly sensitive method for visualising proteins. To prepare 
an alkaline silver stain reagent, 21 ml 0.36% w/v NaOH and 1.6 ml 28% w/v NH3·H2O were 
mixed; then, 4 ml 20% w/v AgNO3 were added dropwise with intensive stirring. The solution 
was diluted to 100 ml with H2O (final working concentration: 0.8% AgNO3; 0.076% NaOH; 
0.45% NH3xH2O) and used within 5 min. 
After SDS-PAGE, the separating gel was fixed in 50% v/v methanol (3x 1 h), washed in 
H2O for 10 min, then stained for 15 min in 100 ml freshly prepared alkaline silver stain 
solution, washed 3x 10 min in H2O and developed in 100 ml developing solution (0.01% w/v 
citric acid; 0.038 % w/v formaldehyde in H2O) until bands appeared. The reaction was 
stopped by immersing the gel in 50% v/v methanol. 
 
 
2.4.5. Estimating the molecular weight of protein bands 
In SDS-PAGE, the migration distance of a protein depends on its molecular mass. The 
relationship between the relative mobility of a protein and the log of its molecular mass 
should be a linear function. A standard curve of log molecular mass versus relative mobility 
was plotted in Microsoft Excel on the basis of migration distances for the standard, and used 
to estimate the molecular masses of unknown proteins. Relative mobility for each band was 
determined by measuring the distance from the top of the gel to the middle of the dye front, 
measuring the distance from the top of the gel to the middle of the band, and dividing the 
second measurement by the first. 
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Tab. 4 List of primers used for quantitative RT-PCR. 
 
Gene symbol 
 
Accession number(s) of 
transcript(s) recognized* 
Gene product Annealing  
temperature 
 
Sequence Product size 
ACTB NM_001101.2 actin, beta 60oC sense: 5’-GTCATAGTCCGCCTAGAA-3’ 
antisense: 5’-CCAGCACAATGAAGATCA-3’ 
175 bp 
AP NM_031313.2 alkaline phosphatase 
 
59oC sense: 5'-AGGTAATGAGTCTTCCTTGC-3' 
antisense: 5'-GATAGCAGTCCAGAGTCCAT-3' 
179 bp 
BMP2 NM_001200.2 bone morphogenetic protein 2 59oC sense: 5'-ATGTTAGGATAAGCAGGTCT-3'  
antisense: 5'-TACAAAGGGTGTCTCTTACA-3' 
178 bp 
 
CBFA1 NM_001024630.2 
NM_001015051.2 
NM_004348.3 
core binding factor 1 
 
58oC sense: 5'-CTCACTACCACACCTACCTG-3' 
antisense: 5'-ACGAAGTGCCATAGTAGAGA-3' 
104 bp 
CDH1 NM_004360.2 cadherin 1, type 1, E-cadherin (epithelial) 55oC sense: 5’-CTTCACAGCAGAACTAACAC-3’ 
antisense: 5’-GTCACTTGGTCTTTATTCTG-3’ 
173 bp 
CDH2 NM_001792.2 cadherin 2, type 1, N-cadherin (neuronal) 
 
55oC sense: 5’-CTCAAGTGTTACCTCAAGAG-3’ 
antisense: 5’-TAGTCACTGGAGATAAAGGA-3’ 
134 bp 
CDH11 NM_001797.2 cadherin 11, type 2, OB-cadherin (osteoblast) 
 
55oC sense: 5’-ATGGCTTAGTCACATACAT-3’ 
antisense: 5’-CTCATCAGCATCTTCTACTG-3’ 
238 bp 
CK2B NM_001320.5 casein kinase II, beta subunit 61oC sense: 5’-CAAGAGACCTGCCAACCA-3’ 
antisense: 5’-GTCAAAGACTGCAGGACAGG-3’ 
153 bp 
CLCA2 NM_006536.4 chloride channel, calcium activated, family member 2 59oC sense: 5’-CCCTATCTTGGACAGCA-3’ 
antisense: 5’-TATCTCCCTGATGCCAG-3’ 
164 bp 
COL1A1 NM_000088.3 collagen type 1, alpha strand 1 59oC sense: 5’-GAACATCACCTACCACTGC-3’ 
antisense: 5’-AGTGACGCTGTAGGTGAAG-3’ 
146 bp 
COL1A2 NM_000089.3 collagen type 1, alpha strand 2 60oC sense: 5’-GTTCATAATACAAAGGTGCT-3’ 
antisense: 5’-ACGATACAACTCAATACAGG-3’ 
99 bp 
DKK1 NM_012242.2 dickkopf homolog 1 64oC sense: 5'-CACTTCTGGTCCAAGATCTG-3' 
antisense: 5'-CCTTCTCCACAGTAACAACG-3' 
116 bp 
EGFR NM_005228.3 epidermal growth factor receptor 60oC sense: 5'-GAGGACAGCATAGACGAC-3’ 
antisense: 5’-GCTGGACAGTGTTGAGAT-3’ 
196 bp 
FOXO3 NM_201559.2 
NM_001455.3 
forkhead box O3 61oC sense: 5’-CTCTTGCCACACTCCAGA-3’ 
antisense: 5’-GGTCCTCCTTCACATTTG-3’ 
165 bp 
GDF15 NM_004864.2 growth differentiation factor 15 58oC sense: 5’-CAGAGCTGGGAAGATTCG-3’ 
antisense: 5’-AACAGAGCCCGGTGAAG-3’ 
164 bp 
IL6 NM_000600.2 interleukin 6 61oC sense: 5'-TAGTGAGGAACAAGCCAGAG-3' 
antisense: 5'-GATGAGTTGTCATGTCCTGC-3' 
173 bp 
IL6R NM_000565.2 interleukin 6 receptor 66oC sense: 5’-TACCACTGCCCACATTCCTG-3’ 
antisense: 5’-GCTTGTCTTGCCTTCCTTCA-3’ 
125 bp 
                                                 
*
 In the case of alternatively spliced mRNAs, primers were designed to recognize as many isoforms as possible, without distinguishing between them. 
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Gene symbol 
 
Accession number(s) of 
transcript(s) recognized 
Gene product Annealing  
temperature 
 
Sequence Product size 
NOG NM_005450.2 noggin 66oC sense: 5’-TGTGCAAGCCGTCCAAGT-3’ 
antisense: 5’-GAGCACTTGCACTCGGAAAT-3’ 
121 bp 
NPPB NM_002521.2 natriuretic peptide precursor B 61oC sense: 5’-TTTGGGAGGAAGATGGAC-3’ 
antisense: 5’-TGTGGAATCAGAAGCAGG-3’ 
109 bp 
OC NM_199173.2 osteocalcin 63oC sense: 5'-GACTGTGACGAGTTGGCTGA-3' 
antisense: 5'-CTGGAGAGGAGCAGAACTGG-3' 
118 bp 
OPG NM_002546.3 osteoprotegerin 57oC sense: 5'-GCTGTTCCTACAAAGTTTAC-3' 
antisense: 5'-TCTACACTCTCTGCGTTTAC-3' 
85 bp 
OPN NM_001040060.1 
NM_001040058.1 
NM_000582.2 
osteopontin 58oC sense: 5'-GATGTGATTGATAGTCAGGA-3'  
antisense: 5'-AGGTGTTTATCTTCTTCCTT-3' 
119 bp 
PLAUR NM_001005377.1 
NM_001005376.1 
NM_002659.2 
plasminogen activator, urokinase receptor 61oC sense: 5’-TTACCGAGGTTGTGTGTG-3’ 
antisense: 5’-ATCCAGGCACTGTTCTTC-3’ 
176 bp 
RANKL NM_033012.2 
NM_003701.2 
receptor activator of NF-κB ligand 58oC sense: 5'-AGGAGGAAGCACCAAGTATT-3' 
antisense: 5'-TCCTCTCCAGACCGTAACTT-3' 
93 bp 
SMAD2 NM_001003652.2 
NM_005901.4 
SMAD family member 2 59oC sense: 5’-TCTTCTGGCTCAGTCTGTTA-3’ 
antisense: 5’-TGTAGAGGTCCATTCAGATG-3’ 
165 bp 
 
SMAD3 NM_005902.3 SMAD family member 3 63oC sense: 5’-CGGAGTACAGGAGACAGACT-3’ 
antisense: 5’-CTAAGACACACTGGAACAGC-3’ 
134 bp 
SMAD7 NM_005904.2 SMAD family member 7 60oC sense: 5’-CCAATGACCACGAGTTTAT-3’ 
antisense: 5’-GCTGTTGAAGATGACCTCTA-3’ 
137 bp 
SQSTM1 NM_003900.3 sequestosome 1 59oC sense: 5’-AAGAAGTGGACCCGTCTA-3’ 
antisense: 5’-GAGAGGGACTCAATCAGC-3’ 
166 bp 
SP3 NM_003111.3 
NM_001017371.3 
Sp3 transcription factor 63oC sense: 5’-CTCATCTGCGTTGGCATT-3’ 
antisense: 5’-ATGTTTGGCAAGGTGGTC-3’ 
179 bp 
STC1 NM_003155.2 stanniocalcin 1 64oC sense: 5’-CTGAAGCCATCACTGAGG-3’ 
antisense: 5’-TCATCACATTCCAGCAGG-3’ 
91 bp 
STMN1 NM_005563.3 
NM_203401.1 
NM_203399.1 
stathmin 1 63oC sense: 5’-AGAGAACCGAGAGGCACA-3’ 
antisense: 5’-CAGCAGGGTCTTTGGATT-3’ 
104 bp 
TGFB1 
 
NM_000660.3 transforming growth factor beta 1 62oC sense: 5’-CAGAAATACAGCAACAATTCCTGG-3’ 
antisense: 5’-TTGCAGTGTGTTATCCCTGCTGTC-3’ 
185 bp 
TGFBR1 NM_004612.2 transforming growth factor beta receptor 1 63oC sense:  5’-GATGCCTTCCTGTTGACTGA-3’ 
antisense: 5’-GATGCCTTCCTGTTGACTGA-3’ 
128 bp 
TGFBR2 NM_003242.5 
NM_001024847.2 
transforming growth factor beta receptor 2 63oC sense:  5’-AACGTGTTGAGAGATCGAGG-3’ 
antisense: 5’-AGATGCTCCAGCTCACTGAA-3’ 
164 bp 
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3. Results 
 
3.1. The response of prostate cancer cells to osteoblasts 
3.1.1. Osteotropic prostate cancer cell lines express elevated levels of bone-associated 
genes. 
To verify and extend already available data [Knerr et al. 2004] and gain a better 
understanding of the osteomimicry phenomenon in the wider context of the bone 
microenvironment, the expression of 7 genes associated with bone formation (BMP22, CBFA1, 
AP, COL1A1, OPN, OC, OPG) and 3 associated with bone loss (RANKL, DKK1, NOG) (Tab. 6) 
was analyzed using quantitative real-time RT-PCR (qRT-PCR) in osteoblasts and in three 
prostate cancer cell lines characterized by different degrees of bone tropism. 
 
Tab. 6 Brief descriptions of genes selected for assays (based on information from Entrez Gene and PubMed 
databases; for link see Materials and methods 2.3.4). 
 
 Gene 
symbol 
Gene product 
 
Description 
BMP2 bone morphogenetic protein 2 
 
Induces osteoblastic differentiation and bone 
formation. 
CBFA1 core binding  
factor 1 
Transcription factor crucial for osteoblastic 
differentiation. 
AP alkaline phosphatase 
 
Enzyme responsible for bone matrix 
mineralization. Expressed at early stages of 
osteoblast differentiation. 
COL1A1 collagen, type I, alpha 1 Pro-alpha chains of a fibril collagen that is 
abundant in the bone matrix. Expressed at early 
stages of osteoblast differentiation. 
OPN osteopontin Noncollagenous bone matrix protein; 
overexpressed in many  malignancies; important 
for adhesion, motility, invasion and survival of 
cancer cells. 
OC osteocalcin Noncollagenous bone matrix protein; marker of the 
terminal stage of osteoblast differentiation. 
 
Bone 
formation 
 
OPG osteoprotegerin Soluble decoy receptor for RANKL. Inhibits bone 
resorption. 
RANKL receptor activator of nuclear 
factor kappa B ligand 
Induces osteoclastic differentiation and bone 
resorption. 
 
NOG noggin 
 
Antagonist of BMP signaling; inhibits osteoblastic 
differentiation and bone formation. 
 
Bone loss 
DKK1 dickkopf homolog 1 
 
Antagonist of WNT signaling; inhibits osteoblastic 
differentiation and bone formation. 
 
 
                                                 
2
 In accordance with guidelines for gene nomenclature advocated by the HUGO Gene Nomenclature Committee 
(HGNC) [Wain et al. 2002], human gene symbols have been designated by upper-case letters and italicized, while 
protein symbols are represented in upper-case standard font. 
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Fig. 10 Steady-state mRNA expression of bone-associated genes (A) and of CK2B, a housekeeping gene (B) by 
prostate cancer cells and osteoblasts. Values in (A) are expressed as the ratio to CK2B. Error bars represent the 
mean ± SD of at least three independent determinations. * p<0,05; ** p<0,01; *** p<0,001 (vs. LNCaP) 
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Confluent human fetal osteoblasts (hfOB) cultured at 37oC, a temperature that enables this 
cell line to differentiate, but not mineralize [Harris et al. 1995], express high levels of CBFA1, 
COL1A1, OPN, OC, OPG, DKK1 and NOG, and low levels of BMP2, AP and RANKL (Fig. 
10A). 
The osteolytic PC3 cells have a high expression of DKK1 and NOG, which inhibit bone 
formation, whereas baseline expression of DKK1 and NOG in LNCaP and C4-2B4 is very low. 
However, PC3 also express very high levels of BMP2, and elevated levels of CBFA1, COL1A1, 
OPN and OPG, all associated with increased bone formation. On the other hand, the bone 
metastasis-derived C4-2B4 subline has a higher baseline expression of AP, COL1A1 and OPG, 
but also of RANKL and NOG than its parental line LNCaP. All three prostate cancer cell lines 
express OC (Fig. 10A). 
In sum, the two bone metastasis-derived, osteotropic lines, C4-2B4 and PC3, both express 
significantly higher levels of COL1A1, OPG, RANKL and NOG than the lymph node-derived, 
less aggressive LNCaP. Additionally, C4-2B4 show a higher expression of AP than either 
LNCaP or PC3 (Fig. 10A). 
It was confirmed that CK2B, the housekeeping gene [Pyerin & Ackermann 2003] that was 
used as a basis for comparing levels of all other mRNAs, is expressed at equal levels in all the 
investigated cell lines (Fig. 10B). 
 
 
3.1.2. Osteoblast-released factors induce osteomimicry in prostate cancer cells. 
The expression of bone-associated genes became modulated in prostate cancer cells after 
exposure to osteoblast-released factors. The cells were either cocultured with osteoblasts in a 
model that enables cell crosstalk via soluble molecules, or treated with conditioned medium, CM 
(thus with no dynamic cell crosstalk contributing to the results). 
LNCaP, which had a low baseline expression of 9 out of 10 tested genes (Fig. 10A), 
showed the most dramatic gene expression changes in response to osteoblast-released factors. 
Coculture with osteoblasts for 24 or 48 h caused strong upregulation of BMP2, AP, OPN, OPG, 
RANKL, DKK1 and NOG, and slight upregulation of COL1A1. Treatment with hfOB CM 
produced similar effects (Tab. 7). Time-course curves performed for BMP2, OPG and RANKL 
showed that significant gene expression changes were already established at early time points: 
after 16 h of coculture in the case of OPG and RANKL, and after 24 h in the case of BMP2 (Fig. 
11). 
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Tab. 7 Changes in bone-associated gene expression induced in prostate cancer cells by osteoblast-released 
factors.  RNA was isolated, reverse transcribed and qRT-PCR was performed on cDNA from prostate cancer cell 
lines cocultured with hfOB or cultured in the presence of hfOB CM diluted 1:1 with fresh medium. Alterations with 
a t-test p value < 0,05 were considered significant. , fold change ≥ 2; , fold change ≥ 1,45; , fold change ≤ 
0,69 (-1,45); , fold change ≤ 0,5 (-2); nc, no change). [X]hfOB, hfOB-cocultured prostate cancer cells; hfOB CM 
- osteoblast-conditioned medium. 
 
 
 
Gene 
symbol 
LNCaPhfOB 24 h LNCaPhfOB 48 h LNCaP  
+ hfOB CM 48 h 
BMP2    
CBFA1 nc nc  
AP    
COL1A1   nc 
OPN nc   
OC nc nc nc 
OPG    
RANKL    
DKK1    
NOG    
 
Gene 
symbol 
C4-2B4hfOB 24 h C4-2B4hfOB 48 h C4-2B4  
+ hfOB CM 48 h 
BMP2    
CBFA1 nc nc  
AP nc   
COL1A1 nc nc nc 
OPN nc   
OC nc  nc 
OPG    
RANKL nc   
DKK1   nc 
NOG nc   
 
Gene 
symbol 
PC3hfOB 24 h PC3hfOB 48 h PC3  
+ hfOB CM 48 h 
BMP2   nc 
CBFA1 nc  nc 
AP nc  nc 
COL1A1  nc nc 
OPN nc nc  
OC nc nc nc 
OPG   nc 
RANKL nc   
DKK1 nc  nc 
NOG   nc 
 
 
 
In C4-2B4, coculture with osteoblasts consistently induced strong upregulation of BMP2, 
OPN, OPG, RANKL, DKK and NOG, and slight upregulation of AP and OC. COL1A1 levels 
remained unaltered. After treatment with hfOB CM, only OPN and RANKL became strongly 
upregulated, while BMP2, CBFA1, AP, OPG and NOG showed tendential upregulation (Tab. 7). 
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In PC3, only RANKL consistently became upregulated both after coculture and after 
treatment with hfOB CM. Upregulation of BMP2, CBFA1, AP and NOG and downregulation of 
OPG and DKK1 occurred after coculture, but not after treatment with hfOB CM (Tab. 7). 
In sum, osteoblast-released factors induced the upregulation of a number of bone-
associated genes in prostate cancer cells. Significantly, LNCaP and C4-2B4 began to express 
higher levels of BMP2, OPG, DKK1 and NOG, which all show high baseline expression in PC3. 
BMP2 and RANKL became strongly upregulated in all three prostate cancer cell lines. 
Additionally, LNCaP began to overexpress COL1A1, constitutively highly expressed by C4-2B4 
and PC3, and AP, constitutively highly expressed by C4-2B4. Thus, osteoblast-released factors 
apparently lead prostate cancer cells to assume an osteomimetic phenotype, which has become 
permanently enforced in cell lines derived from bone metastases. Significantly, expression of 
genes characteristic of osteomimicry is not restricted to osteoblastic prostate cancer cell lines. 
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Fig. 11 Time-course curves of BMP2, OPG and RANKL mRNA in LNCaP cocultured with osteoblasts or 
treated with osteoblast-conditioned medium. For details see legend to Tab. 7. Error bars represent the mean ± SD 
of at least three independent experiments. [X]hfOB, hfOB-cocultured prostate cancer cells; hfOB CM - osteoblast-
conditioned medium. * p < 0,05; ** p < 0,01 
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Fig. 12 Production of putative osteomimetic factors by cancer cells and osteoblasts.  
(A) Factor presence in whole-cell lysates and in conditioned medium. The cells were grown to 80% confluence 
in medium containing 10% FCS, then switched to serum-free medium for 24 h, after which CM was collected and 
the cells lysed in lysis buffer. CM was concentrated 60x by ultrafiltration on centrifuge filter devices and subjected 
to protein precipitation by acetone at -20oC. The precipitates and lysate samples containing 30 µg total protein were 
mixed with SDS-PAGE sample buffer. SDS-PAGE was performed, followed by electrotransfer to a PVDF 
membrane and immunodetection using chemiluminescence. Cells: 1, hfOB; 2, LNCaP; 3, C4-2B4; 4, PC3.  
(B) Comparison of factor levels in hfOB and LNCaP. Cell lysates were prepared from monocultured hfOB, 
LNCaP and LNCaP cocultured with hfOB. Protein separation, transfer and immunodetection were performed as 
described above. Blots were scanned and densitometric quantification of bands was carried out. Results were 
normalized to CKIIβ. LNCaP(hfOB), hfOB-cocultured LNCaP. 
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3.1.3. Osteoblast-released IL6 and TGFβ1 participate in the induction of 
osteomimicry in prostate cancer cells. 
Some of the genes affected by the cell crosstalk are known targets of interleukin 6 (IL6) 
[Palmqvist et al. 2002, Li et al. 2008] and transforming growth factor beta 1 (TGFβ1) [Noda et 
al. 1988, Thirunavukkarasu et al. 2001, Wrana et al. 2001], which belong to the rich cocktail of 
bioactive molecules present in bone. IL6 [Bellido et al. 1997, Erices et al. 2002, Li et al. 2008] 
and TGFβ1 [Janssens et al. 2005, Kanaan & Kanaan 2006] are well established as regulators of 
osteoblast differentiation, and are also strongly implicated in prostate cancer progression [Chung 
et al. 1999, Shariat et al. 2001, Wikstrom et al. 1998, Wikstrom et al. 2001]. Another important 
regulator of osteoblast differentiation and function, fibroblast growth factor 2 (FGF2) 
[Franceschi & Xiao 2003, Marie 2003] is also presumed to play a significant role in prostate 
cancer [Kwabi-Addo et al. 2004]. It was confirmed that osteoblasts in vitro secrete high amounts 
of all three molecules (Fig. 12A). Although the levels of intracellular protein are only an indirect 
indicator of how much is actually secreted, it appears that in a coculture with LNCaP cells, 
osteoblasts are the main source of FGF2 and IL6, and also contribute large amounts of TGFβ1 to 
the coculture environment both at 24 h and at 48 h (Fig. 12B). Consequently, the role of all three 
factors in the induction of selected osteomimetic genes was investigated using neutralizing 
antibodies and recombinant proteins. A similar approach has been used by Lu et al. to 
investigate the contribution of osteoblast-released IL6 to the induction of prostate cell 
proliferation and prostate-specific antigen (PSA) expression [Lu et al. 2004]. 
Neutralizing antibodies against IL6 or TGFβ1 added to hfOB CM abolished the 
upregulation of OPG mRNA in LNCaP, whereas an antibody against FGF2 had no effect. 
RANKL upregulation was prevented by neutralizing TGFβ1, but not IL6 or FGF2. None of the 
three antibodies blocked the upregulation of BMP2 mRNA (Fig. 13A). 
Treating LNCaP cells with recombinant IL6 or TGFβ1 for 24 h resulted in significant 
upregulation of OPG mRNA (Fig. 13B); however, recombinant TGFβ1 did not induce 
upregulation of RANKL or of the known TGFβ target gene OPN. Recombinant FGF2 had no 
effect on OPN, OPG or RANKL mRNA expression after 24 h.  
In sum, it could be shown that osteoblast-released IL6 and TGFβ1 increase OPG 
expression in LNCaP. Osteoblast-released TGFβ1 also appears to contribute to RANKL 
upregulation, but additional factors present in CM are apparently needed to cause this effect. 
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Fig. 13 Effect of candidate factors on osteomimetic gene expression by cancer cells.  
(A) Effect of neutralizing antibodies on the upregulation of osteomimetic genes in LNCaP by osteoblast-
conditioned medium. Error bars represent the mean ± SD of at least three independent experiments. 
* p < 0,05; ** p < 0,01 (vs. LNCaP); # p < 0,05 (vs. LNCaP + hfOB CM).  
(B) Effect of recombinant proteins on osteomimetic gene expression in LNCaP. Alterations with a t-test p value 
< 0,05 were considered significant. , fold change ≥ 2; , fold change ≥ 1,45; nc, no change.  
qRT-PCR was performed on cDNA from LNCaP cells cultured in FCS-free conditions (A) in plain medium 
(controls) or in hfOB CM diluted 1:1 with fresh medium, with or without the indicated antibodies (400 ng/ml), or 
(B) in plain medium in the presence of the indicated recombinant proteins. LNCaP cells cultured in plain medium 
served as the control. 
 
 
 
The OPG promoter has been cloned and characterized [Morinaga et al. 1998]. It has been 
demonstrated that TGFβ treatment increases OPG mRNA and protein levels in osteoblasts, and 
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that a 183-bp proximal region (-372 to -190) of the OPG promoter is necessary and sufficient for 
mediating TGFβ effects [Thirunavukkarasu et al. 2001]. An in silico analysis (Transcription 
Element Search System - TESS, www.cbil.upenn.edu/tess) of the OPG promoter sequence 
reveals a number of potential binding sites for transcription factors inducible both by IL6 (IL6 
RE-BP, IRF-1,2) and by TGFβ (Sp1) (Fig. 14). Significantly, a number of predicted Sp1 binding 
sites are located in the TGFβ-responsive region characterized by Thirunavukkarasu et al. 
 
 
 
Fig. 14 In silico analysis of the OPG promoter sequence - GenBank accession number AB008822. Potential 
transcription factor binding sites are listed along with the upstream signaling pathways known to activate those 
transcription factors.  
 
Green - TESS analysis 
Blue - Morinaga 1998 
Red - Thirunavukkarasu 2001 
TIS - transcription initiation sites [Morinaga et al. 1998]       
 
 
 
                                             AP-2α                                        LEF-1 Wnt/β-catenin    
1 ctggagacat ataacttgaa cacttggccc tgatggggaa gcagctctgc agggactttt tcagccatct 
                                                 c-Myb 
71 gtaaacaatt tcagtggcaa cccgcgaact gtaatccatg aatgggacca cactttacaa gtcatcaagt 
                                                                                          TCF-4 Wnt/β-catenin    
141 ctaacttcta gaccagggaa ttaatggggg agacagcgaa ccctagagca aagtgccaaa cttctgtcga 
                 Sp1TGFβ   NF-AT 
211 tagcttgagg ctagtggaaa gacctcgagg aggctactcc agaagttcag cgcgtaggaa gctccgatac 
TCF-1,3,4/LEF-1 Wnt/β-catenin  Sp1TGFβ                                              Sp1TGFβ /AP-2           
281 caatagccct ttgatgatgg tggggttggt gaagggaaca gtgctccgca aggttatccc tgccccaggc 
                                                                                 GATA-1 
351 agtccaattt tcactctgca gattctctct ggctctaact accccagata acaaggagtg aatgcagaat                                                                    
                                     AP-1 
421 agcacgggct ttagggccaa tcagacatta gttagaaaaa ttcctactac atggtttatg taaacttgaa 
                                                                                                         Sp1TGFβ   
491 gatgaatgat tgcgaactcc ccgaaaaggg ctcagacaat gccatgcata aagaggggcc ctgtaatttg 
                                
 TIS 3                              TIS 2                                         
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                              IRF1/2IL6   AP-1                                                              AP-2 
561 aggtttcaga acccgaagtg aaggggtcag gcagccgggt acggcggaaa ctcacagctt tcgcccagcg 
                         IL-6 RE-BP IL6  Msx-1                                                       Sp1TGFβ 
631 agaggacaaa ggtctgggac acactccaac tgcgtccgga tcttggctgg atcggactct cagggtggag 
                                        Sp1TGFβ     AP-2/Sp1TGFβ  AP-2/Sp1TGFβ                                                                                               
701 gagacacaag cacagcagct gcccagcgtg tgcccagccc tcccaccgct ggtcccggct gccaggaggc 
                                                                    
 
-372       TGFβ-responsive region 
      AP-2     Sp1 TGFβ/ERα  Sp1 TGFβ   OSE2          AP-2                      Sp1 TGFβ                                   
771 tggccgctgg cgggaagggg ccgggaaacc tcagagcccc gcggagacag cagccgcctt gttcctcagc 
                                                    
                     IL-6 RE-BP IL6/AP-2  SBE/Sp1 TGFβ   Sp1 TGFβ/AP-2/GATA-1  Sp1TGFβ   
841 ccggtggctt ttttttcccc tgctctccca ggggacagac accaccgccc cacccctcac gccccacctc 
                                   TGFβ-responsive region [Thirunavukkarasu et al. 2001] 
       AP-2α           Sp1TGFβ   Sp1TGFβ 
911 cctgggggat cctttccgcc ccagccctga aagcgttaat cctggagctt tctgcacacc ccccgaccgc                                   
                
 
-190 (relative to TIS 1)    
           Sp1 TGFβ           TBP      AREB6                     c-Fos/TCF-1,3,4/LEF-1Wnt/β-catenin    
981 tcccgcccaa gcttcctaaa aaagaaaggt gcaaagtttg gtccaggata gaaaaatgac tgatcaaagg                                             
                        c-Ets-1                          TFIID 
1051 caggcgatac ttcctgttgc cgggacgcta tatataacgt gatgagcgca cgggctgcgg agacgcaccg 
                                                                                                           
 TIS 1 
1121 gagcgctcgc ccagccgccg cctccaagcc cctgaggttt ccggggacca caatgaacaa 
                                                                                                             MetAsnLys                                                 
1181 gttgctgtgc tgcgcgctc 
          LeuLeuCysCysAlaLeu 
 
 
3.1.4. Osteoblast-released factors increase the expression of IL6 and TGFβ signaling 
pathway components in prostate cancer cells. 
Since the neutralization experiments indicated a possible role for IL6 and TGFβ1 in the 
induction of osteomimicry, it was investigated whether osteoblast-released factors affect the 
expression of these molecules and their receptors in prostate cancer cells. 
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Different groups have reported either that LNCaP secrete no IL6 [Okamoto et al. 1997, 
Chung et al. 1999, Giri et al. 2001] or secrete it in low amounts [Siegall et al. 1990]. The highly 
sensitive qRT-PCR assay used here showed that LNCaP and C4-2B4 expressed small but 
detectable amounts of IL6 mRNA. Furthermore, in the cell lysate of LNCaP and C4-2B4, an 
antibody against IL6 detected three bands between 23,6 and 27,8 kDa, corresponding to three 
glycosylation variants of IL6 (Fig. 12A), a cytokine which may range in size from 21 to 28 kDa. 
It has been reported that prostate cancer cells express IL6R, the ligand-binding receptor for IL6 
[Siegall et al. 1990, Okamoto et al. 1997, Chung et al. 1999]. Here, IL6R mRNA expression 
could be confirmed in LNCaP, C4-2B4 and PC3 (Fig. 15). qRT-PCR data showed that IL6 and 
IL6R both became significantly upregulated in LNCaP and C4-2B4 after crosstalk with 
osteoblasts or exposure to hfOB CM. In LNCaP, IL6 upregulation became firmly established 
after only 16 h of coculture (Fig. 16). In PC3 cells, which constitutively expressed and secreted 
very high levels of IL6, crosstalk with osteoblasts did not cause changes in either IL6 or IL6R 
expression (Tab. 8). 
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Fig. 15 Steady-state mRNA levels of IL6 and TGFβ1 pathway components in prostate cancer cells and 
osteoblasts. Error bars represent the mean ± SD of at least three independent values.  
* p < 0,05; ** p < 0,01; *** p < 0,001 (vs. LNCaP) 
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Tab. 8 Changes in the expression of IL6 and TGFβ1 pathway components, induced in prostate cancer cells by 
osteoblast-released factors.  For details see legend to Tab. 7. Alterations with a t-test p value < 0,05 were 
considered significant. , fold change ≥ 2; , fold change ≥ 1,45; , fold change ≤ 0,69 (-1,45); , fold 
change ≤ 0,5 (-2); nc, no change; V, variable (clear tendency, but standard deviation too high; p > 0,05). [X]hfOB, 
hfOB-cocultured prostate cancer cells; hfOB CM - osteoblast-conditioned medium diluted 1:1.  
 
 
 
Gene 
symbol 
LNCaPhfOB 24 h LNCaPhfOB 48 h LNCaP  
+ hfOB CM 48 h 
IL6    
IL6R   nc 
 
TGFB1    
TGFBR1 nc  nc 
TGFBR2  nc  
SMAD2 nc nc nc 
SMAD3    
SMAD7 nc nc nc 
 
Gene 
symbol 
C4-2B4hfOB 24 h C4-2B4hfOB 48 h C4-2B4  
+ hfOB CM 48 h 
IL6    
IL6R    
 
TGFB1 nc  V 
TGFBR1   nc 
TGFBR2  nc  
SMAD2   nc 
SMAD3    
SMAD7 nc nc nc 
 
Gene 
symbol 
PC3hfOB 24 h PC3hfOB 48 h PC3  
+ hfOB CM 48 h 
IL6 nc nc nc 
IL6R nc nc nc 
 
TGFB1 nc nc nc 
TGFBR1 nc  nc 
TGFBR2 nc nc nc 
SMAD2 nc nc nc 
SMAD3 nc  nc 
SMAD7 nc  V 
 
 
All three prostate cancer cell lines expressed TGFβ1 mRNA and protein (Fig. 15). There is 
controversy in literature regarding the expression of TGFβ receptors and sensitivity to TGFβ 
signaling in LNCaP, with some researchers reporting a lack of sensitivity due to a lack of 
expression of the type I (TGFBR1) [Kim et al. 1996a; for description of the TGFβ signaling 
pathway see Discussion 4.2.2] or type II (TGFBR2) TGFβ receptors, possibly due to silencing 
mediated by promoter methylation [Zhang et al. 2005b], while others observed sensitivity under 
certain conditions of growth factor or androgen stimulation [Schuurmans et al. 1991, Kim et al. 
1996b]. The results presented here show that LNCaP and C4-2B4 both expressed high amounts 
of TGFBR1 and low but detectable amounts of TGFBR2 mRNA, and thus were potentially 
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responsive to TGFβ. Furthermore, expression of TGFB1 and TGFBR2 mRNA was clearly higher 
in the osteotropic lines C4-2B4 and PC3 as compared to non-osteotropic LNCaP (Fig. 15).  
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Fig. 16 Time-course curves of IL6 and TGFβ pathway component mRNAs in LNCaP cocultured with 
osteoblasts or treated with osteoblast-conditioned medium. For details see legend to Tab. 7. Error bars represent 
the mean ± SD of at least three independent experiments. * p < 0,05; ** p < 0,01 
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Osteoblast-released factors caused an increase in the levels of TGFβ receptor mRNA in 
prostate cancer cells. TGFBR1 became upregulated in all three prostate cancer cell lines after 
coculture with osteoblasts (Tab. 8). TGFBR2 was also upregulated after 24 h of coculture and 
after 48 h of hfOB CM treatment in LNCaP and C4-2B4. TGFB1 itself became upregulated only 
in LNCaP, the cell line which showed the lowest baseline expression of TGFB1 mRNA. Time-
course curves performed in LNCaP show that TGFB1 became strongly upregulated after only 8 
h of coculture with osteoblasts and the upregulation was still noticeable at 24 h, but disappeared 
after 48 h. When LNCaP cells were treated with hfOB CM, TGFB1 was upregulated after 24 h 
and after 48 h (Fig. 16).  
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Fig. 17 Levels of intracellular IL6 and TGFβ1 protein in LNCaP after coculture with osteoblasts. Shown are 
densitometric quantifications of respective bands (A) and representative blots (B). Results were normalized to 
CKIIβ. For details see legend to Tab. 12. Error bars represent the mean ± SD of three independent experiments. 
Cells: 1, LNCaP 24 h; 2, LNCaP 48 h; 3, LNCaPhfOB 24 h; 4, LNCaPhfOB 48 h. 
 
 
In sum, expression of the mRNAs encoding TGFβ1 and its receptors apparently increased 
when prostate cancer cells became exposed to the bone microenvironment. These results 
underscore a possible link between enhanced TGFβ signaling and the establishment of bone 
metastases. Differences in results obtained after coculture and after CM treatment suggest that 
dynamic cell crosstalk may modulate the final effect of osteoblast-released factors on TGFβ 
signaling in prostate cancer cells.   
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Intracellular protein levels of IL6 and TGFβ1 remained unchanged in LNCaP after 24 h 
and 48 h of coculture with osteoblasts, indicating that the entire newly synthesized protein may 
be efficiently secreted (Fig. 17). 
Expression of the TGFβ signaling mediators SMAD2, SMAD3 and SMAD7 was 
investigated as well. SMAD2 and SMAD3 belong to the class of receptor-activated SMADs; 
they become phosphorylated after ligand binding to the TGFβ receptor, associate with SMAD4 
and translocate into the nucleus, where they activate or repress the expression of target genes 
[Brown et al. 2007]. SMAD7 inhibits TGFβ signaling both at the receptor level and in the 
nucleus and plays an essential role in the negative feedback regulation of this pathway [Afrakhte 
et al. 1998, Zhang et al. 2007]. Baseline SMAD3 expression was significantly higher in C4-2B4 
and PC3 than in LNCaP, whereas SMAD2 and SMAD7 levels did not differ significantly 
between the analyzed prostate cancer cell lines (Fig. 15). Furthermore, osteoblast-released 
factors caused strong upregulation of SMAD3, but not SMAD2 mRNA in LNCaP and C4-2B4, 
both after coculture and after CM treatment (Fig. 16).  
In the case of PC3 cells, coculture with osteoblasts for 48 h increased the mRNA levels of 
TGFBR1 and SMAD3, but also of SMAD7, a negative regulator of TGFβ signaling. It could be 
hypothesized that in LNCaP and C4-2B4, the levels of autocrine TGFβ signaling are lower due 
to a lower constitutive expression of TGFB1 and TGFBR2 as compared with PC3, and thus, the 
negative feedback mechanism is not immediately activated after TGFβ stimulation. 
Significantly, all the investigated components of the TGFβ pathway except for SMAD2 were 
much more abundantly expressed by osteoblasts than by prostate cancer cells (Fig. 15), 
underscoring the importance of TGFβ signaling in osteoblast biology.  
TGFB1 is a known target gene of FGF2 [Fenig et al. 2001] and of TGFβ signaling [Van 
Obberghen-Schilling et al. 1988]. It was investigated whether osteoblast-released FGF2, IL6 or 
TGFβ1 contribute to TGFB1 upregulation in LNCaP. Neutralizing antibodies against TGFβ1, 
but not against FGF2 or IL6 abolished TGFB1 mRNA upregulation in LNCaP in response to 
hfOB CM (Fig. 18A). The neutralizing antibody against TGFβ1 also significantly reduced 
baseline expression of TGFB1 mRNA, to ca. 60% of the control. However, treatment with 
recombinant TGFβ1 alone did not induce TGFB1 mRNA in LNCaP (Fig. 18B). Thus, baseline 
TGFB1 expression in LNCaP cells appears to be maintained, at least in part, by autocrine TGFβ 
signaling and becomes elevated in response to TGFβ1 (autocrine and paracrine) acting in 
synergism with other factors secreted by osteoblasts, whereas TGFβ1 alone added to the medium 
is not enough to cause such an effect.  
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The baseline expression of IL6 mRNA in LNCaP is so low that antibody neutralization 
experiments were not employed to investigate the mechanisms of its upregulation, since the error 
margin would have been very high. IL6 is a known target gene of TGFβ signaling [Franchimont 
2000], but treatment with recombinant TGFβ for 24 h did not increase IL6 expression in LNCaP 
(Fig. 18B). 
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Fig. 18 Effect of candidate factors on the expression of signaling pathway components by cancer cells. 
(A) Effect of neutralizing antibodies on the upregulation of TGFB1 in LNCaP by osteoblast-conditioned 
medium. * p < 0,05; ** p < 0,01 (vs. LNCaP); # p < 0,05 (vs. LNCaP + hfOB CM). Error bars represent the mean ± 
SD of at least three independent experiments. (B) Effect of recombinant proteins on the expression of IL6 and 
TGFβ pathway components in LNCaP. For details see legend to Fig 13. Alterations with a t-test p value < 0,05 
were considered significant. nc, no change.  
 
 
3.2. The response of osteoblasts to prostate cancer cells 
3.2.1. Exposure of osteoblasts to the secretome of prostate cancer cells significantly 
alters their pattern of gene expression. 
To investigate early effects of the prostate cancer cell secretome on osteoblasts, 
immortalized human fetal osteoblasts (hfOB 1.19) were cocultured with three different prostate 
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cancer cell lines: the osteolytic PC3 [Nemeth et al. 1999, Fisher et al. 2002], the mixed 
osteolytic/osteoblastic LNCaP [Nemeth et al. 1999] or the osteoblastic C4-2B4 [Thalmann et al. 
2000]. The cellular crosstalk was allowed to proceed for 48 h, followed by cell harvesting, RNA 
preparation and RNA quality check. Large-scale transcript profiling was then performed using 
Human Genome U133A 2.0 oligonucleotide array chips (Affymetrix) containing more than 
22,000 probe sets corresponding to 14,500 well-characterized genes. Two individual biological 
replicate samples were assayed per coculture set. Transcript level differences between cocultured 
and monocultured osteoblasts were rated as significant when 2-fold or higher. Differences 1.5-
fold or higher, but smaller than 2-fold were rated as tendentious.  
The crosstalk between prostate cancer cells and osteoblasts for 48 h strongly affected the 
osteoblast transcriptome. Altogether, the expression of 309 genes became significantly altered, 
i.e., roughly 2% of all probed genes, and a tendency to expression alterations was noted for more 
than 1,100 genes (Fig. 19). The three employed prostate cancer cell lines contributed differently 
to these alterations. PC3 had the broadest effect; 242 genes showed significant expression 
changes, 117 of these were upregulated and 125 repressed. LNCaP was less effective, altering 
expression of 166 genes, of which 89 were upregulated and 77 repressed. C4-2B4 showed the 
weakest effect, changing expression of 138 genes, of which 61 were upregulated and 77 
repressed. 
Various genes in the osteoblast transcriptome responded selectively to either only one of 
the prostate cancer lines, to two, or to all three of them. Of these, the groups of genes responsive 
selectively to a certain type of prostate cancer cells only (cell type-specific osteoblast responses) 
and responsive unspecifically to all three prostate cancer lines (universal osteoblast responses) 
appeared to be of particular importance for the metastatic process (see below). Thus, 110 
significantly altered genes were selectively responsive to PC3, 38 upregulated and 72 repressed; 
33 genes were responsive only to LNCaP, 12 upregulated and 21 repressed; and 18 genes were 
only responsive to C4-2B4, 1 upregulated and 17 repressed. 89 genes were significantly affected 
by all three of the employed prostate cancer lines, i.e., regardless of their respective osteolytic or 
osteoblastic nature. Of these 89, 48 genes became upregulated and 41 repressed. 
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Fig. 19 Gene expression alterations in osteoblasts due to their crosstalk with prostate cancer cells via released 
factors (Venn diagram). Large-scale transcript profiling was performed using the Human Genome U133A 
GeneChip arrays (Affymetrix) comprising 14,500 gene equivalents. Transcript profiles of hfOB cocultured with 
each of three prostate cancer cell lines (PC3, LNCaP or C4-2B4) for 48 h in a bicompartment system were 
compared to noncocultured hfOB. Numbers indicate genes with significant (≥2-fold) expression alterations; 
numbers in parentheses indicate the total sum of altered genes, comprising genes with significant and with 
tendentious (≥1.5-fold) alterations. Note: Genes altered significantly in 1 coculture combination and tendentiously 
in the 2 others were treated as tendentiously altered in 3 combinations, not as significantly altered only in 1. This 
approach was chosen to gain a more stringent selection of selectively altered genes. 
 
 
3.2.2. Universal osteoblast responses - genes similarly affected in osteoblasts by both 
osteolytic and osteoblastic prostate cancer cells. 
Osteolytic and osteoblastic processes are interactively involved in bone metastasis. 
Therefore, genes affected similarly in osteoblasts by the secretomes of osteolytic and 
osteoblastic cancer cells are of particular importance, because among these one would expect 
candidate genes playing general roles in bone metastasis. Their identification may offer clues as 
to the universal osteoblast response at a very early stage of prostate cancer metastasis, and thus 
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provide insights into potential mechanisms of the formation of osteoblastic lesions, as well as 
effects on prostate cancer stem cell niches. 
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Fig. 20 Functional classification of genes altered ≥2-fold in osteoblasts by coculture for 48 h with each of 
three prostate cancer cell lines. For further details see Fig. 19. 
 
 
Our analysis indicates that 89 genes became significantly affected by all three of the 
employed prostate cancer cell lines, i.e., by osteolytic and osteoblastic cancer cells. Functionally, 
this group comprises genes linked to various cellular processes. Among the 48 transcripts most 
strongly elevated in hfOB cocultured with all three prostate cancer cell lines, 6 were genes 
associated with stress response, 7 were associated with cell signaling and 5 with regulation of 
transcription, while 6 coded for solute carriers and proteins involved in vesicle trafficking, 
suggesting a switch of transcription programs and modulation of transport and secretory 
activities. Among the 41 transcripts most strongly repressed in all three coculture combinations, 
13 coded for various enzymes, 7 represented extracellular matrix components, adhesion 
molecules and cytoskeletal proteins, 6 were associated with DNA replication, transcription or 
translation, and 5 with immune response and inflammation (Fig. 20). Interestingly, while the 
majority of functional groups encoding enzymes, signaling elements, etc. included, as one would 
expect, both upregulated and repressed transcripts, transcripts encoding stress-associated 
molecules were present only among the 41 upregulated genes, whereas transcripts associated 
with immune response and inflammation were found only in the downregulated group. (For full 
list see Supplementary Data).                                                                                                                                                                                                                                               
In order to disclose details of the gene-to-function relationships, we have utilized 
information provided by available databases (Entrez Gene and PubMed; see Materials and 
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methods 2.3.4). Genes affected by the cell crosstalk have been arranged, according to major 
cellular tasks of gene products, into groups relating to modulation of pro- and antiapoptotic 
mechanisms, DNA and RNA synthesis, signaling, immune response, etc. Tab. 9 presents a broad 
selection of transcripts which were altered in osteoblasts - either significantly or tendentiously - 
by all three prostate cancer cell lines, and which represent the relevant functional groups. 
The overall pattern of transcriptional alterations was suggestive of stress-related growth 
arrest, with upregulation of stress-responsive transcripts encoding cell cycle repressors - DUSP1, 
coding for a specific antiproliferative phosphatase, and TTK, which encodes a kinase that halts 
mitosis in response to spindle damage. Also upregulated were other stress-induced transcripts, 
such as PPP1R15A, RORA and TAF9B, encoding a phosphatase, an orphan receptor, and a 
TATA box binding protein-associated factor, respectively. A concomitant elevation of genes 
encoding the apoptosis effector CASP3, the potentially proapoptotic CLCA2 and LRDD, the pro-
survival kinase PIK3C2A and of the antiapoptotic regulator BCL2A1 could be observed, while 
proapoptotic molecules such as BECN1, GLIPR1, FADD and IFI27 were downregulated, 
suggesting an overall pro-survival effect. 
Simultaneously, there was evidence for strongly repressed proliferation, with concomitant 
repression of DNA, RNA and protein synthesis. Upregulation of genes encoding cell cycle 
repressors, such as BTG1 and COPS2,  was observed together with downregulation of transcripts 
such as CIRBP, DDX5, MCM4 and NASP, associated with DNA replication and cell cycle 
progression. Similarly, the translation repressor gene EIF4EBP1 was upregulated, while 
transcripts coding for tRNA synthetases (MARS, NARS) and components of translational 
machinery (EIF5, PAIP1, SRP19) were downregulated. An overall decrease of metabolic 
activity was also apparent, especially of lipid biosynthesis, as evidenced by upregulation of the 
negative regulator INSIG1 and downregulation of enzymes participating in biosynthesis of fatty 
acids and cholesterol (ACACA, ACLY, DHCR24, FASN). Genes associated with proteasome 
function (DSCR2, PSMA3, PSMA4, PSMD6) were downregulated as well, suggesting a decrease 
in ubiquitin-dependent protein degradation. 
Further important changes could be seen in regulons associated with cell adhesion, 
cytoskeletal organization and extracellular matrix formation, as well as genes linked to 
osteoblast differentiation and bone remodeling. The observed changes in signaling pathways 
suggested a repression of TGFβ  signaling, with upregulation of genes of negative regulators 
PPM1A and SNF1LK, downregulation of the type II receptor TGFBR2, and the accessory 
molecule DAB2. Moreover, there was a corresponding downregulation of TGFβ target genes, 
including adhesion molecules (CDH11, THBS1), extracellular matrix components (COL1A1, 
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COL1A2, COL3A1, TNC) and cytokines (CTGF, FST, FGF2). Multiple genes associated with 
immune response and inflammation were strongly downregulated as well. Among them were 
NEDD9, encoding a cell cycle regulator and target of inflammatory cytokines; STAT1, encoding 
a central mediator of inflammatory signaling; genes for the chemokines CCL2, CXCL6 and 
CXCL12; the proinflammatory cytokine IL6; PTX3, a marker of inflammation; and three 
molecules involved in inflammation-induced bone remodeling - ADAMTS1, HMGB1 and 
PAPPA.  
The changes seen in the osteoblast differentiation regulon included upregulation of genes 
encoding bone-stimulatory cytokines (ADM, STC1), signaling pathway components (FGFR1, 
IRS2) and transcription factors (HES1, SP3) associated with increased differentiation. By 
contrast, DKK1 and FST, genes encoding inhibitors of osteoblast differentiation and bone 
formation, became downregulated. 
To verify the array data, the expression of a number of up- and downregulated genes, with 
a varied intensity of the effect, was also analyzed by qRT-PCR performed on four to six 
individual biological replicate samples. In all the investigated cases, including tendentious 
alterations, gene expression changes observed on the array could be confirmed by qRT-PCR, 
showing that the array analysis was robust (Fig. 21 A-B).  
Many of the gene expression changes which occurred universally in osteoblasts cocultured 
with all three prostate cancer cell lines were also caused by coculture with the non-osteotropic 
cancer cell line HeLa or the non-cancerous lung fibroblast line IMR-90. To exclude the 
possibility that the presence of a plastic transwell insert could interfere with experimental results, 
hfOB grown in wells with an empty insert were also assayed by qRT-PCR. It was found that the 
presence of an insert in itself either did not alter transcript levels at all or changes were very 
slight, causing no significant differences in the outcome of calculated relative expression values 
of the investigated genes (Fig. 21 A-B).  
It is also unlikely that the expression alterations were due to increased medium exhaustion 
in coculture, since significant changes could already be observed after 24 h, e.g., upregulation of 
NPPB and repression of CDH2, CDH11, IL6 and TGFBR2 (Fig. 22). On the other hand, the 
transcript level of STC1 remained unaltered during the first 24 h but became upregulated after 48 
h (Fig. 22).  
The possibility that a switch between culturing cells in wells and in inserts might affect 
gene expression has previously been excluded by Knerr et al., 2004. 
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Tab. 9 Universal transcription alterations in osteoblasts cocultured with prostate cancer cells.  
Genes were divided into functional groups on the basis of information from the Entrez Gene and PubMed databases (www.ncbi.nlm.nih.gov). 
The table shows genes with known function, belonging to the described groups and upregulated, either significantly or tendentiously, in all three 
coculture combinations. For further details see the legend to Fig. 19.  
hfOBX, X-cocultured hfOB; , ≥ 2-fold elevation; , ≥ 1,5-fold elevation; , ≥ 2-fold repression; , ≥ 1,5-fold repression;  
nc, no change; * ,verified by qRT-PCR; #, transcript upregulated by TGFβ; I , immune response; ** , change seen only in qRT-PCR 
 
 
Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description hfOBPC3  
48 h 
hfOBLNCaP  
48 h 
hfOBC4-2B4  
48 h 
 
Stress response; modulation of pro-and antiapoptotic mechanisms 
597 BCL2A1 BCL2-related protein A1 Antiapoptotic regulator.     
836 CASP3  caspase 3, apoptosis-related cysteine peptidase Central role in the execution-phase of cell apoptosis.    
9635 CLCA2* chloride channel, calcium activated, family member 2 Ion channel; possible role in the early stages of the apoptotic cascade.    
1843 DUSP1 dual specificity phosphatase 1 Response to environmental stress, negative growth regulation.    
1647 GADD45A growth arrest and DNA-damage-inducible, alpha Transcript levels increase in stressful growth arrest conditions.     
55367 LRDD leucine-rich repeats and death domain containing May function as adaptor protein in cell death-related signaling.    
5286 PIK3C2A phosphoinositide-3-kinase, class 2, alpha polypeptide Crucial in pro-survival signaling; downregulation induces apoptosis.    
5494 PPM1A 
protein phosphatase 1A (formerly 2C), magnesium-
dependent, alpha isoform 
Negative regulator of cell stress response pathways (p38, JNK kinase 
cascades); role in cell cycle control.    
23645 PPP1R15A 
protein phosphatase 1, regulatory (inhibitor) subunit 
15A Transcript levels increase in stressful growth arrest conditions.    
3516 RBPJ 
recombination signal binding protein for 
immunoglobulin kappa J region 
Transcriptional repressor; antiapoptotic action in response to Notch 
signaling.    
6095 RORA RAR-related orphan receptor A Involved in cellular stress response.     
51616 TAF9B 
TAF9B RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 31kDa 
Regulates initiation of transcription by RNA Pol II; essential for cell 
viability, upregulated by apoptotic stimuli.    
7272 TTK  TTK protein kinase 
Component of spindle assembly checkpoint - halts mitosis in response to 
spindle damage.    
 
8678 BECN1 
beclin 1 (coiled-coil, myosin-like BCL2 interacting 
protein) Proapoptotic protein.    
11010 GLIPR1 GLI pathogenesis-related 1 (glioma) Proapoptotic protein.    
8772 FADD Fas (TNFRSF6)-associated via death domain Mediates cell apoptotic signals.    
3429 IFI27 I interferon, alpha-inducible protein 27 Proapoptotic protein; impacts normal mitochondrial function.    
4599 MX1 I 
myxovirus (influenza virus) resistance 1, interferon-
inducible protein p78 (mouse) Proapoptotic protein (putative).    
4739 NEDD9 I  
neural precursor cell expressed, developmentally 
down-regulated 9 
Cell cycle regulator (low levels cause mitotic arrest); involved in cell 
signaling and actin dynamics; target of inflammatory cytokines.    
7157 TP53 tumor protein p53 (Li-Fraumeni syndrome) Stress response, cell cycle arrest, apoptosis.    
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Tab. 9 (continued) 
 
Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBLNCaP  
48 h 
hfOBC4-2B4  
48 h 
 
Decreased DNA and RNA synthesis, suppressed proliferation 
694 BTG1 B-cell translocation gene 1, anti-proliferative 
Member of an anti-proliferative gene family that regulates cell growth and 
differentiation.     
9318 COPS2 
COP9 constitutive photomorphogenic homolog subunit 
2 (Arabidopsis) 
Transcriptional corepressor. Inhibits expression of the cell cycle regulator 
E2F1 and cell proliferation.    
 
8883 APPBP1 amyloid beta precursor protein binding protein 1 Required for cell cycle progression through the S/M checkpoint.    
1153 CIRBP cold inducible RNA binding protein Enhances cell proliferation.    
1655 DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 RNA-dependent ATPase, proliferation-associated nuclear antigen.    
3015 H2AFZ H2A histone family, member Z Structural component of chromatin.    
4173 MCM4 minichromosome maintenance complex component 4 Essential for initiation of DNA replication.    
4678 NASP nuclear autoantigenic sperm protein (histone-binding) Involved in transporting histones into the nucleus of dividing cells.    
6421 
 SFPQ 
splicing factor proline/glutamine-rich (polypyrimidine 
tract binding protein associated) Multiple functions in many nuclear processes.    
6432 SFRS7 splicing factor, arginine/serine-rich 7, 35kDa Role in mRNA splicing.    
3925 STMN1* stathmin 1/oncoprotein 18 
Prevents assembly and promotes disassembly of microtubules; inhibiting 
expression of this protein reduces cell proliferation.  ** ** 
 
Decreased protein synthesis 
1978 EIF4EBP1 
eukaryotic translation initiation factor 4E binding 
protein 1 Translation repressor.    
 
708 C1QBP 
complement component 1, q subcomponent binding 
protein Subunit of pre-mRNA splicing factor.    
1983 EIF5 eukaryotic translation initiation factor 5 Translation initiation factor.    
4141 MARS methionyl-tRNA synthetase tRNA synthesis.    
4677 NARS asparaginyl-tRNA synthetase tRNA synthesis.    
10605 PAIP1 poly(A) binding protein interacting protein 1 Involved in translational initiation and protein biosynthesis.    
6728 SRP19 signal recognition particle 19kDa Ribonucleoprotein, component of translational machinery.    
 
Decreased proteasomal degradation of proteins 
8624 DSCR2 Down syndrome critical region gene 2 Involved in the maturation of mammalian 20S proteasomes.    
5684 PSMA3 proteasome (prosome, macropain) subunit, alpha type, 3 Protein degradation.    
5685 PSMA4 proteasome (prosome, macropain) subunit, alpha type, 4 Protein degradation.    
9861 PSMD6 
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 6 Protein degradation.    
  78 
Tab. 9 (continued) 
 
Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBLNCaP  
48 h 
hfOBC4-2B4  
48 h 
 
Decreased lipid metabolism and cholesterol biosynthesis 
3638 INSIG1 insulin induced gene 1 Regulator of lipid metabolism. Inhibits lipid synthesis. 
 
 
 
  
 
31 ACACA acetyl-Coenzyme A carboxylase alpha Fatty acid synthesis.    
47 ACLY ATP citrate lyase Synthesis of acetyl-CoA; lipogenesis, cholesterogenesis.    
8560 DEGS1 
degenerative spermatocyte homolog 1, lipid desaturase 
(Drosophila) Membrane fatty acid desaturase.    
1718 DHCR24 24-dehydrocholesterol reductase Cholesterol biosynthesis.    
3295 HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 Beta-oxidation of fatty acids.    
2194 FASN fatty acid synthase Synthesis of long-chain saturated fatty acids.    
 
Cytoskeleton 
60 ACTB* actin, beta Major constituent of the cell contractile apparatus.  ** ** 
10092 ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa Implicated in the control of actin polymerization.    
4771 NF2 neurofibromin 2 (bilateral acoustic neuroma) Interacts with proteins involved in cytoskeletal dynamics.    
 
Cell adhesion 
1009 CDH11 # cadherin 11, type 2, OB-cadherin (osteoblast) 
Component of adherens junctions; osteoblast-specific, role in osteoblast 
differentiation.    
7057 THBS1 # thrombospondin 1 Adhesion molecule (cell-cell, cell-matrix). Activates latent TGFβ.    
 
Extracellular matrix 
1277 COL1A1*# collagen, type I, alpha 1 Bone matrix component (collagen).    
1278 COL1A2*# collagen, type I, alpha 2 Bone matrix component (collagen).    
1281 COL3A1# 
collagen, type III, alpha 1 (Ehlers-Danlos syndrome 
type IV, autosomal dominant) ECM component (collagen).    
1301 COL11A1 collagen, type XI, alpha 1 ECM component (collagen).    
2202 EFEMP1 
EGF-containing fibulin-like extracellular matrix 
protein 1 ECM component (non-collagenous).    
3371 TNC # tenascin C (hexabrachion) ECM component (non-collagenous).    
 
Bone remodeling 
1437 CSF2  colony stimulating factor 2 (granulocyte-macrophage) Promotes osteoclastogenesis. Enhances osteolytic breast cancer metastasis.    
5329 PLAUR* plasminogen activator, urokinase receptor 
Membrane receptor for urokinase plasminogen activator, upregulation 
facilitates ECM remodeling.     
 
9510 ADAMTS1 I 
ADAM metallopeptidase with thrombospondin type 1 
motif, 1 Inflammation-associated ECM remodeling.     
1956 EGFR* 
epidermal growth factor receptor (erythroblastic 
leukemia viral (v-erb-b) oncogene homolog, avian) 
Cell surface growth factor receptor. EGFR signaling in osteoblasts 
stimulates osteoclastogenesis by suppressing OPG expression. ** **  
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Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBLNCaP  
48 h 
hfOBC4-2B4  
48 h 
3146 HMGB1 I high-mobility group box 1 
Proinflammatory cytokine; osteoclastogenic factor, mediator of 
inflammatory bone loss.    
5069 PAPPA # I pregnancy-associated plasma protein A 
Metalloproteinase, target of inflammatory cytokines; involved in bone 
remodeling and bone formation.    
 
Osteoblast differentiation 
133 ADM adrenomedullin Potent anabolic agent for bone tissue; enhances cancer cell invasion.    
2260 FGFR1 
fibroblast growth factor receptor 1 (fms-related 
tyrosine kinase 2, Pfeiffer syndrome) 
Membrane receptor for fibroblast growth factors (FGFs). FGF signaling 
stimulates osteoblast differentiation.    
3280 HES1 hairy and enhancer of split 1, (Drosophila) 
Transcription factor, cooperates with core binding factor 1 (CBFA1), 
stimulates osteoblast differentiation.    
8660 IRS2 insulin receptor substrate 2 
Cytoplasmic mediator of cytokine signaling. Necessary for osteoblast 
differentiation and matrix synthesis.    
6670 SP3* Sp3 transcription factor Transcription factor essential for late bone development.   ** ** 
6781 STC1* stanniocalcin 1 
Antiapoptotic cytokine. Stimulates osteoblast differentiation; putative 
factor in osteoblastic bone metastasis.    
 
22943 DKK1* dickkopf homolog 1 (Xenopus laevis) 
Wnt signaling antagonist; inhibits osteoblast differentiation and bone 
formation.      
2247 FGF2 # fibroblast growth factor 2 (basic) 
Can stimulate osteoblast differentiation or apoptosis, depending on the 
differentiation stage.    
10468 FST # follistatin Antagonist of activin A signaling; inhibits osteoblast differentiation.     
6772 STAT1 I 
signal transducer and activator of transcription 1, 
91kDa 
Signaling mediator of JAK/STAT pathway; involved in inflammatory 
signaling.  Attenuates osteoblast differentiation and bone formation.    
 
Cell signaling - TGFβ pathway 
5494 PPM1A 
protein phosphatase 1A (formerly 2C), magnesium-
dependent, alpha isoform Terminates TGFβ signaling by dephosphorylating activated Smad 2/3.    
150094 SNF1LK SNF1-like kinase Negative regulation of TGFβ signaling.    
 
1490 CTGF # connective tissue growth factor Enhances TGFβ binding to its receptors.    
1601 DAB2 # 
disabled homolog 2, mitogen-responsive 
phosphoprotein 
Links cell surface receptors to downstream signaling pathways. 
Participates in TGFβ signaling via Smads and JNK.    
7048 TGFBR2* 
transforming growth factor, beta receptor II 
(70/80kDa) 
 
Receptor for TGFβ.    
 
Cell signaling - other 
3556 IL1RAP interleukin 1 receptor accessory protein Regulates cell sensitivity to interleukin 1.    
6236 RRAD Ras-related associated with diabetes Ras-related small G protein.    
25907 TMEM158 transmembrane protein 158 Marker of activated Ras signaling.    
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GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBLNCaP  
48 h 
hfOBC4-2B4  
48 h 
 
6347 CCL2 I chemokine (C-C motif) ligand 2 Chemoattractant for monocytes.    
6387 CXCL12 # I 
chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1) Chemoattractant for hematopoietic cells and metastasizing cancer cells.    
3569 IL6 # I interleukin 6 (interferon, beta 2) Proinflammatory, pleiotropic cytokine.  ** ** 
5156 PDGFRA 
platelet-derived growth factor receptor, alpha 
polypeptide Mitogen for cells of mesenchymal origin.    
5567 PRKACB protein kinase, cAMP-dependent, catalytic, beta Central role in cell signaling. 
 
   
5806 PTX3 I pentraxin-related gene, rapidly induced by IL-1 beta Involved in inflammatory processes; marker of inflammation.    
5999 RGS4 regulator of G-protein signaling 4 Inhibits G protein signaling.    
 
Genes altered in osteoblasts by two but not three prostate cancer cell lines, confirmed by qRT-PCR 
2309 FOXO3* forkhead box O3 Transcription factor; functions as a trigger for apoptosis in osteoblasts.  nc ** 
9518 GDF15* growth differentiation factor 15 
Increases the osteolytic component of prostate cancer bone metastases - 
induces osteoclast differentiation and activation.  ** nc 
4879 NPPB* natriuretic peptide precursor B Promotes endochondral ossification and stem cell proliferation.  nc  
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Tab. 10 Comparison of transcription alterations selective for osteoblasts cocultured with PC3 (osteolytic) and C4-2B4 (osteoblastic) 
prostate cancer cells.  
Genes were divided into functional groups on the basis of information from the Entrez Gene and PubMed databases (www.ncbi.nlm.nih.gov). 
For further details see the legend to Fig. 19. Transcription alterations observed in only one coculture combination on the array, but confirmed by 
qRT-PCR as present in two or three coculture combinations have been included in Table 1. 
hfOBX, X-cocultured hfOB; , ≥ 2-fold elevation; , ≥ 1,5-fold elevation; , ≥ 2-fold repression; , ≥ 1,5-fold repression;  
nc, no change; * ,verified by qRT-PCR; #, transcript upregulated by TGFβ; I , immune response; ** , change seen only in qRT-PCR 
  
 
Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBC4-2B4  
48 h 
 
Stress response; modulation of pro- and antiapoptotic mechanisms 
3708 ITPR1 inositol 1,4,5-triphosphate receptor, type 1 Calcium channel required for apoptotic cell death.  nc 
9467 SH3BP5 SH3-domain binding protein 5 (BTK-associated) Mitochondrial protein, phosphorylated by stress-activated protein kinase 3.  nc 
7133 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B Suppressor of death receptor-mediated apoptosis.  nc 
 
10628 TXNIP thioredoxin interacting protein 
Glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced 
apoptosis. nc  
 
Decreased DNA and RNA synthesis, suppressed proliferation 
1028 CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) Negative regulator of cell proliferation - strong inhibitor of G1 cyclin/Cdk complexes.  nc 
    
  
1020 CDK5 cyclin-dependent kinase 5 Cell cycle control.  nc 
11052 CPSF6 cleavage and polyadenylation specific factor 6, 68kDa Subunit of a cleavage factor required for 3' RNA cleavage and polyadenylation processing.  nc 
1503 CTPS CTP synthase Nucleotide synthesis.  nc 
2071 ERCC3 
excision repair cross-complementing rodent repair 
deficiency, complementation group 3 (xeroderma 
pigmentosum group B complementing) 
ATP-dependent DNA helicase, functions in nucleotide excision repair. Also functions in class II 
transcription (as a subunit of TFIIH).  nc 
64785 GINS3 GINS complex subunit 3 (Psf3 homolog) Essential for the initiation of DNA replication.  nc 
8520 HAT1 histone acetyltransferase 1 
Acetylation of newly synthesized cytoplasmic histones, which plays an important role in 
replication-dependent chromatin assembly.  nc 
3182 HNRPAB heterogeneous nuclear ribonucleoprotein A/B RNA binding protein, associates with pre-mRNA in the nucleus.  nc 
5654 HTRA1 HtrA serine peptidase 1 Regulates availability of insulin-like growth factors and possibly cell growth.  nc 
3609 ILF3 interleukin enhancer binding factor 3, 90kDa 
Complexes with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene 
expression and stabilize mRNAs.  nc 
4331 MNAT1 
menage a trois homolog 1, cyclin H assembly factor 
(Xenopus laevis) 
Involved in the assembly of the kinase complex that activates cyclin-dependent kinases, which 
participate in cell cycle control.  nc 
51728 POLR3K 
polymerase (RNA) III (DNA directed) polypeptide K, 
12.3 kDa 
Small essential subunit of RNA polymerase III, the polymerase responsible for synthesizing transfer 
and small ribosomal RNAs in eukaryotes.  nc 
80324 PUS1 pseudouridylate synthase 1 Converts uridine into pseudouridine after the nucleotide has been incorporated into RNA.   nc 
3431 SP110 SP110 nuclear body protein 
Component of the nuclear body, a multiprotein complex that may participate in the regulation of 
transcription. May play a role in transcription activation and in ribosome biogenesis.  nc 
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Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBC4-2B4  
48 h 
54962 TIPIN TIMELESS interacting protein 
Nuclear protein. Depletion of endogenous tipin results in reduced growth rate, which may be due in 
part to inefficient progression of S phase and DNA synthesis.  nc 
8295 TRRAP transformation/transcription domain-associated protein 
 
Recruitment of histone acetyltransferase complexes to chromatin during transcription, replication 
and DNA repair.  nc 
79084 WDR77 WD repeat domain 77 Component of methyltransferase complex that modifies spliceosomal proteins.  nc 
 
8317 CDC7 cell division cycle 7 homolog (S. cerevisiae) Cell division cycle protein with kinase activity that is critical for the G1/S transition. nc  
2965 GTF2H1 general transcription factor IIH, polypeptide 1, 62kDa Transcription initiation. nc  
 
10614 HEXIM1 hexamethylene bis-acetamide inducible 1 
Suppresses transcription elongation. Directly associates with glucocorticoid receptor to suppress 
glucocorticoid-inducible gene activation. nc  
 
Gene-specific regulation of transcription 
23253 ANKRD12 Ankyrin repeat domain 12 Transcriptional coregulator.  nc 
1195 CLK1 CDC-like kinase 1 Kinase indirectly involved in pre-mRNA processing, may influence splice site selection.  nc 
4601 MXI1 MAX interactor 1 Transcriptional repressor.  nc 
864 RUNX3 runt-related transcription factor 3 Transcription factor.  nc 
8091 HMGA2 high mobility group AT-hook 2 Transcriptional regulator.  nc 
4150 MAZ 
MYC-associated zinc finger protein (purine-binding 
transcription factor) Transcription factor, inflammation-responsive.  nc 
9111 NMI I N-myc (and STAT) interactor 
Interacts with transcription factors, augments STAT-mediated transcription in response to 
interferon.  nc 
 
1997 ELF1 E74-like factor 1 (ets domain transcription factor) Transcription factor. nc  
 
Protein synthesis, modification and degradation 
1917 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 Component of translational machinery.  nc 
29071 C1GALT1C1 C1GALT1-specific chaperone 1 Molecular chaperone.  nc 
54431 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 Putative co-chaperone in the endoplasmic reticulum.  nc 
60681 FKBP10 FK506 binding protein 10, 65 kDa Molecular chaperone localized in the ER.  nc 
23463 ICMT isoprenylcysteine carboxyl methyltransferase Posttranslational protein modification in the ER.  nc 
5696 PSMB8 I 
proteasome (prosome, macropain) subunit, beta type, 8 
(large multifunctional peptidase 7) Protein degradation (proteasome subunit). Interferon-induced.  nc 
871 SERPINH1 
serpin peptidase inhibitor, clade H (heat shock protein 
47), member 1, (collagen binding protein 1) 
Putative molecular chaperone involved in the maturation of collagen molecules. Localizes to the 
ER.  nc 
54982 CLN6 ceroid-lipofuscinosis, neuronal 6, late infantile, variant Possibly involved in the degradation of posttranslationally modified proteins in lysosomes. nc  
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hfOBPC3  
48 h 
hfOBC4-2B4  
48 h 
 
Transport 
4864 NPC1 Niemann-Pick disease, type C1 Membrane protein, intracellular cholesterol transport.  nc 
5172 SLC26A4 solute carrier family 26, member 4 Transport across membranes.  nc 
51312 SLC25A37 solute carrier family 25, member 37 Transport across membranes.  nc 
1174 AP1S1 adaptor-related protein complex 1, sigma 1 subunit 
Part of the clathrin coat assembly complex which links clathrin to receptors in coated vesicles. 
These vesicles are involved in endocytosis and Golgi processing.  nc 
3839 KPNA3 karyopherin alpha 3 (importin alpha 4) Involved in nuclear protein import.  nc 
9688 NUP93 nucleoporin 93kDa Component of nuclear pore complex.  nc 
6522 SLC4A2 
solute carrier family 4, anion exchanger, member 2 
(erythrocyte membrane protein band 3-like 1) Membrane-bound protein, mediates anion exchange.   nc 
6747 SSR3 
signal sequence receptor, gamma (translocon-
associated protein gamma) Glycosylated ER membrane receptor associated with protein translocation across the ER membrane.  nc 
23404 EXOSC2 exosome component 2 Exosome component (cellular transport). nc  
8675 STX16 syntaxin 16 Found on cell membranes, permits specific synaptic vesicle docking and fusion. nc  
 
Cytokines, cell surface receptors and cell signaling 
394 ARHGAP5 Rho GTPase activating protein 5 Negatively regulates Rho GTPases.  nc 
960 CD44 CD44 molecule (Indian blood group) Cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration.  nc 
7852 CXCR4 chemokine (C-X-C motif) receptor 4 Cell surface chemokine receptor.  nc 
9289 GPR56 G protein-coupled receptor 56 Cell signaling.  nc 
2872 MKNK2 MAP kinase interacting serine/threonine kinase 2 Cell signaling.  nc 
5801 PTPRR protein tyrosine phosphatase, receptor type, R Regulator of cell signaling cascades.  nc 
5979 RET ret proto-oncogene Cell surface receptor tyrosine kinase.  nc 
58528 RRAGD Ras-related GTP binding D G protein. Cell signaling.  nc 
57124 CD248 CD248 molecule, endosialin Cell surface adhesion molecule.  nc 
8760 CDS2 
CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 2 Cell signaling - regulates the amount of phosphatidylinositol available for signaling.  nc 
91851 CHRDL1 chordin-like 1 Antagonist of bone morphogenetic protein-4.  nc 
 
2919 CXCL1 I 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) Proinflammatory chemokine.  nc 
1825 DSC3 desmocollin 3 Calcium-dependent adhesive glycoprotein, component of  the desmosome cell-cell junction.  nc 
1906 EDN1# endothelin 1 Osteoblast mitogen, pro-osteoblastic factor in osteoblastic prostate cancer metastasis. TGFβ target.  nc 
2150 F2RL1 coagulation factor II (thrombin) receptor-like 1 Cell signaling - transmembrane receptor, couples to G proteins.  nc 
166647 GPR125 G protein-coupled receptor 125 Initiates signaling via G proteins.  nc 
3434 IFIT1 I 
interferon-induced protein with tetratricopeptide 
repeats 1 Interferon-induced negative-feedback regulator of virus-triggered signaling.  nc 
9562 MINPP1 
multiple inositol polyphosphate histidine phosphatase, 
1 Cell signaling - hydrolyzes inositol phosphate metabolites.  nc 
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Gene Product Description 
 
hfOBPC3  
48 h 
hfOBC4-2B4  
48 h 
56106 
 
PCDHGA10 /// 
PCDHGA11 /// 
PCDHGA12 /// 
PCDHGA3 /// 
PCDHGA5 /// 
PCDHGA6 
protocadherin gamma subfamily A, 12/// protocadherin gamma 
subfamily A, 11/// protocadherin gamma subfamily A, 10 /// 
protocadherin gamma subfamily A, 6 /// protocadherin gamma 
subfamily A, 5 /// protocadherin gamma subfamily A, 3 Cell-cell adhesion protein.  nc 
8434 RECK 
reversion-inducing-cysteine-rich protein with kazal 
motifs Membrane glycoprotein.  nc 
7424 VEGFC vascular endothelial growth factor C Cytokine, mediator of angiogenesis.  nc 
 
NF-κB pathway components and target genes 
4792 NFKBIA 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha Upregulated by NF-κB (negative feedback), marker of activated NF-κB pathway.  nc 
54101 RIPK4 receptor-interacting serine-threonine kinase 4 Ser/Thr protein kinase, can activate NF-κB.  nc 
8878 SQSTM1* sequestosome 1 Mediates NF-κB activation.  nc 
6648 SOD2 superoxide dismutase 2, mitochondrial Upregulated by NF-κB.  nc 
 
Metabolism 
10840 ALDH1L1 aldehyde dehydrogenase 1 family, member L1 Metabolic enzyme.  nc 
3099 HK2 hexokinase 2 Metabolic enzyme.  nc 
5209 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Metabolic enzyme.  nc 
1743 DLST 
dihydrolipoamide S-succinyltransferase (E2 
component of 2-oxo-glutarate complex)  Metabolic enzyme.  nc 
55568 GALNT10 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) Synthesis of mucin-type oligosaccharides.  nc 
3052 HCCS holocytochrome c synthase (cytochrome c heme-lyase) Metabolic enzyme.  nc 
262 AMD1 adenosylmethionine decarboxylase 1 Intermediate enzyme in polyamine biosynthesis. nc  
9517 SPTLC2 serine palmitoyltransferase, long chain base subunit 2 Key enzyme in sphingolipid biosynthesis. nc  
 
Structural proteins 
2201 FBN2 fibrillin 2 (congenital contractural arachnodactyly) Component of connective tissue microfibrils.  nc 
3017 HIST1H2BD histone cluster 1, H2bd Chromatin component (histone).  nc 
72 ACTG2 actin, gamma 2, smooth muscle, enteric Cytoskeleton component.  nc 
10097 ACTR2 ARP2 actin-related protein 2 homolog (yeast) Involved in cytoskeletal dynamics.  nc 
1634 DCN decorin Binds to collagen fibrils, plays a role in matrix assembly.  nc 
4281 MID1 midline 1 (Opitz/BBB syndrome) 
Associates with microtubules in the cytoplasm, likely involved in the formation of multiprotein 
structures acting as anchor points to microtubules.  nc 
3916 LAMP1 lysosomal-associated membrane protein 1 Membrane glycoprotein.  nc 
81493 SYNC1 syncoilin, intermediate filament 1 Member of the intermediate filament family. nc  
7094 TLN1 talin 1 Cytoskeletal protein, concentrated in areas of cell-substratum and cell-cell contacts.  nc  
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Figure continued on next page. 
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Fig. 21 Verification and extension of array data. (A) Upregulated genes.  (B) Downregulated genes.  qRT-PCR 
was performed on cDNA from hfOB cocultured with the described cell lines or cultured with an empty transwell 
insert. Shown are the means of expression alterations in comparison to noncocultured hfOB (control bar). hfOBX, 
X-cocultured hfOB. Error bars represent the mean ± SD of at least three independent determinations. * p<0,05; ** 
p<0,01; *** p<0,0001 
Note: In array data FOXO3, GDF15, NPPB, SP3, SQSTM1, ACTB, IL6 and STMN1 were altered only in hfOBPC3, 
whereas EGFR was downregulated only in hfOBC4-2B4. 
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Fig. 22 Transcription alterations in osteoblasts cocultured with prostate cancer cells for 24 h.  
hfOBX, X-cocultured hfOB. Error bars represent the mean ± SD of at least three independent determinations.  
* p<0,05; ** p<0,01; *** p<0,0001 
 
 
For a number of markers of the bone regulon, the array yielded no useful data. The signals 
were either insufficient due to the limited sensitivity of microarrays or the respective genes were 
not represented on the array. These genes were subjected to additional analysis by qRT-PCR 
(Table 11). The transcripts of the osteoinductive molecule BMP2 and the osteoblast-specific 
transcription factor CBFA1 became upregulated in osteoblasts due to coculture with both 
osteolytic and osteoblastic prostate cancer cell lines, whereas OPN and OPG, two transcriptional 
targets of TGFβ, showed strong downregulation. This is perfectly in accordance with the 
patterns of increased osteoblast differentiation and repressed TGFβ signaling suggested by the 
array data. The expression of AP and OC, two further markers of osteoblast differentiation, and 
of RANKL remained unchanged in osteoblasts cocultured with all three prostate cancer cell lines. 
NOG, which encodes a BMP signaling antagonist, and IL6R, which encodes the IL6 receptor, 
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were strongly upregulated, perhaps as an autocrine response to the rising levels of BMP2 and 
decreasing levels of IL6, respectively (Tab. 11). 
RANKL and OPG expression was analyzed after 24 h of coculture as well. It was found 
that OPG was already significantly downregulated after 24 h, while RANKL expression 
remained unchanged at both time points (Fig. 23) 
 
 
Tab. 11 Transcription alterations in osteoblasts cocultured with prostate cancer cells. Osteoblast 
differentiation and bone remodeling.  To investigate the expression of transcripts from the bone regulon for which 
the array yielded no useful data (genes not represented on the array, or insufficient signal), qRT-PCR was 
performed on cDNA from hfOB cocultured with each of three prostate cancer cell lines or cultured with an empty 
transwell insert. Shown are the means of expression alterations in comparison to noncocultured hfOB, from at least 
three independent determinations.  
, fold change ≥ 2; , fold change ≥ 1,45; , fold change ≤ 0,69 (-1,45); , fold change ≤ 0,5 (-2); nc, no 
change; nd, no data. U  - transcript levels undetectable. hfOBX, X-cocultured hfOB; # , transcript upregulated by 
TGFβ. p < 0,05 
 
 
Entrez 
GeneID 
Gene 
Symbol 
Gene Product hfOBPC3  
48 h 
hfOBLNCaP 
48 h 
hfOBC4-2B4 
48 h 
hfOBHeLa 
 48 h 
hfOBIMR90 
48 h 
hfOB 
+insert  
48 h 
650 BMP2 bone morphogenetic 
protein 2 
    
nc nc 
860 CBFA1 core binding factor 1    nc nc nc 
3570 IL6R interleukin 6 receptor     U  
9241 NOG noggin      nc 
 
4982 OPG # osteoprotegerin      nc 
6696 OPN # osteopontin       
 
249 AP alkaline phosphatase nc nc nc nc nc nd 
632 OC osteocalcin nc nc nc nc nc nd 
8600 RANKL receptor activator of nuclear 
factor kappa B ligand nc nc nc nc nc nd 
 
 
To further address the possibility that medium exhaustion could be affecting the 
expression changes seen in osteoblasts after coculture, the levels of selected transcripts from the 
bone regulon and the TGFβ signaling pathway were also compared between hfOB after 24 and 
48 h of monoculture. The observed changes did not tally with the changes caused by coculture 
with prostate cancer cells.  Only 4 transcripts out of 16 were significantly affected; the short 
period of culture at 37oC appeared to increase the expression of AP, COL1A1 and IL6 in hfOB 
and downregulate OPG (Fig. 24). 
Significantly, the levels of three transcripts became elevated in osteoblasts after coculture 
with all three prostate cancer cell lines, but not with HeLa or IMR-90. These transcripts, 
potentially having a special importance for prostate cancer metastasis, were CBFA1, NPPB and 
PLAUR. 
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Fig. 23 Transcription alterations of OPG and RANKL in osteoblasts cocultured with prostate cancer cells. 
Error bars represent the mean ± SD of at least three independent determinations. *** p<0,0001 
 
 
 
 
A.                                                                   B. 
Gene Symbol Expression change  
- 48h vs. 24h 
AP  (+5,44)*** 
COL1A1  (+2,19)** 
OPG  (-3,45)*** 
IL6  (+3,16)*** 
 
** p<0,01; ***p < 0,001 
CK2B
hfOB 
24 h
hfOB 
48 h
0
5
10
15
20
25
[C
t]
 
 
Fig. 24 Differences in gene expression between osteoblasts after 24 h and 48 h of growth in monoculture. (A) 
Osteoblast-specific genes and signaling pathway components. qRT-PCR data, expressed as the ratio to CK2B 
mRNA, were compared for the following 16 genes: BMP2, CBFA1, AP, COL1A1, OPN, OPG, RANKL, DKK1, 
NOG (bone regulon); TGFB1, TGFBR1, TGFBR2, SMAD3, SMAD7 (TGFβ signaling); IL6, IL6R. Genes not 
included in the table remained unaltered. , fold change ≥ 2; , fold change ≤ 0,5 (-2); (B) CK2B mRNA 
levels in osteoblasts after 24 h and 48 h. 
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3.2.3. Universal osteoblast responses – both osteolytic and osteoblastic prostate 
cancer cells suppress proliferation, but to different extents. 
To explore the question whether prostate cancer cells exert negative effects on osteoblast 
proliferation as the expression data seem to suggest, and whether osteolytic PC3 and osteoblastic 
C4-2B4 cells differ in their effect, hfOB cells were treated for 72 h with CM from these cell 
lines in varying concentrations, containing 5% FCS. The MTT assay was used to quantify 
viable, metabolically active cells. It was found that factors released by both cell lines and active 
in CM inhibited hfOB proliferation - to ca. 60% of the control in the case of PC3 and ca. 80% of 
the control in the case of C4-2B4. Thus, the upregulation of negative cell cycle regulators and 
repression of proliferation factors seen in array data appears to have the expected functional 
consequences. Both prostate cancer cell lines negatively influenced hfOB proliferation, but the 
effect of PC3 was stronger and this difference was statistically significant (Fig. 25A). 
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Fig. 25 Secretomes of different cancer cell lines differ in the extent of their effect on osteoblast proliferation. 
(A) Effect of medium conditioned by prostate cancer cells on osteoblast proliferation after 72 h. Cell viability 
was determined using the MTT test.  Error bars represent the mean ± SD of at least three independent 
determinations. (B) SDS-PAGE gel of secreted proteins from osteoblasts and prostate cancer cell lines.  
Cells: 1,  hfOB; 2, PC3; 3, LNCaP; 4, C4-2B4. Orange arrows indicate protein bands of ca. 54 and 24 kDa present 
in PC3 CM, but not LNCaP CM or C4-2B4 CM. 
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Importantly, the secretome of PC3 cells differs significantly from the secretomes of 
LNCaP and C4-2B4. Already a simple 1D SDS-PAGE gel shows differences in the band pattern 
(Fig. 25B). In a project aimed at identifying the factors responsible for the osteolytic properties 
of PC3, the proteins with an apparent molecular weight of ca. 54 and 24 kDa which are secreted 
in high amounts by PC3, but not by LNCaP or C4-2B4, could be interesting candidates to 
consider.  
 
 
3.2.4. Cell type-specific osteoblast responses - osteolytic and osteoblastic prostate 
cancer cell lines may have differing effects on the osteoblast transcriptome.  
As Fig. 19 shows, some gene expression changes were selectively caused in osteoblasts by 
only one prostate cancer cell line, but not by the others. Since the prostate cancer lines used 
produce different types of bone lesions in immunocompromised mice, we hypothesized that 
these selectively induced transcriptional alterations may give an insight as to the early 
molecular events that ultimately give rise to differing metastasis phenotypes - impaired 
osteoblast differentiation in the case of osteolytic lesions, enhanced osteoblast differentiation 
in the case of osteoblastic ones. Since LNCaP causes mixed-type metastatic bone lesions in 
the nude mouse model, a comparison of expression alterations between osteoblasts 
cocultured with the osteolytic PC3 and the osteoblastic C4-2B4 appeared to be particularly 
appropriate to get hints as to expression patterns possibly specific for an osteolytic and an 
osteoblastic metastasis phenotype.  
The osteolytic PC3 line caused relatively dramatic gene expression changes in osteoblasts 
as opposed to rather moderate changes caused by the osteoblastic C4-2B4; 110 and 18 genes 
became selectively affected by PC3 and C4-2B4, respectively (see Fig. 19). Table 10 provides a 
compilation of genes altered ≥ 2-fold only by PC3 or by C4-2B4, ordered into functional groups 
on the basis of information from the databases Entrez Gene and PubMed (see Materials and 
methods 2.3.4).    
The genes affected in osteoblasts exclusively by PC3 cells appeared to strengthen stress 
response and further suppress proliferation, as indicated by the upregulation of genes encoding 
stress response molecules ITPR1, SH3BP5 and TNFRSF1B and the inhibitor of cell proliferation 
CDKN1C, as well as the downregulation of numerous genes associated with DNA replication, 
transcription and cell division, such as CDK5 and MNAT1, linked to cell cycle control, GINS3, 
encoding a molecule necessary for DNA replication, and GTF2A, ILF3 and POL3RK, linked to 
RNA synthesis. Several genes involved in protein synthesis and modification were also 
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downregulated, fitting in with this picture. Further effects caused in osteoblasts by PC3, but not 
C4-2B4, included the up- or downregulation of genes encoding a number of transcription 
factors, cell surface receptors, cytokines, signaling mediators and molecules involved in 
transport, as well as metabolic enzymes and structural proteins. Interestingly, among the 
signaling pathway components selectively upregulated by PC3 cells were genes encoding two 
activators of NF-κB signaling (RIPK4, SQSTM1) and two NF-κB target genes (NFKBIA, 
SOD2). 
In contrast to the quite dramatic alterations induced by PC3, C4-2B4 cells only 
downregulated a handful of genes (Tab. 10). Among these were TXNIP, ELF1, EXOSC2 and 
STX16, encoding an apoptosis mediator, a transcription factor and two molecules 
participating in vesicle transport respectively, as well as AMD1 and SPTLC2, which encode 
two anabolic enzymes - one participating in the biosynthesis of polyamines, the other of 
sphingolipids. None of these molecules have previously been described as playing a role in 
osteoinductive processes. 
 
 
Tab. 12 Transcription alterations in osteoblasts cocultured with prostate cancer cells. TGFβ signaling 
pathway. qRT-PCR data (no expression changes seen in array, or undetectable signal). Shown are the means of 
expression alterations in comparison to noncocultured hfOB, from at least three independent determinations. 
, fold change ≥ 2; , fold change ≥ 1,45; , fold change ≤ 0,69 (-1,45); , fold change ≤ 0,5 (-2);  
nc, no change; nd, no data. hfOBX, X-cocultured hfOB; # , transcript upregulated by TGFβ. p < 0,05 
 
 
Entrez 
GeneID 
Gene 
Symbol 
Gene Product hfOBPC3  
48 h 
hfOBLNCaP 
48 h 
hfOBC4-2B4 
48 h 
hfOBHeLa 
 48 h 
hfOBIMR90 
48 h 
7040 TGFB1 transforming factor beta 1 nc nc nc nc  
7046 TGFBR1 transforming factor beta 
receptor I 
nc nc nc nc nc 
4087 SMAD2 SMAD family member 2 nc nc nc nd nd 
4088 SMAD3 SMAD family member 3  nc nc nc nc 
4092 SMAD7 SMAD family member 7  nc nc nc nc 
 
 
Together, these results suggest that at a very early stage of metastasis formation, osteolytic 
cancer cells perturb osteoblast function much more strongly than osteoblastic ones, although the 
data for individual genes must be interpreted with caution due to limited sensitivity of the array. 
Data verification and extension by qRT-PCR showed that, although on the array the levels of 
some transcripts appeared to change in osteoblasts cocultured only with one prostate cancer cell 
line, these genes in fact became altered in all three coculture combinations (ACTB, EGFR, IL6, 
SP3, STMN1). Nonetheless, it could be shown using qRT-PCR that various gene expression 
changes were indeed selectively induced by one or two prostate cancer cell lines (Fig. 21, Tab. 
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12). FOXO3 and NPPB became upregulated after 48 h in osteoblasts due to coculture with 
PC3 and C4-2B4, but not LNCaP, whereas SQSTM1, SMAD3 and SMAD7 were upregulated 
after 48 h only by PC3 cells. Also the extent of expression alterations might indicate 
selective effects, e.g., a slight upregulation of NPPB occurred after 24 h due to LNCaP, 
whereas C4-2B4 and, especially, PC3 cells caused a pronounced effect (Fig. 22). Thus, the 
possibility of determining an early transcriptional footprint (for in vivo footprints see 
Eisenberger et al., 2008) of osteolytic vs. osteoblastic metastasis in osteoblasts reacting to 
factors secreted by cancer cells presents an interesting ground for further study. A full list of 
the genes altered significantly in only one coculture combination on the array can be found 
as Supplementary  Data.  
 
 
3.2.5. The effect of prostate cancer cells on IL6 production by osteoblasts can depend 
on the experimental model. 
IL6 transcript levels dropped to ca. 15-20% of the control in hfOB after 48 h of coculture 
with PC3, LNCaP or C4-2B4 (Fig. 21B). Yet a study published in 2002 by Garcia-Moreno et al. 
has described increased production of IL6 by osteoblasts treated with medium conditioned by 
PC3 cells [Garcia-Moreno et al. 2002]. The discrepancy in results may be due to the fact that 
these investigators conducted their experiments in a FCS-free setting, while the coculture model 
described here involves growing cells with medium containing 10% FCS. Treating FCS-starved 
cells with conditioned medium is a popular experimental model [Blaszczyk et al. 2004, Lu et al. 
2004 and others], but the presence or absence of FCS is often discussed as the reason for varying 
results reported by different laboratories.  
It was confirmed that IL6, which became strongly downregulated both on mRNA (Fig. 
21B) and on protein level (Fig. 26A) in osteoblasts cocultured with prostate cancer cells with 
10% FCS, indeed did become upregulated on the mRNA level in osteoblasts treated with FCS-
free medium conditioned by PC3 or LNCaP cells (Fig. 26A). Garcia-Moreno et al. reported very 
low IL6 secretion by PC3, but the PC3 cells used here secreted high amounts of this cytokine 
(Fig. 12A), so in assays involving the protein level, hfOB were treated with conditioned medium 
from the LNCaP line, which secretes almost no IL6. While IL6 intracellular levels remained 
unchanged in hfOB treated with LNCaP-CM (Fig. 26B), a significant increase in secreted IL6 
protein could be seen (Fig. 26C), mirroring the results obtained by Garcia-Moreno et al. in 
osteoblasts treated with PC3-CM. However, data from the coculture model are probably more 
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representative of the in vivo situation, since FCS deprivation creates additional strong stress for 
osteoblasts. 
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Fig. 26 The effect of prostate cancer cells on IL6 production by osteoblasts can depend on the experimental 
model. (A) IL6 mRNA levels in osteoblasts after treatment with CM from prostate cancer cells. (B) IL6 
intracellular protein levels (normalized to CKIIβ) in osteoblasts in the insert coculture system and after 
treatment with CM from prostate cancer cells. (C) IL6 secretion by osteoblasts after treatment with CM 
from prostate cancer cells. Error bars represent the mean ± SD of at least three independent determinations.  
* p < 0,05; ** p < 0,01; *** p < 0,001 
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3.2.6. BNP may be potentially relevant in prostate cancer bone metastasis. 
The NPPB gene encodes the precursor of the brain natriuretic peptide (BNP), a member of 
a family of three natriuretic peptides, which play a crucial role in cardiovascular and renal 
homeostasis [Woodard & Rosado 2007]. BNP overexpression in mice causes increased 
endochondral ossification and skeletal overgrowth [Chusho et al. 2000]. NPPB is one of the 
transcripts that became upregulated in hfOB after coculture with PC3, LNCaP or C4-2B4, but 
not with the non-prostate cell lines HeLa or IMR-90 (Fig. 21A). 
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Fig. 27 NPPB expression by prostate cancer cells and osteoblasts. (A) NPPB mRNA levels in osteoblasts after 
treatment with CM from prostate cancer cells. (B) Changes in NPPB mRNA expression in prostate cancer 
cells after coculture with osteoblasts. (C) Steady-state levels of NPPB mRNA in osteoblasts and prostate 
cancer cells.  Error bars represent the mean ± SD of at least three independent determinations. * p < 0,05; ** p < 
0,01; *** p < 0,001 
 
 
NPPB became significantly elevated in osteoblasts after only 24 h of coculture with all 
three prostate cancer cell lines, but especially with PC3 (Fig. 23) and the effect was still evident 
after 48 h in hfOBPC3 and hfOBC4-2B4(Fig. 21A). Treatment with prostate cancer cell-conditioned 
medium in a FCS-free setting similarly enhanced the expression of this transcript (Fig. 27A). 
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Even more interestingly, NPPB became strongly upregulated in all three prostate cancer cell 
lines after coculture with hfOB (Fig. 27B) and the osteotropic C4-2B4 cells showed a much 
higher steady-state expression of NPPB mRNA than the parental line LNCaP (Fig. 27C). These 
early results suggest a potential importance of BNP in the skeletal metastases of prostate cancer. 
There are 3 receptors for natriuretic peptides: NPR (natriuretic peptide receptor)-A, NPR-
B and NPR-C, also known respectively as GC (guanylyl cyclase)-A, GC-B and GC-C. GC-A 
and GC-B have guanylyl cyclase activity and mediate most biological effects of the ligands, 
while GC-C is implicated in biological clearance of the ligands (negative feedback mechanism). 
BNP binds to GC-A with high affinity, but also with lower affinity to GC-B [Waschek 2004]. 
The Affymetrix array showed that hfOB express the mRNA for GC-A, GC-B and GC-C, and the 
levels of those transcripts did not become altered after crosstalk with prostate cancer cells (data 
not shown). Thus, hfOB are potentially responsive to BNP both in the absence and in the 
presence of prostate cancer cells. 
The NPPB promoter has been cloned and characterized [Weidemann et al. 2008]. In silico 
analysis (TESS) of the NPPB promoter (Fig. 28) showed potential binding sites for the 
transcription factor HES1, which according to the array data becomes strongly upregulated in 
hfOB after coculture with prostate cancer cells (Tab. 9), as well as 3 putative binding sites for 
IRF1/2 and 1 putative binding site for C-EBPβ, two known downstream targets of IL6 signaling. 
Interestingly, NPPB is induced most strongly in osteoblasts cocultured with PC3 cells, which 
secrete very high levels of IL6. The NPPB promoter also contains hypoxia-responsive, HIF1α-
binding elements, characterized by Weidemann et al. [Weidemann et al. 2008] as well as 
putative binding sites for transcription factors inducible by the WNT-β-catenin pathway. 
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Fig. 28 In silico analysis of the NPPB promoter sequence - GenBank accession number AB084517. Potential 
transcription factor binding sites are listed along with the upstream signaling pathways known to activate those 
transcription factors.  
 
 
Blue - Putative hypoxia response elements (HREs): RCGTG (R = purine) [Weidemann et al. 
2008] 
Green - Putative transcription factor binding sites (TESS analysis) 
TIS - Transcription initiation site [Weidemann et al. 2008] 
 
 
 
 
                                HES1 
1 aagcttgctt tttgtagaaa caccttgtga tcaccctggc agtgattatg agcttcaggt ctggaatcag actgctggct 
                                                                    AP-1   
81 agactaatca gactggttag aatccaggat ttatcatgtg tcaattgtgt gacttttgga aagtagatta attcatgaac 
                                 IRF1/2 IL6                                                                      TBP 
161 accatttcct cctctgaagt gaggaataat aaccgtgctt ttctcacctc aggggcagat gctatttttt aggcaagatc 
241 tgcttagagg tcccagtttc ttattgctgc ccttctctgc tgtaactctt ctcccctcat agacagctcc actcctccag  
                                                                         AP-1                                           TBP 
321 cctgctgctt gttgacacca attctctgga aggggagtga catcagtcat atatgcttta ggggggtatt taagctgcta  
                                                    AP-1, Sp1TGFβ, IRF1/2 IL6   
401 tgactcttct caggggcatt tctctccaaa gtctcacttc taatcaccag gccacctgct aatgataatt agatcatggg 
 
481 tggtcagatg aaggaggcac tgggagaggg gaaatcccca tatctctggt atcccagcaa atagataacc atcattccag                                                   
               TCF-4E Wnt/β-catenin    
561 ccatcctttt gttttctttc tttctttctt tctttctttc cttctttctt tctttctttt ttcgctctct gtcaaccagg ctggagtgca 
             HRE                                                              IRF1/2 IL6 
651 gtggcgtgat ctcagctcac tgcaacctcc acctcctggg ttcaagtgat tctccttcct cagcctcccg agtagctggg  
 
731 actacaggcg cctgccacca tgcccagcta atttttggta attttagtag agacggggtt tcaccgtggt ctcgatctcc  
              HES1                   TCF3 Wnt/β-catenin                                               TCF-4E Wnt/β-catenin    
811 tgacctcgtg atccgaccgc ctcggcctct caaagtgctg ggattacagg cgtgaaccac catgcccagc ctatcctttt  
                                                                                     HRE 
891 gttttccatc ctgtgttggc ttggtggggg agaggaggtg ttgacacgtg gaggacacac atataaggca ttcttgggtg 
 
971 acttcgtcat cactggaccc tatctctcaa aattccagcg aaatctgctc ttccctttaa ggagtgaaag aagggtcagc  
________________________________________________________3. Results 
 98 
                                                                                      AP2 
1051 attccagaag ttcctggtca tacccaggct tttaatgaat tgccactggg gaatcagcat cccgttgctg taaggactat  
                                                                                                              HRE 
1131 aagatggcgg attgtgagag catagggaaa ggtctcggag gtctcttgtc cttgctccac gcaggtcttt ctggcctgaa 
 
1211 aatcccgttg aagagagcag ctcttgagag tttgctccaa gttccctcgg ggtgatcagc accacggaca  
                                    HIF ancillary sequence -492    Main hypoxia-responsive HRE -466   
1281 cgcccccgag gacccgcagg caggcagggt gcacagcggc gagcaggtgc tgcgctacgt gcgggccagg 
                                Sp1TGFβ                                                                                      AP-1 
1351 gaactcgcgc ggggagggga gaggcgccgc gggtggcggg gtcttggccg gggctgtttt cgctgtgagt  
                                              HRE                                                         C/EBPβ IL6 
1421 caccccgtgc tccccgcgct cacgtcggtc ctcggaaagc cggggtcctc cctgcctttt ccagcaacgg                                                                          
1491 tggggtgggg aggcaggaag aaagcgccaa cctaggacac ctggacattt gcaggaaagg aagaagcggg 
 
                                                                                                                    TBP 
1561 agacggggac ttgtctgtgt ctccagcgcg ttcctgcccc ccggcccgac ccggcccatt tctatacaag 
                                                       HRE                     Sp1TGFβ     
1631 gtcggctctg cccggtctcc acctcccacg tcgcaggcgc ggaggggctc attcccgggc cctgatctca           
1701 gaggcccgga atgtggctga taaatcagag ataaccctgc atggcagggc aggcccgaca ctcagctcca  
                                                                        +1 
1771 ggataaaagg ccacggtgtc ccgaggagcc aggaggagca ccccgcaggc tgagggcagg tgggaagcaa 
                                                                       
TIS                       
1841 acccggacgc atcgcagcag ctgcagcagc agcagaagca gcagcagcag cctccgcagt ccctccagag 
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4. Discussion 
 
4.1. Bone metastasis - the significance of “seed-soil” interactions and 
validity of the in vitro model. 
The formation of skeletal metastases is a site-specific multistep series of events, dependent 
on peculiar properties of tumor cells and on supportive factors present in the microenvironment 
of the metastatic site. It has long been known that the skeleton presents a particularly hospitable 
terrain for the spread of tumors such as prostate cancer. Elucidation of the molecular 
mechanisms that stand behind prostate cancer metastasis to bone is essential for the development 
of new therapeutic approaches. 
To explain non-random patterns of metastasis, in 1889 Stephen Paget proposed the 
hypothesis, still valid today, that metastases form when the tumor cells (“seeds”) and the target 
organ (“soil”) are compatible [Fidler 2003]. Metastatic cancer cells require properties that allow 
them not only to adapt to a foreign microenvironment but to subvert it in a way that is conducive 
to their continued proliferation and survival [Bacac & Stamenkovic 2008]. Many studies have 
underscored the importance of the bone microenvironment, and especially of osteoblast-derived 
factors, in the establishment of prostate cancer metastases [Logothetis & Lin 2005]. Factors 
produced by osteoblasts stimulate prostate cancer cell growth, chemotaxis and expression of 
matrix proteases, regulate migration, modulate adhesion properties, enhance survival and may 
reduce sensitivity to apoptosis induced by cytostatics [Lang et al. 1995, Festuccia et al. 1999, 
Jacob et al. 1999, Shulby et al. 2000, Tenta et al. 2005].  
The experiments presented here focus on the role of paracrine interactions between 
metastasizing prostate cancer cells and bone cells. The human cell lines used are widely utilized 
by researchers and well described. The human fetal osteoblast line hfOB 1.19 [Harris et al. 1995] 
expresses osteoblast-characteristic genes, as confirmed by qRT-PCR. Knerr et al. (2004) have 
shown that the transcriptional alterations induced in prostate cancer cells by crosstalk with hfOB 
cells closely resemble those induced by crosstalk with primary osteoblasts isolated from mouse 
calvariae. The prostate cancer cell lines LNCaP, C4-2B4 and PC3 can be considered 
representative of different stages of human prostate cancer. Clinically, the lethal phenotypes of 
this malignancy are characterized by their progression to androgen independence and propensity 
to form skeletal metastases [Thalmann et al. 2000]. The bone metastases observed in prostate 
cancer patients are predominantly of a mixed osteoblastic-osteolytic type, where overall bone 
remodeling is increased, but bone formation exceeds bone resorption [Keller & Brown 2004].  
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The LNCaP line, derived from a lymph node metastasis, is androgen-responsive 
[Horoszewicz et al. 1983]. PC3, derived from a bone metastasis, is androgen-independent 
[Kaighn et al. 1979] and C4-2B4, a subline of LNCaP isolated from a bone metastasis after 
rounds of serial selection in immunocompromised mice, is androgen-independent as well 
[Thalmann et al. 2000]. When injected into immunocompromised mice, LNCaP cells form 
tumors at the injection site, but have a low propensity for growth in bone. After intraosseal 
injection of LNCaP into immunocompromised mice, researchers have reported either generation 
of tumors that later spontaneously regressed [Soos et al. 1997] or a complete lack of growth in 
bone [Fisher et al. 2002]. LNCaP cells are, however, able to colonize fragments of human bone 
implanted into severe combined immunodeficient (SCID) mice, in the so-called SCID-hu model 
[Nemeth et al. 1999], forming mixed osteoinductive-osteolytic lesions. In contrast, both C4-2B4 
[Thalmann et al. 2000] and PC3 cells [Soos et al. 1997, Nemeth et al. 1999, Fisher et al. 2002] 
have an enhanced propensity for bone homing and colonization, as shown in vivo in mouse 
models. C4-2B4 form osteoblastic lesions [Thalmann et al. 2000], whereas PC3 form osteolytic 
lesions and have a high invasive capability, infiltrating the bone marrow, bone and surrounding 
soft tissues [Soos et al. 1997, Fisher et al. 2002]. It has not been determined whether these cell 
lines are derived from subpopulations of cancer cells with osteotropic qualities resulting from 
mutations within the primary tumor, or whether their aggressive phenotype evolves as a result of 
interactions with the bone microenvironment. Possibly both mechanisms play a part. 
The in vitro model used here only investigates soluble factor-mediated crosstalk between 
two cell types. It takes into account neither the mechanistics of metastasis nor the complexity of 
interactions at the metastatic site in the organism, where multiple cell types influence each other 
via soluble molecules and adhesive contact. However, it has been utilized by researchers before 
and proven to reflect, to a degree, processes that take place in vivo [Yang et al. 2001, Knerr et al. 
2004]. The altered patterns of gene expression described here also conform to data from 
published in vivo studies, as discussed below. 
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4.2. Modulation of the prostate cancer cell phenotype by the osteoblast 
secretome - an early step on the path to skeletal metastases. 
4.2.1. Osteomimicry is induced in prostate cancer cells by crosstalk with osteoblasts 
and may facilitate cancer cell survival in bone. 
It has been proposed that interaction with osteoblasts enables metastasizing prostate cancer 
cells to assume an osteomimetic, or bone-like phenotype, which aids their survival and growth in 
bone [Koeneman et al. 1999]. It has also been demonstrated that crosstalk solely through soluble 
factors is sufficient to induce gene expression changes in both prostate cancer cells and 
osteoblasts [Yang et al. 2001, Pinski et al. 2001, Zayzafoon et al. 2004]. A study by Knerr et al. 
(2004) has shown that osteoblast-released factors alter the adhesive properties of prostate cancer 
cells, suppress their proliferation and induce osteomimicry.  
The data presented here indicate that the expression of multiple bone-associated genes by 
prostate cancer cell lines is either constitutively high or becomes induced after coculture with 
osteoblasts or exposure to osteoblast-conditioned medium. In the LNCaP line, which represents 
an early stage of prostate cancer, osteoblast-released factors elevated the expression of genes 
such as COL1A1, OPG, RANKL and NOG, which are constitutively highly expressed in the 
osteotropic, bone metastasis-derived cell lines C4-2B4 and PC3. It appears that the osteomimetic 
phenotype induced by exposure to the osteoblast secretome is permanently enforced in cancer 
cells derived from bone metastases. This is in line with findings from a microarray study 
showing that osteoblast-derived factors induce a gene expression pattern in non-metastatic 
cancer cells similar to that found in prostate cancer cells derived from bone metastases [Fu et al. 
2002]. C4-2B4 cells showed a significantly higher baseline expression of AP, COL1A1, OPG, 
RANKL and NOG than their parental line LNCaP, matching a report by Lin et al. (2001) that 
characterized C4-2B as possessing osteoblast-like traits. Moreover, expression of genes 
characteristic of osteomimicry is not restricted to the osteoinductive phenotype in prostate cancer 
cell lines, as the osteolytic PC3 line expressed high levels of BMP2, CBFA1, COL1A1 and OPG. 
However, PC3 also showed a high baseline expression of DKK1 and NOG, which inhibit bone 
formation, whereas baseline expression of DKK1 and NOG in the osteoblastic LNCaP and C4-
2B4 was very low. These data match recent reports that DKK1 and NOG are highly expressed by 
osteolytic cancer cell lines, but not osteoinductive ones, and may be an important determinant of 
the type of metastatic lesions induced in bone [Hall et al. 2005, Schwaninger et al. 2007, Dai et 
al. 2008]. 
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The expression of bone-specific proteins by malignant cells could aid bone colonization in 
many ways. Results presented here show that osteoblast-released factors induced prostate cancer 
cells to express elevated levels of mRNAs such as BMP2, AP, COL1A1, OPN, RANKL and 
OPG. The molecules coded by these mRNAs may facilitate bone metastasis by various 
mechanisms. BMP2 has been shown to stimulate prostate cancer cell migration and invasion, and 
to promote the formation of osteoblastic lesions in mouse tibia [Feeley et al. 2005]. Elevated 
levels of COL1A1 and OPN mRNA have been found in tumors induced by intratibial inoculation 
of PC3 cells in immunocompromised mice [Fisher et al. 2002]. Adhesion to type I collagen 
increases the proliferative capacity of the PC3 line, and may facilitate the colonization and 
growth of prostate cancer cells in the bone microenvironment [Kiefer et al. 2001]. OPN, an 
acidic adhesive glycoprotein, promotes cell motility, invasion and survival. Its role in tumor 
progression and metastasis is well documented [Rangaswami et al. 2006]. OPN may act as a 
paracrine and autocrine mediator of prostate cancer progression, enhancing the proliferative and 
invasive capacity of the cancer cells, as shown by studies using neutralizing antibodies 
[Thalmann et al. 1999] and protein overexpression [Khodavirdi et al. 2006].  
RANKL and OPG, too, are strongly implicated in the pathogenesis of bone metastases 
[Wittrant et al. 2004, Blair et al. 2005]. Analysis of surgical biopsy specimens showed that 
expression of both these molecules correlates with more aggressive, advanced, metastatic 
prostate cancer. Furthermore, bone metastases were consistently immunoreactive for OPG and 
RANKL compared with nonosseous metastases or primary tumors [Brown et al. 2001, Chen et 
al. 2006]. RANKL stimulates bone resorption, which has been postulated as a prerequisite for 
the successful seeding of tumor cells into bone and their development into secondary lesions 
[Keller & Brown 2004]. On the other hand, OPG levels are elevated in the serum of patients with 
advanced prostate cancer [Brown et al. 2001] and OPG can inhibit bone resorption associated 
with prostate cancer bone metastasis, leading to an increase in bone mass [Corey et al. 2005]. 
These findings underscore a possible role for OPG in the development of osteoblastic lesions.  
Moreover, although OPG is a well-known antagonist of RANKL, it not only inhibits 
osteoclastogenesis, but can also promote the survival of cancer cells by binding the tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL) secreted by invading monocytes and 
blocking TRAIL-mediated tumor cell apoptosis [Holen & Shipman 2006]. Such an effect has 
been demonstrated in vitro in prostate cancer [Holen et al. 2002], breast cancer [Holen et al.  
2005] and multiple myeloma [Shipman & Croucher 2003] cells. It has been suggested that 
increased cancer cell survival through the inhibition of TRAIL-induced apoptosis may be a 
mechanism involved in very early metastasis development, when there is only a low number of 
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cancer cells present [Holen & Shipman 2006]. Significantly higher levels of OPG are secreted by 
androgen-independent prostate cancer cells [Holen et al. 2002] and the serum OPG level appears 
to be a strong independent risk factor predictive of prostate cancer-related death [Jung et al. 
2004].  
Importantly, it is the RANKL/OPG ratio that decides whether osteoclast-mediated bone 
resorption becomes stimulated or inhibited [Hofbauer & Heufelder 2001, Hofbauer et al. 2001]. 
In the experimental model described here, expression of RANKL mRNA was low as compared to 
OPG both in prostate cancer cells and in osteoblasts, whereas hfOB expressed much higher 
levels of OPG than any prostate cancer cell line, suggesting that OPG expression by osteoblasts 
might be the factor that has the greatest influence on the overall RANKL/OPG ratio. OPG 
expression in osteoblasts significantly dropped after only 24 h of crosstalk with prostate cancer 
cells, and remained repressed after 48 h; thus, the net result could be an increase in bone 
resorption, regardless of OPG secretion by the cancer cells. The fact that the PC3 line expresses 
OPG at a high level also suggests that the osteoprotective effect of cancer cell-secreted OPG can 
be negated by other concurrently secreted factors.  
Since the concentrations of secreted RANKL and OPG were not measured, it is not 
possible to say, at this stage, how their overall ratio changed as a result of prostate cancer cell 
crosstalk with osteoblasts. However, it can be hypothesized that OPG levels become locally 
elevated in the vicinity of OPG-secreting cancer cells in the bone marrow, protecting them from 
apoptosis induced by immune system cells [Holen et al. 2002, Shipman & Croucher 2003, Holen 
et al. 2005]; thus, OPG upregulation in cancer cells might contribute to disease progression 
regardless of the net RANKL/OPG ratio in the bone microenvironment and its effect on 
osteoclasts.  
In sum, osteomimicry caused by exposure to osteoblast-released factors appears to be an 
example of adaptive changes induced in cancer cells by their microenvironment, leading to 
increased cancer cell survival and growth. 
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4.2.2. The first response of prostate cancer cells to the osteoblast secretome involves 
intensified IL6 and TGFβ signaling, which may participate in the induction of 
osteomimicry. 
When prostate cancer cells metastasize to bone, they encounter an environment rich in IL6 
and TGFβ1. Both IL6 and TGFβ signaling have been linked to prostate cancer progression. 
 
 
 
 
 
 
Fig. 29 Alterations in TGFβ and IL6 signaling in prostate cancer cells exposed to osteoblast-released factors.  
Model based on qRT-PCR data. Red - molecules elevated in LNCaP exposed to osteoblast-released factors AND in 
osteotropic cell lines C4-2B4 and/or PC3 as compared to LNCaP. Orange - molecules elevated in LNCaP exposed 
to osteoblast-released factors. 
 
 
The osteomimetic molecule OPG has been described as a TGFβ-inducible gene, and the 
TGFβ-responsive sites in its promoter have been mapped [Thirunavukkarasu et al. 2001]. IL6 
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has also been shown to increase OPG expression in osteoblasts [Palmqvist et al. 2002]. The data 
presented here demonstrate that IL6 and TGFβ1 are abundantly expressed and secreted both by 
osteoblasts and by the PC3 prostate cancer cell line, which has a high constitutive expression of 
OPG. In LNCaP cells, which represent an early stage of prostate cancer, osteoblast-released IL6 
and TGFβ1 upregulate OPG mRNA, and furthermore, crosstalk with osteoblasts increases the 
expression of these factors and of their receptors (Fig. 29). The net result could be an increased 
propensity for survival in bone. 
IL6 is a pleiotropic cytokine involved in immune responses. It regulates the proliferation, 
apoptosis, angiogenesis and differentiation of various cell types. IL6 binds to its specific 
receptor, IL6 receptor alpha (IL6Rα), an 80 kDa glycosylated transmembrane protein belonging 
to the cytokine receptor superfamily. The activated IL6Rα interacts with gp130, a 
transmembrane cytokine receptor capable of signal transduction through the Janus kinase/signal 
transduction and activator of transcription (JAK/STAT), mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol-3 kinase/Akt (PI3K/Akt) pathways [Kamimura et al. 2003, 
Heinrich et al. 2003]. 
IL6 is an established marker of morbidity in metastatic prostate cancer and a candidate for 
targeted therapy [Drachenberg et al. 1999, Shariat et al. 2001]. This cytokine can act on prostate 
cancer cells both through its own receptor and through the androgen receptor (AR), contributing 
to androgen independence [Culig et al. 2002, Culig et al. 2005]. The concentrations of IL6 and 
IL6R are dramatically elevated in prostate cancer tissues [Giri et al. 2001]. IL6 is a positive 
growth factor for many prostate cancer cell lines, with the exception of IL6-negative LNCaP, in 
which treatment with exogenous IL6 causes growth arrest [Culig et al. 2005]; however, 
ectopically expressed IL6 stimulates cell growth in LNCaP [Lou et al. 2000] and chronic 
treatment of IL6-negative LNCaP cells with exogenous IL6 triggers a positive feedback, 
turning it from a paracrine growth inhibitor to an autocrine growth stimulator [Hobisch et al. 
2001, Lee et al. 2007]. It has been suggested that IL6 undergoes such a functional transition 
during progression of prostate cancer to the androgen-independent phenotype [Chung et al. 
1999, Lee et al. 2007]. IL6, both endogenous and exogenous, also protects prostate cancer 
cells from apoptosis [Cavarretta et al. 2006, Wegiel et al. 2008]. IL6 is abundantly produced 
by osteoblasts, and osteoblast-conditioned medium containing this cytokine can promote 
prostate cancer cell proliferation and progression to androgen independence [Blaszczyk et al. 
2004, Lu et al. 2004].  
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IL6 and other IL6-type cytokines stimulate osteoblast differentiation in murine and human 
osteoblastic cell lines [Bellido et al. 1997]. IL6 in collaboration with the soluble form of its 
receptor stimulates the differentiation of committed osteoprogenitors in the bone marrow [Erices 
et al. 2002]. IL6 receptor expression increases during in vitro osteoblast differentiation and IL6 
enhances the expression of osteoblast-specific differentiation markers in proper sequential order 
[Li et al. 2008b]. 
TGFβ signaling controls a diverse set of cellular processes, including cell proliferation, 
migration, differentiation and apoptosis. TGFβ, the founding member of the TGFβ superfamily, 
mediates its effects through two serine/threonine kinase receptors, termed the TGFβ type I 
(TGFBR1) and type II (TGFBR2) receptors. Ligand binding to TGFBR2 triggers recruitment of 
TGFBR1 and the formation of an active, heterotetrameric receptor complex [Shi & Massague 
2003, ten Dijke & Hill 2004]. Further propagation of TGFβ signaling can occur through SMAD-
dependent (canonical) or SMAD-independent (noncanonical) pathways [Derynck & Zhang 
2003]. Signaling through the SMAD family of proteins is triggered by phosphorylation of the 
receptor-activated (R-) SMADs, SMAD2 and SMAD3, by TGFBR1. After phosphorylation, R-
SMADs form complexes with the required common mediator SMAD, SMAD4, translocate to 
the nucleus and activate or repress transcription of target genes, functionally interacting with 
many other DNA-binding transcription factors. An inhibitory SMAD, SMAD7, plays an 
essential role in the negative-feedback regulation of TGFβ signaling by inhibiting signal 
transduction at the receptor level. It can interfere with R-SMAD binding to receptors, as well as 
facilitate ubiquitin-mediated degradation of activated TGFBR1 [Moustakas et al. 2001, Shi & 
Massague 2003, ten Dijke & Hill 2004]. 
Three closely related mammalian isoforms of TGFβ exist, known as TGFβ1, -β2, and -β3. 
Of these three, TGFβ1 is the most abundant one, and it is present in high amounts in bone 
[Janssens et al. 2005]. TGFβ1 is highly expressed in prostate tumors and can enhance cancer 
growth and metastasis, once the malignant cells acquire resistance to its antiproliferative and 
proapoptotic effects [Wikstrom et al. 2001]. TGFβ1 overproduction is strongly associated with 
poor clinical outcome in prostate cancer [Wikstrom et al. 1998], and inhibition of TGFβ 
signaling suppresses progression of androgen-independent human prostate cancer in 
immunocompromised mice [Zhang et al. 2005b]. In an in vivo model of bone metastasis, TGFβ1 
was shown to stimulate the proliferation of rat prostate cancer cells, osteoclast activation and 
osteolysis [Sato et al. 2008]. Osteoblast-derived TGFβ1 enhances prostate cancer cell 
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chemotaxis, adhesion and their ability to invade bone matrix [Festuccia et al. 1999, Festuccia et 
al. 2000].  
TGFβ1 is the most abundant growth factor in human bone, and affects osteoblast 
differentiation, matrix formation and mineralization. It is stored in the bone matrix in a latent 
form and becomes released and activated upon bone resorption. TGFβ1 inhibits the late 
differentiation of osteoblasts, but stimulates the proliferation and differentiation of osteoblast 
progenitors [Janssens et al. 2005, Kanaan & Kanaan 2006]. It has been shown to activate the 
transcription of genes characteristic for the osteoblast phenotype, such as OPN [Noda et al. 1988, 
Wrana et al. 1991] and OPG [Thirunavukkarasu et al. 2001]. 
Although IL6 and TGFβ1 are a potent example of the common growth factor tropisms 
existing between osteoblasts and prostate cancer cells, an association between these molecules 
and osteomimicry has not been reported in literature. 
The fact that osteoblast-released factors elevate levels of IL6 mRNA in LNCaP is 
particularly interesting in the face of recent reports that directly link the acquisition of autocrine 
IL6 signaling by this cell line with cancer progression [Hobisch et al. 2001, Cavarretta et al. 
2006, Lee et al. 2007]. Osteoblast-released TGFβ1 also appears to increase TGFB1 expression in 
LNCaP, supporting the argument that growth factor tropisms in osteoblasts and prostate cancer 
cells are closely synchronised and a switch from paracrine to autocrine stimulation can easily 
occur. 
The ability of LNCaP cells to respond to TGFβ1 has been controversial, with some 
researchers reporting a lack of sensitivity due to a silenced TGFBR1 [Kim et al. 1996a], while 
others observed sensitivity after growth factor stimulation [Schuurmans et al. 1991]. It has also 
been suggested that LNCaP sensitivity to TGFβ1 could be modulated by androgens such as 
dihydrotestosterone, which affects TGFBR2 expression by this cell line [Kim et al. 1996b]. The 
seemingly contradictory results might be explained by varying promoter methylation status of 
TGFBR1 and TGFBR2 in LNCaP under different experimental conditions, since LNCaP gain 
sensitivity to TGFβ after treatment with demethylating agents [Zhang et al. 2005b].  The data 
presented here show that LNCaP cells express TGFBR1 and low, but detectable amounts of 
TGFBR2 mRNA, and thus are potentially responsive to TGFβ signaling. Both TGFBR1 and 
TGFBR2 become upregulated in LNCaP after exposure to osteoblast-released factors, suggesting 
that factors present in the bone microenvironment may increase the sensitivity of this cell line to 
TGFβ. Enhanced TGFβ signaling has been associated with prostate cancer progression, 
angiogenesis, metastasis and a poor clinical outcome [Wikstrom et al. 1998, Zhang et al. 2005a]. 
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However, in the non-malignant prostate, TGFβ1 inhibits epithelial cell proliferation and induces 
apoptosis, and it has been postulated that prostate cancer cells acquire resistance to its 
antiproliferative and proapoptotic effects by losing their TGFβ receptors [Guo & Kyprianou 
1999, Wikstrom et al. 2001]. Since crosstalk with osteoblasts appears to enhance TGFβ receptor 
expression in prostate cancer cells, presumably other factors present in the bone 
microenvironment render them insensitive to the proapoptotic action of TGFβ1. Such a factor 
might be IL6, capable of exerting an antiapoptotic effect on prostate cancer cells [Cavarretta et 
al. 2006, Wegiel et al. 2008]. 
 
 
 
 
Fig.  30 Development of an osteomimetic phenotype in prostate cancer cells residing in bone. Model 
based on qRT-PCR data. 
 
 
Baseline expression of TGFB1, TGFBR2 and SMAD3, but not SMAD2, was positively 
correlated with the osteomimetic and osteotropic characteristics of prostate cancer cell lines. 
SMAD3, but not SMAD2, became upregulated in LNCaP after crosstalk with osteoblasts or 
exposure to osteoblast-conditioned medium. Although TGFβ activates both SMAD2 and 
SMAD3 in most cells, there is evidence that these two proteins mediate differing transcriptional 
responses and play distinct roles in the pathophysiological effects of TGFβ. E.g. SMAD3 and not 
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SMAD2 is the key mediator of pathogenic effects in fibrosis [Roberts et al. 2003, Brown et al. 
2007]. A hierarchical model of gene regulation by TGFβ has been proposed, where SMAD3 was 
demonstrated to be the critical mediator for expression of immediate-early target genes [Yang et 
al. 2003]. It has been suggested that TGFβ receptors directly activate SMAD3 and that SMAD2 
merely transmodulates the signals [Brown et al. 2007]. Furthermore, SMAD3 appears to play a 
role in bone formation by osteoblasts, as SMAD3 overexpression mimicked the stimulatory 
effects of TGFβ on the expression of bone matrix proteins in a mouse osteoblastic cell line 
[Sowa et al. 2002]. It is tempting to speculate that osteomimicry might be mediated in part by 
TGFβ signaling via SMAD3.  
A model of the molecular events associated with prostate cancer progression in bone, 
based on the experimental data presented here, is shown in Fig. 30. 
Transcript profiling of cells in an in vitro metastasis model makes it possible to study the 
earliest stages of the processes which culminate in the formation of lethal metastatic lesions in 
bone. It appears that osteoblast-released soluble factors trigger osteomimicry in prostate cancer 
cells and this phenotype becomes permanent in cell lines derived from bone lesions. OPG, an 
osteomimetic gene and tumor survival factor, becomes upregulated in prostate cancer cells by 
osteoblast-secreted IL6 and TGFβ1. Furthermore, crosstalk with osteoblasts leads to 
enhancement of autocrine IL6 and TGFβ signaling in prostate cancer cells. These data provide a 
new insight into the role of the bone microenvironment in the progression of metastatic prostate 
cancer. 
 
 
4.3. The osteoblast response to prostate cancer cells - potential 
consequences for the microenvironment and for the whole organism. 
4.3.1. Alterations of the osteoblast phenotype induced by crosstalk with prostate 
cancer cells. 
4.3.1.1. Gene expression pattern suggestive of preosteocytic differentiation. 
A distinctive feature of skeletal lesions in prostate cancer is dysregulated osteoblast 
proliferation and differentiation, leading to increased formation of woven bone. Prostate cancer 
cells secrete multiple factors that perturb osteoblast biology [Keller et al. 2001, Chirgwin et al. 
2004, Keller & Brown 2004, Logothetis & Lin 2005, Virk & Lieberman 2007 and others]. Thus, 
we hypothesized that the transcriptional response of osteoblasts to the secretome of prostate 
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cancer cells might yield an insight into the molecular events that take place at the earliest stage 
of bone metastasis. 
The immortalized human fetal osteoblast line hfOB 1.19 expresses osteoblast-specific 
markers, and provides a suitable model for the study of osteoblast differentiation [Harris 1995]. 
Large-scale transcript profiling of hfOB after coculture with prostate cancer cells has shown 
transcription alterations suggestive of suppressed proliferation together with decreased 
metabolic activity, matrix synthesis and adhesion. Changes in the expression of signaling 
molecules were also observed; there has been evidence for a general repression of TGFβ 
signaling, as well as downregulation of transcripts associated with immune response and 
inflammation. On the other hand, several factors associated with increased osteoblast 
differentiation became upregulated. 
Human osteoblast differentiation can be divided into four stages: preosteoblast, osteoblast, 
preosteocyte and osteocyte. Each stage is characterized by expression of distinct protein markers 
as well as by individual morphological features [Billiard et al. 2003, Franz-Odendaal et al. 
2006]. In a study by Billiard et al. (2003), conditionally immortalized adult human osteoblast 
cell lines representing various stages of differentiation were subjected to transcript profiling and 
provided expression patterns suggesting decreased proliferation and increased apoptosis in 
preosteocytic cells. The levels of transcripts representing the cytoskeleton, extracellular matrix, 
and adhesion regulons also changed. Moreover, dramatic downregulation of several immune 
response factors was observed. These results bear a striking similarity to the transcriptional 
alterations which we find to occur in hfOB cocultured with prostate cancer cells. Among the 
gene expression changes observed by Billiard et al. between the preosteoblastic and 
preosteocytic stage of differentiation was downregulation of COL1A1, COL3A1, CDH11, 
OPG, CTGF, FST, CXCL12 and PTX3; all these alterations were also found to occur in hfOB 
after 48 h of coculture with prostate cancer cells. Thus, it appears that factors released by 
prostate cancer cells may induce osteoblasts to exhibit signs of differentiation towards 
preosteocytes. Significantly, the transformation from osteoblast to osteocyte can take as little 
as 2-5 days in rabbit and rat models [Franz-Odendaal et al. 2006], so the time window of 48 
h could be long enough to observe a gene expression pattern characteristic for preosteocytes. 
Furthermore, the suppression of the TGFβ pathway in hfOB after coculture fits well into that 
picture, since recent investigation by Borton et al. (2001) has suggested that attenuating 
TGFβ-related signaling mechanisms can increase the propensity of an osteoblast to mature 
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into an osteocyte. Further implications of inhibited TGFβ signaling will be discussed in 
section 4.3.4. 
Interestingly, CBFA1, the transcription factor that plays a central role in osteogenic gene 
expression and bone formation [Ducy et al. 2000] became upregulated in osteoblasts cocultured 
with prostate cancer cells. This effect occurred simultaneously with the upregulation of 
transcription factors HES1, known to stimulate osteoblast differentiation by augmenting the 
protein level and activity of CBFA1 [Suh et al. 2008] and SP3, which acts downstream of 
CBFA1 to induce skeletal ossification in mice [Goellner et al. 2001], as well as the 
downregulation of STAT1, which can function as a cytoplasmic attenuator of CBFA1 
[Takayanagi et al. 2005]. These alterations appear to underscore the potential significance of 
elevated CBFA1 expression. Transcriptional upregulation of CBFA1 can also be considered an 
indication of inhibited canonical TGFβ signaling, since it has been reported that TGFβ 
stimulation causes repression of the CBFA1 promoter in osteoblasts, with SMAD3 mediating the 
repressive effect [Alliston et al. 2001]. 
It has been reported that soluble factors released by bone-derived prostate cancer cell lines 
can promote the differentiation of osteoblast precursors through a CBFA1-dependent pathway 
[Yang et al. 2001]. However, in the study by Yang et al., CBFA1 upregulation on the mRNA 
and protein level was observed together with elevated alkaline phosphatase activity and 
increased expression of osteoblast markers, whereas the data presented here indicate that in 
hfOB cocultured with prostate cancer cells, the expression of the main osteoblastic markers other 
than CBFA1 was either unchanged (AP, OC) or downregulated (COL1A1, OPN). Furthermore, it 
has been reported that CBFA1 negatively controls osteoblast terminal differentiation to 
osteocytes, helping maintain cells of the osteoblastic lineage in an immature state [Liu et al. 
2001]. Thus, CBFA1 upregulation in hfOB after coculture with prostate cancer cells does not 
fully fit into a preosteocytic gene expression pattern and would need further study to elucidate its 
implications. 
It has also been reported that prostate cancer cells can promote early osteoblast 
differentiation by activating the sonic hedgehog pathway in preosteoblasts [Zunich et al. 
2009]. It must be noted that the effect of prostate cancer cells on osteoblast differentiation 
may depend on factors such as the initial differentiation stage of the osteoblasts, the 
osteoblast and prostate cancer cell lines used, and other experimental conditions. 
Significantly, another study showed that OPG expression became reduced in primary mouse 
osteoblasts cultured in the presence of prostate cancer cells [Fizazi et al. 2001], and we could 
observe an analogous effect in hfOB, becoming established after only 24 h of coculture. 
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Reduced OPG production by osteoblasts promotes bone resorption by osteoclasts - a crucial 
step in the establishment and progression of skeletal metastatic lesions [Keller & Brown 
2004, Roato et al. 2008, Zheng et al. 2008]; it is also observed in the course of osteoblast 
differentiation to preosteocytes [Billiard et al. 2003]. 
The levels of some transcripts which became altered in hfOB after coculture with prostate 
cancer cells (CDH2, OPN, IL6R) also became slightly altered in hfOB cultured with an empty 
insert. A likely explanation could be that the diffusion of bioactive molecules through the well 
becomes impaired by the presence of a membrane, so the hfOB growing under an insert receive a 
stronger cue to differentiate through autocrine stimulation by the factors they themselves are 
secreting into the medium. The fact that CDH2 became significantly downregulated under these 
conditions after only 24 h suggests that medium exhaustion under the insert is not the cause. 
However, out of 23 surveyed transcripts affected in hfOB by the prostate cancer cell secretome, 
20 were not significantly altered in the presence of an empty insert, so this interfering factor 
apparently has minimal influence on results. 
It was found that many of the transcriptional alterations induced in hfOB by crosstalk with 
prostate cancer cells can also be induced by coculture with the cervical cancer line HeLa or with 
normal lung fibroblasts. Here it must be noted as an important point that, while the factors 
secreted by prostate cancer cells facilitate the development of bone metastases, they do not 
determine bone tropism. The special propensity of prostate cancer cells to arrest, survive and 
grow in bone is thought to stem from mechanisms such as the expression of adhesion 
molecules that facilitate interaction with blood vessel endothelium, extravasation and 
subsequent attachment to the bone matrix, as well as sensitivity to chemotactic cues. In 
particular, chemokine signaling can affect organ-specific metastasis development, depending 
on the profile of chemokine receptors expressed by the cancer cells [Chambers et al. 2002, 
Cooper et al. 2003, Buijs & van der Pluijm 2009]. Once the prostate cancer cells become 
lodged in bone, the local concentration of released bioactive molecules will be much higher 
than their levels in systemic circulation, and the impact on the bone microenvironment 
correspondingly drastic. Thus, although other cell types may secrete factors capable of 
producing the same transcriptional changes in osteoblasts as the factors secreted by prostate 
cancer cells, these changes could still be important in the context of prostate cancer bone 
metastases. 
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4.3.1.2. Potential osteoinductive mechanisms with significance for metastasis. 
Osteoblasts cocultured with all three prostate cancer cell lines expressed increased levels of 
transcripts coding for secreted molecules capable of promoting osteoblast proliferation and 
differentiation, such as ADM, STC1 and BMP2. ADM codes for adrenomedullin (ADM), a 
peptide which acts as a strong mitogen for osteoblasts and increases indices of bone formation 
[Cornish et al. 2003]. STC1 codes for stanniocalcin 1 (STC1), a glycoprotein hormone highly 
expressed in osteoblasts during embryonic mouse osteogenesis [Yoshiko et al. 2002], and 
capable of accelerating osteogenic development in osteoblast colonies [Yoshiko et al. 2003]. 
BMP2 codes for bone morphogenetic protein-2 (BMP2), member of a family of signaling 
molecules that play a pivotal role in skeletal morphogenesis [Wan & Cao 2005] and are essential 
for expression of the osteoblast phenotype [Phimphilai et al. 2006]. BMPs enhance osteoblast 
differentiation and function [Canalis et al. 2003] and appear to contribute significantly to 
dysregulated bone formation in osteoblastic metastases [Feeley et al. 2005, Schwaninger et al. 
2007]; it has been suggested that ADM and STC1 might facilitate this process as well [Chirgwin 
et al. 2004]. Apart from an autocrine effect on osteoblasts, these factors could also promote the 
development of metastatic lesions in other ways as well, e.g. by stimulating the proliferative and 
invasive capacities of the malignant cells and by inducing osteomimicry. It has been shown that 
osteoblast-derived BMP2 enhances prostate cancer cell motility, promoting their migration [Lai 
et al. 2008], while ADM can stimulate the proliferation and invasion of pancreatic cancer cells 
[Ramachandran et al. 2007]. 
A concomitant coculture-induced effect noted in hfOB is the downregulation of genes 
coding for two soluble inhibitors of osteoblast differentiation, FST and DKK1. FST codes for 
follistatin, a TGFβ target molecule [Zhang et al. 1997] that inhibits activin A signaling in 
osteoblasts [Hashimoto et al. 1992] and delays activin-induced endochondral ossification 
[Funaba et al. 1996]. The role of DKK1 in bone and implications of its downregulation are 
discussed in more detail below. In sum, the proposed model would be that in response to factors 
released by prostate cancer cells, differentiated osteoblasts expressing high levels of collagen 
type I shift into the preosteocytic stage, decreasing matrix production. However, they also 
release molecules that stimulate the commitment of mesenchymal stem cells to osteoprogenitors, 
osteoprogenitor proliferation and differentiation into osteoblasts, simultaneously downregulating 
the expression of molecules that inhibit these processes. In effect, osteoblastic differentiation 
becomes increased in the manner typical for prostate cancer metastatic lesions. 
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Fig. 31 Effect of prostate cancer cells on cells of the osteoblast lineage. Model based on array data. 
 
 
A further transcript, PLAUR, became upregulated in hfOB cocultured with prostate cancer 
cells, but not with HeLa or with normal lung fibroblasts. PLAUR encodes uPAR, the membrane 
receptor of urokinase-type plasminogen activator (uPA), a serine protease. Upon binding to its 
receptor, uPA catalyzes the formation of plasmin from plasminogen, initiating a proteolytic 
cascade that contributes to ECM breakdown. The uPA/uPAR system has been implicated in 
multiple biological processes, including angiogenesis, monocyte migration, trophoblast 
implantation and wound healing, as well as in cancer invasion and metastasis [Wang 2001]. It 
has been shown that uPA expression by prostate cancer cells contributes to bone matrix 
degradation and intraosseous tumor growth [Dong et al. 2008] and that uPA stimulates 
osteoblast proliferation [Rabbani et al. 1990]; an increase in uPAR expression by osteoblasts 
would facilitate these processes as well. 
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4.3.1.3. DKK1 in prostate cancer bone metastasis. 
The WNT proteins are a large family of soluble glycoproteins that are essential for normal 
bone development, enhancing osteoblast differentiation, function and lifespan, and thus 
increasing bone mass [Emami & Corey 2007, Krishnan et al. 2006, Yavropoulou & Yovos 2007, 
Milat & Ng 2009 and others]. DKK1, a soluble inhibitor of WNT signaling, blocks osteoblastic 
differentiation and bone formation [Qiang et al. 2008] and may also promote osteoclastogenesis 
by inhibiting OPG transcriptional induction by WNTs [Fujita & Janz 2007]. There is strong 
evidence that DKK1 is one of the key factors mediating the formation of osteolytic lesions of 
multiple myeloma [Tian et al. 2003, Qiang et al. 2008] and metastatic breast cancer [Bu et al. 
2008]. Accordingly, downregulation of DKK1 in osteoblasts, for example by tumor-secreted 
ET1 [Clines et al. 2007], has been proposed as one of the mechanisms that contribute to 
increased bone formation in prostate cancer. Furthermore, evidence exists that DKK1 expression 
by prostate cancer cells can act as a switch that transitions the phenotype of prostate cancer 
metastases from osteolytic to osteoblastic. Prostate cancer cells express WNT ligands and when 
concomitant DKK1 expression is low, the osteoinductive activity of WNTs becomes unmasked, 
leading to increased bone formation at the metastatic site [Hall et al. 2005, Hall et al. 2006, Hall 
et al. 2006b].  
The fact that DKK1 became strongly repressed in hfOB after coculture with prostate cancer 
cells reinforces the possibility that reduced DKK1 expression is a significant factor in the 
development of osteoblastic metastases (Fig. 32). It is worth noting that the osteolytic PC3 cells 
reduced DKK1 expression in hfOB in the same degree as LNCaP and C4-2B4; however, in 
contrast to these osteoinductive cell lines, PC3 itself expresses DKK1 at a high level, 
matching the model put forward by Hall et al. (2006). Conditioned medium from PC3 cells 
has been found to inhibit osteoblast differentiation and bone nodule formation [Kido et al. 
1997].  Interestingly, Hall et al. have proposed that DKK1 is upregulated in primary prostate 
tumors, but as the cancer progresses, DKK1 expression declines, particularly in advanced 
bone metastases, which is corroborated by in vivo data from tissue microarrays  [Hall et al. 
2008]. Hence, the fact that DKK1 expression by PC3 cells decreases after coculture with 
osteoblasts would fit this model. 
DKK1 downregulation in the osteoblastic niche may also have direct implications for the 
cancer cells. The WNT signaling pathway leads to tumor formation when aberrantly activated, 
and WNT signaling is active in many cancers [Giles et al. 2003]. In prostate cancer cells, 
autocrine WNT effects can include enhanced proliferation and protection against apoptosis [Hall 
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et al. 2006]. DKK1 secreted by mesenchymal stem cells has been shown to inhibit cancer cell 
proliferation by blocking WNT signaling [Qiao et al. 2008, Zhu et al. 2009]. Thus, reduced 
DKK1 production by osteoblasts may contribute to making the bone microenvironment more 
conducive to cancer cell growth. However, prostate cancer cells can also gain resistance to 
DKK1 by acquiring constitutive activation of the WNT pathway through mutations in its 
regulatory components leading to increased transcription activation by β-catenin, as is 
commonly the case in colon cancer [Giles et al. 2003]; thus, high autocrine DKK1 expression by 
cancer cells, as exemplified by the PC3 line, does not have to translate into suppressed 
proliferation and survival. 
 
 
 
 
 
 
Fig. 32 A model of the role of DKK1 in determining the phenotype of metastatic lesions in bone. Model based 
on qPCR data and on literature [Hall et al. 2006, Hall et al. 2006b]. A - Osteoblastic/mixed metastasis (LNCaP, C4-
2B4). B - Osteolytic metastasis (PC3). 
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4.3.1.4. The potential significance of BNP in prostate cancer bone metastasis. 
Changes in NPPB expression by osteoblasts have not previously been discussed in the 
context of bone metastasis. This gene codes for the precursor of the brain natriuretic peptide 
(BNP). BNP belongs to a family of three structurally related signaling molecules, involved in 
cardiovascular homeostasis and in organ development. There are three guanylyl cyclase 
receptors for these ligands, known as GC-A, GC-B and GC-C. Natriuretic peptides exert their 
effects primarily by modulating intracellular cGMP levels [Waschek 2004, Woodard & Rosado 
2007]. One of the members of this family, type C natriuretic peptide (CNP), is a known regulator 
of osteoblast function; it decreases DNA synthesis in osteoblasts [Suda et al. 1996] and 
stimulates osteoblastic differentiation, acting via GC-B [Inoue et al. 1996]. BNP also activates 
the GC-B receptor, although with a lesser affinity than CNP. When BNP is overexpressed in 
mice, they exhibit elevated plasma cGMP levels, increased endochondral ossification and 
skeletal overgrowth, and effects of BNP on bone are likely to be mediated at least partly by GC-
B, since a cross between BNP-overproducing mice and mice lacking GC-A yields mice with no 
skeletal defects [Chusho et al. 2000]. BNP has also been shown to exert functional opposition to 
TGFβ in primary fibroblasts, abrogating TGFβ-induced effects on gene expression [Kapoun et 
al. 2004]. 
The transcript for the BNP precursor became elevated after just 24 h in hfOB cocultured 
with prostate cancer cells or treated with prostate cancer cell-conditioned medium. Elevated 
expression of NPPB was maintained in hfOB after 48 h of coculture with prostate cancer cells, 
but no upregulation was noted in hfOB cocultured for 48 h with non-osteotropic HeLa cells or 
with normal fibroblasts. Interestingly, this transcript also became strongly upregulated in 
LNCaP, C4-2B4 and PC3 after coculture with hfOB, and was elevated in the osteotropic, 
osteoinductive prostate cancer cell line C4-2B4 in comparison to its parental line LNCaP. Higher 
expression of NPPB by C4-2B4 as compared to LNCaP has also been noted in a transcript 
profiling study by Fu et al. (2002). Thus, a link between this transcript and the pathogenesis of 
prostate cancer bone metastases appears highly probable. The Affymetrix array showed that 
hfOB expressed the mRNA for BNP receptors both before and after coculture, and thus are 
potentially responsive to this molecule. Increased BNP levels might, largely by autocrine 
stimulation, contribute to increased differentiation of osteoblasts and also decrease their 
sensitivity to TGFβ, thus mediating some of the effects on gene expression seen on the array.  
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4.3.3. Prostate cancer cells may suppress the host’s immune response. 
Although the immune system can recognize and destroy developing tumors, it is well 
known that tumor cells employ many mechanisms to evade, thwart or subvert immune responses, 
ultimately resulting in tumor growth in immunocompetent hosts. These mechanisms include 
tumor-induced impairment of antigen presentation, activation of negative costimulatory signals, 
and upregulation of immunosuppressive factors [Croci et al. 2007, Rabinovich et al. 2007]. 
The skeletal and immune systems appear to function in tight interplay and possess 
overlapping regulatory mechanisms [Lorenzo et al. 2008]. Remarkably, the genes encoding a 
number of immune response factors became downregulated in hfOB after coculture with all three 
prostate cancer cell lines. Among them were chemokines, proapoptotic proteins, markers of 
inflammation such as STAT1 and IL6, a central mediator of inflammatory signaling and a 
proinflammatory cytokine respectively, and three molecules associated with inflammation-
induced bone remodeling - ADAMTS1, HMGB1 and PAPPA.  
Inflammation, the body’s reaction to trauma or infection, is characterized by an influx of 
soluble mediators and cells that eliminate pathogens and initiate tissue repair. Current opinion 
holds that inflammation can stimulate, but also inhibit the progression of malignant disease, 
depending on the context [Le Bitoux & Stamenkovic 2008]. Importantly, in inflammatory states, 
local production of proinflammatory cytokines by inflamed tissues leads to stimulation of 
osteoclastogenesis and bone destruction [Lorenzo et al. 2008]. The observed changes in the 
osteoblast transcriptome could, thus, have a mixed impact on metastasizing cancer cells. 
Reduced bone remodeling would slow down the release of growth factors that fuel cancer cell 
proliferation, but at the same time, decreased production of cytokines and chemokines by the 
bone microenvironment could impair the response of immune system cells to cancer cell 
antigens, contributing to creation of a niche that enables the survival of prostate cancer stem cells 
in bone.   
Downregulation of proteasomal components, as well as proteins participating in 
proteasome assembly and protein ubiquitination, also occurred in hfOB after coculture with all 
three prostate cancer cell lines and can be interpreted as a further indication of impaired immune 
response mechanisms. Misfolded, foreign and other abnormal proteins are degraded through the 
ubiquitin- and proteasome-dependent pathway; this proteolytic system generates peptides from 
intracellular antigens, which are then presented to T cells. In this way, the proteasome plays a 
central role in cellular immunity [Konstantinova et al. 2008]. 
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Kinder et al. (2007) have reported that osteoblasts undergo an inflammatory stress 
response after treatment with medium conditioned by breast cancer cells, exhibiting impaired 
matrix production, increased apoptosis, and increased secretion of osteoclastogenic cytokines 
such as IL6. The experimental model employed by these researchers involved culturing 
osteoblasts with conditioned medium in the presence of 10% FCS, the same serum concentration 
as the one used in the coculture model described here. Thus, the difference in results cannot be 
due to the presence or absence of serum, but rather to other reasons, e.g. possibly, osteoblast 
responses to breast and prostate cancer cells may differ. 
 
 
4.3.4. Modulation of TGFβ signaling in osteoblasts as one of the switches 
differentiating between osteolytic and osteoblastic metastasis?  
The strength and duration of TGFβ signaling is largely dependent on negative feedback 
initiated during signal progression. The array data indicate that canonical TGFβ signaling was 
strongly inhibited in osteoblasts after coculture with all three prostate cancer cell lines, as 
evidenced by upregulation of the negative regulators PPM1A and SNF1LK, and concomitant 
downregulation of the TGFβ receptor TGFBR2, the accessory protein DAB2 and of numerous 
target genes (Fig. 33, Tab. 16). 
In canonical TGFβ signaling, receptor-activated SMAD proteins translocate into the 
nucleus, where they regulate transcription [Shi & Massague 2003]. TGFβ receptors can also 
activate other signaling molecules which modulate SMAD activity, as well as allow SMAD-
independent, or noncanonical TGFβ responses. TGFβ can activate the ERK, JNK and p38 
MAPK kinase pathways, as well as Rho-like GTPases which mediate changes in cytoskeletal 
organization and epithelial-to-mesenchymal transition [Derynck & Zhang 2003]. The type II 
TGFβ receptor kinase, TGFBR2, functions as a ligand-binding molecule and phosphorylates the 
type I receptor, initiating both canonical and noncanonical signaling [Shi & Massague 2003]. 
Signal transduction downstream is facilitated by the adaptor molecules SARA (SMAD anchor 
for receptor activation) [Tsukazaki et al. 1998] and disabled 2 (DAB2). DAB2 expression is 
induced by TGFβ and this protein is required for TGFβ-induced epithelial-mesenchymal 
transition, while its absence induces apoptosis [Prunier & Howe 2005]. DAB2 forms a critical 
link in the TGFβ pathway, aiding in signal transmission from the receptor complex to SMADs 
[Hocevar et al. 2001], but also stimulating activation of the JNK pathway via the TGFβ-
activated kinase 1 (TAK1) [Hocevar et al. 2005].  
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Tab. 16 Target genes of TGFβ signaling downregulated in osteoblasts cocultured with prostate cancer cells. 
 
Gene Gene product TGFβ  
isoform 
TGFβ signaling 
pathway 
Cell type References 
ACTN1 actinin, alpha 1 TGFβ1 
Canonical (via 
SMAD2/3), 
noncanonical (p38) 
Normal mammary epithelium, 
various cancer cell lines (e.g. 
breast, cervix) Bakin et al. 2004 
CDH2 
cadherin 2, type 1, N-
cadherin (neuronal) TGFβ1 Noncanonical (JNK) Stromal myofibroblasts De Wever et al. 2004 
CDH11 
cadherin 11, type 2, 
OB-cadherin 
(osteoblast) TGFβ1 Not determined Cytotrophoblasts Getsios et al. 1998 
COL1A1 
collagen, type I,  
alpha 1 TGFβ1 
Canonical (via 
SMAD3) Normal fibroblasts Verrecchia et al. 2001 
COL1A2 
collagen, type I,  
alpha 2 TGFβ1 
Canonical (via 
SMAD3) Normal fibroblasts Verrecchia et al. 2001 
COL3A1 
collagen, type III, 
alpha 1 (Ehlers-
Danlos syndrome type 
IV, autosomal 
dominant) TGFβ1 
Canonical (via 
SMAD3) Normal fibroblasts Verrecchia et al. 2001 
CTGF 
connective tissue 
growth factor TGFβ1 
Canonical (via 
SMAD3) and JNK 
activation both 
necessary  Normal fibroblasts 
Holmes et al.  2001,  
Utsugi et al. 2003 
CXCL12 
chemokine (C-X-C 
motif) ligand 12 
(stromal cell-derived 
factor 1) TGFβ1 Not determined Peritoneal mesothelial cells Kajiyama et al. 2007 
DAB2 
disabled homolog 2, 
mitogen-responsive 
phosphoprotein TGFβ2 Not determined 
Non-transformed epithelial 
cells Prunier et al. 2005 
FGF2 
fibroblast growth 
factor 2 (basic) TGFβ1 
Canonical (via 
SMAD3) Prostate stromal fibroblasts Yang et al. 2008 
FST follistatin 
Not 
specified Not determined Normal hepatocytes Zhang et al. 1997 
IL6 interleukin 6  TGFβ1 Not determined Primary osteoblasts  Franchimont et al. 2000 
PAPPA 
pregnancy-associated 
plasma protein A TGFβ1 Not determined Primary osteoblasts  Ortiz et al. 2003 
OPG osteoprotegerin 
TGFβ1,  
-2, -3 
Canonical (via 
SMAD2/3) 
Bone stromal cells, 
osteosarcoma 
Thirunavukkarasu et al. 
2001 
OPN osteopontin TGFβ1 Not determined 
Osteosarcoma, primary 
osteoblasts 
Noda et al. 1988, Wrana 
et al. 1991 
THBS1 thrombospondin 1 TGFβ1 Noncanonical (p38) Osteosarcoma Okamoto et al. 2002 
TNC 
tenascin C 
(hexabrachion) TGFβ1 
Canonical (via 
SMAD3) Dermal fibroblasts Jinnin et al. 2004 
TPM1 tropomyosin 1 (alpha) TGFβ1 
Canonical (via 
SMAD2/3), 
noncanonical (p38) 
Normal mammary epithelium, 
various cancer cell lines (e.g. 
breast, cervix) Bakin et al. 2004 
UGDH 
UDP-glucose 
dehydrogenase 
Not 
specified Not determined 
Various, e.g. normal 
fibroblasts, breast cancer 
cells, hepatoma  Bontemps et al. 2003 
 
 
The SNF1LK and PPM1A genes encode proteins that inhibit SMAD-dependent signaling. 
The sucrose nonfermented 1-like kinase (SNF1LK) is a serine/threonine kinase which cooperates 
with SMAD7 to downregulate the activated type I receptor, participating in negative feedback 
regulation [Kowanetz et al. 2008]. The protein phosphatase 1A (PPM1A) is responsible for 
SMAD2 and SMAD3 dephosphorylation, which results in their dissociation from SMAD4 and 
nuclear export [Lin et al. 2006]. Thus, SMAD-dependent signaling in osteoblasts after coculture 
with prostate cancer cells appears repressed. Analysis of the literature data available for 
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downregulated target genes (Tab. 16) supports this premise. COL1A1, COL1A2, COL3A1 
[Verrecchia et al. 2001], FGF2 [Yang et al. 2008], OPG [Thirunavukkarasu et al. 2001] and 
TNC [Jinnin et al. 2004] are all established targets of canonical signaling via SMADs, while the 
transcriptional induction of CTGF [Holmes et al. 2001, Utsugi et al. 2003] by TGFβ requires 
both canonical and noncanonical signaling. CDH2 upregulation by TGFβ in stromal 
myofibroblasts is mediated by signaling via JNK [De Wever et al. 2004] and THBS1 
upregulation by TGFβ in osteosarcoma cells occurs via p38 [Okamoto et al. 2002], but the 
possibility of SMAD participation in these effects has not been excluded, and it is known that 
MAPK kinase pathways may cooperate with SMAD signaling, for example by phosphorylating 
and activating SMADs [Derynck & Zhang 2003]. 
 
 
 
 
 
Fig.  33 Inhibition of canonical TGFβ signaling in osteoblasts cocultured with prostate cancer cells.   
Model based on array data. Red - upregulated molecules; green - downregulated molecules. 
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The effects of TGFβ on osteoblast differentiation depend on the extracellular milieu and 
the differentiation stage of the cells. TGFβ promotes osteoblast proliferation, as well as the early 
stages of differentiation and the expression of matrix proteins, but inhibits osteoblast maturation 
and matrix mineralization [Janssens et al. 2005]. TGFβ-induced repression of CBFA1 by 
SMAD3 decreases CBFA1 and OC expression and blocks terminal osteoblast differentiation 
[Alliston et al. 2001], while expression of a dominant negative TGFβ receptor type II in 
osteoblasts leads to decreased bone remodeling and increased trabecular bone formation in mice 
[Filvaroff et al. 1999]. TGFβ secreted by an osteolytic breast cancer cell line has been reported 
to seriously impair osteoblast function, inhibiting their differentiation and capability to 
mineralize a matrix, as well as reducing adhesion and causing disassembly of actin fibers 
[Mercer et al. 2004], possibly leading to decreased bone formation and mechanical strength. 
Thus, inhibition of TGFβ signaling in osteoblasts could be proposed as a mechanism leading to 
increased osteoblast maturation and contributing to the formation of osteoblastic metastases in 
prostate cancer. BNP, upregulated in osteoblasts by crosstalk with prostate cancer cells, could 
further contribute to the blockade of TGFβ effects on transcription, as described by Kapoun et al. 
(2004), and increase osteoblastic differentiation, as suggested by Chusho et al. (2000).  
In a model consisting of human bone fragments implanted in SCID mice, PC3 cells 
induced osteolytic metastases after inoculation, whereas the tumors induced by LNCaP 
represented a mixed osteolytic-osteoblastic type [Nemeth et al. 1999]. C4-2B4, a bone 
metastasis-derived, androgen-independent subline of LNCaP, forms osteoinductive skeletal 
lesions when injected into immunocompromised mice [Thalmann et al. 2000]. The osteolytic 
PC3 line secretes a different profile of bioactive factors than the osteoblastic C4-2B4, e.g., 
producing high levels of the osteoblast-inhibitory molecules DKK1 and NOG [Hall et al.  
2005, Schwaninger et al. 2007]. For this reason, we hypothesized that osteoblasts might react 
differently to coculture with PC3 than with osteoblastic CaP cell lines, providing additional 
clues as to early mechanisms of osteolytic and osteoblastic metastasis. Interestingly, 
coculture with PC3 appeared to uniquely affect the expression of many more genes than 
coculture with C4-2B4, with evidence for a more pronounced stress response, stronger 
repression of the cell cycle, DNA, RNA and protein synthesis. A cell proliferation assay 
confirmed that factors released by PC3 inhibited hfOB proliferation more strongly than 
factors released by C4-2B4. PC3 cells also selectively modulated the expression of a number 
of transcription factors, signaling pathway components, cytokines and adhesion molecules, 
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suggesting that osteolytic and osteoinductive prostate cancer cells may create and occupy 
differing osteoblastic niches. 
We could confirm by qRT-PCR that two downstream targets of TGFβ signaling - SMAD3 
and SMAD7 - became upregulated in hfOB cocultured with PC3 cells, suggesting that some 
activity of the TGFβ pathway was selectively retained, since SMAD3 is a TGFβ signaling 
mediator [Shi & Massague 2003] and SMAD7 represents a TGFβ target gene upregulated as a 
negative feedback mechanism [Afrakhte et al. 1998]. Also upregulated in this coculture 
combination was the transcript encoding sequestosome 1 (SQSTM1). SQSTM1 is a 
scaffolding protein that functions as a coactivator of NF-κB signaling [Wooten et al. 2005]. 
Evidence exists that NF-κB and TGFβ pathways influence each other. For example, it has 
been shown by Eliseev et al. that in osteosarcoma cells, NF-κB represses BMP/SMAD 
signaling and BMP2-induced differentiation through SMAD7 [Eliseev et al. 2006]. 
Tentatively, a mechanism could be proposed where increased NF-kB activation leads to 
upregulation of SMAD7 in osteoblasts cocultured with osteolytic prostate cancer cells, with 
further consequences for osteoblast function. Interestingly, it has been shown that autocrine 
stimulation with TGFβ2 maintains constitutive NF-κB signaling in PC3 cells, protecting 
them against apoptosis [Lu et al. 2004]; thus, TGFβ2 secreted by PC3 might activate NF-κB 
signaling in osteoblasts as well. 
As a further point, differential activation of the TGFβ pathway has been proposed to occur 
in osteocytes in response to different types of bone disease. Osteoporosis, bone metastases and 
multiple myeloma appear to induce distinct transcriptional footprints in osteocytes, involving the 
SMAD and MAPK branches of TGFβ signaling [Eisenberger et al. 2007]. It is possible that 
similar mechanisms of differing stress responses involving TGFβ pathway components might 
function in all cells of the osteoblast/osteocyte lineage. 
 
 
4.4. Crosstalk between prostate cancer cells and osteoblasts in light of the 
cancer stem cell hypothesis: does the bone furnish a niche for cancer stem 
cells? 
The cancer stem cell (CSC) model states that tumors contain a reservoir of self-renewing 
cells, which are resistant to conventional therapies and can survive to repopulate the tumor. 
Normal stem cells have the ability to perpetuate themselves through self-renewal and to generate 
_____________________________________________________4. Discussion 
 
 124 
mature cells of a particular tissue through differentiation [Reya et al. 2001] and CSCs probably 
arise from mutated stem or progenitor cells which acquire the ability to proliferate uncontrollably 
[Li & Neaves 2006, Kasper 2008]. Evidence is accumulating that prostate cancers contain such a 
therapy-resistant stem cell fraction that mediates the progression of this malignancy after 
androgen deprivation [Kasper 2008, Kelly & Yin 2008, Lang et al. 2009].  
It is thought that CSCs and normal stem cells utilize similar molecular mechanisms to 
drive self-renewal, and similar signaling pathways may induce them to differentiate. To maintain 
their pluripotency, stem cells require a niche where they can undergo self-renewal in response to 
balanced signals provided by specialized niche cells [Reya et al. 2001, Li & Neaves 2006]. 
Recent publications suggest that osteoblasts are a crucial component of the hematopoietic stem 
cell (HSC) niche, responsible for maintaining HSC quiescence and shielding them from harmful 
influences. The functions of the HSC niche depend on the expression of a broad array of 
adhesion molecules and cytokines [Suda et al. 2005]. The transcriptional changes observed by us 
in osteoblasts may be important in the light of their potential niche function. On the one hand, 
the functional alterations induced by crosstalk with prostate cancer cells might impair their 
ability to act properly as a niche component. Even more intriguingly, osteoblasts may also 
furnish a niche for prostate CSCs and their crosstalk with prostate cancer cells may contribute to 
this ability. The presence of disseminated cancer cells in the bone marrow of prostate cancer 
patients is an early event; it has been suggested that the bone marrow enables these cells to stay 
quiescent and survive for long periods [Pantel & Brakenhoff 2004, Buijs & van der Pluijm 
2009].  
It has been demonstrated that TGFβ/SMAD signaling is required to keep human embryonic 
stem cells in their pluripotent, undifferentiated state [James et al. 2005]. TGFβ plays a key role 
in regulating self-renewal and differentiation within normal and malignant breast tissue. Putative 
breast CSCs have a mesenchymal phenotype and active TGFβ signaling [Tan et al. 2009]. 
Global gene expression profiling has shown a prominent role of TGFβ/SMAD signaling in the 
maintenance of adult murine prostate stem cells. The results also suggested that the prostate 
progenitor lineage may be more similar to embryonic than to hematopoietic stem cells [Blum et 
al. 2009]. Other researchers have reported that TGFβ is responsible for maintaining the 
dormancy of prostatic stem cells in the normal mouse prostate [Salm et al. 2005]. In the light of 
the above reports, it is interesting that TGFB1, TGFBR1, TGFBR2 and SMAD3 become 
upregulated in prostate cancer cells after crosstalk with osteoblasts, a cell type known to provide 
stem cell niche signals [Wilson & Trumpp 2006, Zhu & Emerson 2004, Neiva et al. 2005, Suda 
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et al. 2005] and an abundant source of TGFβ1. Furthermore, high endogenous levels of TGFB1, 
TGFBR2 and SMAD3 mRNA can be observed in the PC3 line, which is poorly differentiated 
[Kaighn et al. 1979], highly invasive [Soos et al. 1997, Fisher et al. 2002] and has been shown to 
possess a stem cell-like subpopulation, capable of self-renewal and initiating serially 
transplantable tumors [Li et al. 2008]. 
Another osteoblast-released factor which can potentially enhance the survival of prostate 
CSCs is FGF2, abundantly secreted by hfOB. The FGF2 pathway is one of the most significant 
regulators of human embryonic stem cells, sustaining their self-renewal and pluripotency. It is 
also strongly implicated in tumorigenesis [Dvorak et al. 2006] FGF2 is known to play a role in 
prostate cancer development and progression [Kwabi-Addo et al. 2004], although its role in the 
maintenance of prostate CSCs remains unclear. 
Interestingly, a role for BNP in embryonic stem cell maintenance has recently been 
reported. Abdelalim and Tooyama (2009) discovered that endogenous BNP signaling is 
essential for the proliferation of murine embryonic stem cells, whereas BNP knockdown 
increased apoptosis rates. An intriguing question to investigate would be whether BNP 
promotes the proliferation and survival of the stem cell subpopulation in prostate cancer cell 
lines.  
Finally, type 1 collagen, abundantly secreted by osteoblasts [Mackie 2003], has been 
implicated in the maintenance of CSCs. It is highly expressed along the invasive front of 
colorectal cancer and has been reported to promote the expression of a stem cell phenotype 
in human colorectal carcinoma cells [Kirkland et al. 2009]. Although COL1A1 and COL1A2 
mRNA levels sank in hfOB after crosstalk with prostate cancer cells, type 1 collagen would 
remain a significant component of the osteoblast niche, since the initial levels of expression 
were very high. Furthermore, in the model presented in Fig. 31, decreased expression of 
collagens and other ECM proteins by osteoblasts differentiating to preosteocytes is 
accompanied by increased differentiation of osteoprogenitors, which would be a rich 
collagen source.  
In sum, the presented in vitro data together with published reports suggest possible 
mechanisms through which osteoblasts might support the survival and growth of prostate CSCs 
in bone. These mechanisms include secretion of TGFβ1 and stimulation of canonical TGFβ 
signaling in prostate cancer cells, secretion of FGF2, BNP and of type 1 collagen. 
To conclude, the changes induced in osteoblasts by crosstalk with prostate cancer cells 
indicate possible mechanisms by which osteoblasts might enhance the invasive, osteomimetic 
and stem cell-like properties of tumor cells, as well as contribute to the abnormal bone formation 
_____________________________________________________4. Discussion 
 
 126 
seen in metastatic lesions. Moreover, some of the crosstalk-induced changes in osteoblasts might 
be a reflection of the generalized impairment of immunity which is often a feature of advanced 
cancer. Although all the hypotheses presented in the above section on the basis of array data 
from an in vitro setting must be considered tentative, they match data published by other groups, 
outlining potentially interesting directions for further study. 
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5. Conclusions 
•   Transcriptional alterations caused by cell crosstalk via soluble factors are a very early 
event in cancer metastasis to bone. 
•   Prostate cancer cells exposed to the osteoblast secretome show evidence of osteomimicry, 
concomitant with intensified IL6 and TGFβ signaling. 
•   Osteoblasts exposed to the secretome of prostate cancer cells exhibit gene expression 
alterations suggestive of repressed proliferation, decreased matrix synthesis and inhibited 
immune response, which together indicate enhanced preosteocytic differentiation.  
• The changes induced in osteoblasts by crosstalk with prostate cancer cells suggest possible 
mechanisms by which osteoblasts might enhance the invasive, osteomimetic and stem cell-
like properties of tumor cells, as well as contribute to the abnormal bone formation seen in 
metastatic lesions and to the generalized impairment of immunity which is often a feature 
of advanced cancer. 
•   At the early stages of prostate cancer bone metastasis, TGFβ signaling appears to become 
differently modulated in osteoblasts and in cancer cells as a result of their crosstalk, with 
accompanying changes in gene transcription. 
 
_______________________________________________________References 
 128 
References 
 
Abdelalim EM, Tooyama I. (2009) BNP signaling is crucial for embryonic stem cell proliferation. PLoS ONE. 4: e5341. 
Afrakhte M, Moren A, Jossan S, Itoh S, Sampath K, Westermark B, Heldin CH, Heldin NE, ten Dijke P. (1998) Induction of 
inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun. 249: 505-511. 
Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. (2001) TGF-beta-induced repression of CBFA1 by Smad3 decreases 
cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 20: 2254-2272. 
Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. (2005) Wnt proteins prevent apoptosis of both uncommitted 
osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving 
Src/ERK and phosphatidylinositol 3-Kinase/AKT. J Biol Chem. 50: 41342-41351. 
Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. (2006) The metastatic cascade in prostate cancer. Surg 
Oncol. 15: 117-128. 
Bacac M, Stamenkovic I. (2008) Metastatic cancer cell. Annu Rev Pathol Mech Dis. 3: 221-47. 
Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary J, Helfman DM. (2004) A critical role of tropomyosins in TGF-beta 
regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell. 15: 4682-4694. 
Bellido T, Borba VZ, Roberson P, Manolagas SC. (1997) Activation of the Janus kinase/STAT (signal transducer and 
activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. 
Endocrinology. 138: 3666-3676. 
Billiard J, Moran RA, Whitley MZ, Chatterjee-Kishore M, Gillis K, Brown EL, Komm BS, Bodine PVN. (2003) 
Transcriptional profiling of human osteoblast differentiation. J Cell Biochem. 89: 389-400. 
Blair JM, Zhou H, Seibel MJ, Dunstan CR (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the 
pathophysiology of skeletal metastasis. Nat Clin Pract Oncol. 3: 41-49. 
Blaszczyk N, Masri BA, Mawji NR, Ueda T et al. (2004) Osteoblast-derived factors induce androgen-dependent 
proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res. 10: 1860-1869. 
Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, 
Zavadil J, Moscatelli D, Wilson EL. (2009) Molecular signatures of prostate stem cells reveal novel signaling pathways and 
provide insights into prostate cancer. PLoS One. 4: e5722. 
Bogdanos J, Karamanolakis D, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C, Koutsilieris M. (2003) 
Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen 
ablation and chemotherapy refractoriness of prostate cancer metastasis in the skeleton. Endocr Relat Cancer. 10: 279-289. 
Bontemps Y, Vuillermoz B, Antonicelli F, Perreau C, Danan JL, Maquart FX, Wegrowski Y. (2003) Specific protein-1 is a 
universal regulator of UDP-glucose dehydrogenase expression: its positive involvement in transforming growth factor-beta 
signaling and inhibition in hypoxia. J Biol Chem. 278: 21566-21575. 
Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS. (2001) The loss of Smad3 results in a lower rate of bone 
formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res. 16: 1754-1764. 
Boyce BF, Xing L. (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 9 Suppl 1: S1. 
Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL (2001) Osteoprotegerin and RANK ligand 
expression in prostate cancer. Urology 57: 611–616. 
Brown KA, Pietenpol JA, Moses HL. (2007) A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in 
TGF-beta signaling. J Cell Biochem. 101: 9-33. 
Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y. (2008) Breast cancer-derived Dickkopf1 inhibits 
osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer. 
123(5): 1034-1042. 
Buijs JT, van der Pluijm G. (2009) Osteotropic cancers: from primary tumor to bone. Cancer Lett. 273: 177-193. 
Byers BA, Garcia AJ. (2004) Exogenous Runx2 expression enhances in vitro osteoblastic differentiation and mineralization 
in primary bone marrow stromal cells. Tissue Eng. 10(11–12):1623–1632. 
Canalis E, Economides AN, Gazzerro E. (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr 
Rev. 24: 218-235. 
Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, 
Culig Z. (2006) The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by 
Mcl-1. Oncogene: 1–11. 
Chambers AF, Groom AC, MacDonald IC. (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev 
Cancer. 2: 563-572. 
Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA (2006) Expression of RANKL/RANK/OPG in primary and 
metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 107: 289-298. 
Chirgwin JM, Mohammad KS, Guise TA. (2004) Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet 
Neuronal Interact. 4: 308-318. 
Chomczynski P, Sacchi N. (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform 
extraction. Anal Biochem. 162: 156-159. 
Choueiri MB, Tu SM, Yu-Lee LY, Lin SH (2006) The central role of osteoblasts in the metastasis of prostate cancer. 
Cancer Metastasis Rev. 25: 601–609. 
Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW (1999) Characterization of the role of IL-6 in the progression of 
prostate cancer. Prostate. 38(3): 199-207. 
Chusho H, Ogawa Y, Tamura N, Suda M, Yasoda A, Miyazawa T, Kishimoto I, Komatsu Y, Itoh H, Tanaka K, Saito Y, 
Garbers DL, Nakao K. (2000) Genetic models reveal that brain natriuretic peptide can signal through different tissue-specific 
receptor-mediated pathways. Endocrinology. 141: 3807-3813. 
_______________________________________________________References 
 129 
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. (2006) Cancer stem 
cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66: 9339-9344. 
Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Foz JW, Chirgwin JM, Guise TA. (2007) 
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol. 21: 486-498. 
Cocciadiferro L, Miceli V, Kang KS, Polito LM, Trosko JE, Carruba G. (2009) Profiling cancer stem cells in androgen-
responsive and refractory human prostate tumor cell lines. Ann N Y Acad Sci. 1155: 257-262. 
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. (2005) Prospective identification of tumorigenic prostate cancer 
stem cells. Cancer Res. 65: 10946-10951. 
Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. (2003) 
Stromal factors involved in prostate carcinoma metastasis to bone. Cancer. 97: 739-747. 
Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. (2005) Osteoprotegerin in prostate cancer bone 
metastasis. Cancer Res. 65: 1710-1718. 
Cornish J, Naot D, Reid IR. (2003) Adrenomedullin - a regulator of bone formation. Regul Pept. 112: 79-86. 
Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and 
immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 
56: 1687–1700. 
Culig Z, Bartsch G, Hobisch A. (2002) Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. 
Mol Cell Endocrinol. 197: 231-238. 
Culig Z, Steiner H, Bartsch G, Hobisch A. (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 
95(3): 497-505. 
Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. (2008) Prostate cancer induces bone metastasis through 
Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 68: 5785-5794. 
Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. (2008) The cell biology of bone metabolism. J Clin Pathol. 61: 577-
587. 
De Wever O, Westbroek W, Verloes A, Bloemen N, Bracke M, Gespach C, Bruyneel E, Mareel M. (2004) Critical role of N-
cadherin in myofibroblast invasion and migration in vitro stimulated by colon cancer cell-derived TGF-beta or wounding. J Cell 
Sci. 117: 4691-4703. 
Derynck R, Zhang YE. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 
425: 577-584. 
Devlin HL, Mudryj M. (2009) Progression of prostate cancer: Multiple pathways to androgen independence. Cancer Lett. 
274: 177-186. 
Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, Cher ML. (2008) Prostate cancer cell-
derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia. 10: 439-
449. 
Dorai T, Dutcher JP, Dempster DW, Wiernik PH. (2004) Therapeutic potential of curcumin in prostate cancer--V: 
Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate. 60: 1-17. 
Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients 
with hormone refractory prostate cancer. Prostate. 41: 127-133. 
Ducy P (2000) Cbfa1: A molecular switch in osteoblast biology. Dev Dynamics. 219: 461-471. 
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast 
differentiation. Cell. 89: 747-754. 
Dvorak P, Dvorakova D, Hampl A. (2006) Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS 
Letters. 580: 2869-2874. 
Edlund M, Sung SY, Chung LW. (2004) Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem. 
91: 686-705. 
Eisenberger S, Ackermann K, Voggenreiter G, Sueltmann H, Kasperk C, Pyerin W. (2008) Metastases and multiple myeloma 
generate distinct transcriptional footprints in osteocytes in vivo. J Pathol. 214: 617-626. 
Eliseev RA, Schwarz EM, Zuscik MJ, O’Keefe RJ, Drissi H, Rosier RN. (2006) Smad7 mediates inhibition of Saos2 
osteosarcoma cell differentiation by NF-kappaB. Exp Cell Res. 312: 40-50. 
Emami KH, Corey E. (2007) When prostate cancer meets bone: control by Wnts. Cancer Lett. 253: 170-179. 
Erices A, Conget P, Rojas C, Minguell JJ. (2002) gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances 
osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res. 280: 24-32. 
Fakhry A, Ratisoontorn C, Vedchalam C, Salhab I, Koyama E, Leboy P, Pacifici M, Kirschner RE, Nah HD. (2005) Effects 
of FGF-2/9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and 
noggin, and enhancement of osteogenic potential. Bone. 36: 254-266. 
Farhadi J, Jaquiery C, Barbero A, Jakob M, Schaeren S, Pierer G, Heberer M, Martin I. (2005) Differentiation-dependent 
upregulation of BMP-2, TGF-beta1, and VEGF expression by FGF2 in human bone marrow stromal cells. Plast Reconstr Surg. 
116: 1379-1386. 
Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR (2005) Influence of BMPs on the 
formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res. 20: 2189-2199. 
Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Albini A, Bologna M. (2000) Osteoblast-derived TGF-beta1 
modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer. 85(3): 407-415. 
Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D, Teti A. (1999) Osteoblast 
conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with 
extracellular matrix components. Int J Cancer. 81(3): 395-403. 
Fidler I. (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3: 1-6. 
_______________________________________________________References 
 130 
Filvaroff E, Erlenbacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R. (1999) Inhibition of TGF-beta receptor 
signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development. 126: 4267-
4279. 
Fisher JL, Schmitt JF, Howard ML, Mackie PS, Choong PF, Risbridger GP. (2002) An in vivo model of prostate carcinoma 
growth and invasion in bone. Cell Tissue Res. 307: 337-345. 
Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, 
Navone NM. (2003) Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate 
cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 9(7): 2587-2597. 
Franceschi RT, Xiao G. (2003) Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple 
signal transduction pathways. J Cell Biochem. 88(3): 446-454. 
Franchimont N, Rydziel S, Canalis E. (2000) Transforming growth factor-beta increases interleukin-6 transcripts in 
osteoblasts. Bone. 26: 249-253. 
Franz-Odendaal TA, Hall BK, Witten PE. (2006) Buried alive: How osteoblasts become osteocytes. Dev Dyn. 235: 176-190. 
Fu Z, Dozmorov IM, Keller ET. (2002) Osteoblasts produce soluble factors that induce a gene expression pattern in non-
metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.  Prostate. 51: 10-20. 
Fujita K, Janz S. (2007) Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation 
and expression of OPG, RANKL and M-CSF. Mol Cancer. 6:71. 
Funaba M, Ogawa K, Murata T, Fujimura H, Murata E, Abe M, Takahashi M, Torii K. (1996) Follistatin and activin in 
bone: expression and localization during endochondral bone development. Endocrinology. 137: 4250-4259. 
Garcia-Moreno C, Mendez-Davila C, de la Piedra C, Castro-Errecaborde NA, Traba ML. (2002) Human prostatic carcinoma 
cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate. 50: 241-246. 
Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PVN, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian 
JB. (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 280: 
33132-33140. 
Getsios S, Chen GT, Huang DT, MacCalman CD. (1998) Regulated expression of cadherin-11 in human extravillous 
cytotrophoblasts undergoing aggregation and fusion in response to transforming growth factor beta-1. J Reprod Fertil. 114: 357-
363. 
Gey GO, Coffman WD, Kubicek MT. (1952) Tissue culture studies of the proliferative capacity of cervical carcinoma and 
normal epithelium. Cancer Res. 12: 264-265. 
Giles RH, van Es JH, Clevers H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 1653: 
1-24. 
Giri D, Ozen M, Ittmann M. (2001) Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 159: 
2159-2165. 
Glass DA, Bialek P, Ahn JD, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lan RA, Karsenty G. (2005) 
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 8: 751-764. 
Goellner H, Dani C, Phillips B, Philipsen S, Suske G. (2001) Impaired ossification in mice lacking the transcription factor 
Sp3. Mech Dev. 106: 77-83. 
Guillen C, de Gortazar AR, Esbrit P. (2004) The interleukin-6/soluble interleukin-6 receptor system induces parathyroid 
hormone-related protein in human osteoblastic cells. Calcif Tissue Int. 75: 153-159. 
Guise TA. (2000) Molecular mechanisms of osteolytic bone metastases. Cancer. 88: 2892-2898. 
Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, 
Chirgwin JM. (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 12: 6213-
6216. 
Guo Y, Kyprianou N (1999) Restoration of transforming growth factor β signaling pathway in human prostate cancer cells 
suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res. 59: 1366-1371. 
Hadjidakis DJ, Androulakis II. (2006) Bone remodeling. Ann NY Acad Sci. 1092: 385-396. 
Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. (2005) Prostate cancer cells promote osteoblastic bone metastases 
through Wnts. Cancer Res 65: 7554-7560. 
Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. (2008) Dickkopf-1 expression increases early in prostate cancer 
development and decreases during progression from primary tumor to metastasis. Prostate. 68: 1396-1404. 
Hall CL, Kang S, MacDougald OA, Keller ET. (2006) Role of Wnts in prostate cancer bone metastases. J Cell Biochem. 97: 
661-672. 
Hall CL, Keller ET. (2006) The role of Wnts in bone metastases. Cancer Metastasis Rev. 25: 551-558. 
Harris SA, Enger RJ, Riggs BL, Spelsberg TC. (1995) Development and characterization of a conditionally immortalized 
human fetal osteoblastic cell line. J Bone Miner Res. 10(2): 178-186. 
Hashimoto M, Shoda A, Inoue S, Yamada R, Kondo T, Sakurai T, Ueno N, Muramatsu M. (1992) Functional regulation of 
osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem. 267: 4999-5004. 
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Uller-Newen GM, Schaper F. (2003) Principles of interleukin (IL)-6-type 
cytokine signalling and its regulation. Biochem J. 374: 1-20. 
Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. (2001) Prostate cancer cells (LNCaP) 
generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin 
Cancer Res. 7: 2941-2948. 
Hocevar BA, Prunier C, Howe PH. (2005) Disabled-2 (Dab2) mediates transforming growth factor β (TGFβ)-stimulated 
fibronectin synthesis through TGFβ-activated kinase 1 and activation of the JNK pathway. J Biol Chem. 280: 25920-25927. 
Hocevar BA, Smine A, Xu XX, Howe PH. (2001) The adaptor molecule Disabled-2 links the transforming growth factor 
beta receptors to the Smad pathway. EMBO J. 20: 2789-2801. 
_______________________________________________________References 
 131 
Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. (1998) Osteoprotegerin production by human osteoblast 
lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun. 250: 
776-781.  
Hofbauer LC, Heufelder AE. (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone 
cell biology. J Mol Med. 79: 243-253. 
Hofbauer LC, Neubauer A, Heufelder AE. (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: 
potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer. 92: 460-470. 
Holen I, Cross SS, Neville-Webber HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, 
Eaton CL. (2005) Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in 
tumour cell survival? Breast Cancer Res Treat. 92: 207-215. 
Holen I, Croucher PI, Hamdy FC, Eaton CL. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer 
cells. Cancer Res. 62(6):1619-1623. 
Holen I, Shipman CM. (2006) Role of osteoprotegerin (OPG) in cancer. Clin Sci. 110: 279-291. 
Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. (2001) CTGF and SMADs, maintenance of scleroderma 
phenotype is independent of SMAD signaling. J Biol Chem. 276: 10594-10601. 
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Ming Chu T, Mirand EA, Murphy GP (1983) LNCaP model 
of human prostatic carcinoma. Cancer Res. 43: 1809-1818. 
Hosokawa K, Arai F, Yoshihara H, Nakamura Y, Gomei Y, Iwasaki H, Miyamoto K, Shima H, Ito K, Suda T. (2007) 
Function of oxidative stress in the regulation of hematopoietic stem cell-niche interaction. Biochem Biophys Res Commun. 363: 
578-583. 
Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC, 
Chung LW (2006) β2-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. 
Cancer Res. 66: 9108-9116. 
Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW. (2005) Human osteocalcin and bone sialoprotein mediating 
osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res. 65(6): 2303-
2313. 
Inoue A, Hiruma Y, Hirose S, Yamaguchi A, Furuya M, Tanaka S, Hagiwara H. (1996) Stimulation by C-type natriuretic 
peptide of the differentiation of clonal osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun. 221: 703-707. 
Jacob K, Webber M, Benayahu D, Kleinman HK (1999) Osteonectin promotes prostate cancer cell migration and invasion: 
a possible mechanism for metastasis to bone. Cancer Res. 59: 4453-4457. 
James D, Levine AJ, Besser D, Hemmati-Brianlou A. (2005) TGFbeta/activin/nodal signaling is necessary for the 
maintenance of pluripotency in human embryonic stem cells. Development. 132: 1273-1282. 
Janssens K, ten Dijke P, Janssens S, Van Hul W (2005) Transforming growth factor-β1 to the bone. Endocr Rev. 26(6): 743-
774. 
Jemal A, Siegel R, Ward E, Hao Y, Xu J,  Murray T, Thun MJ. (2008) Cancer statistics, 2008. CA Cancer J Clin. 58: 71-96. 
Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. (2004) Tenascin-C upregulation by transforming growth 
factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene. 23: 1656-1667. 
Juarez J, Bendall L. (2004) SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol. 19: 299-309.  
Jung K, Lenn M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA. (2004) Comparison of 10 serum bone 
turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J 
Cancer. 111: 783-791. 
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. (1979) Establishment and characterization of a human 
prostatic carcinoma cell line (PC-3). Invest Urol. 17(1): 16-23. 
Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. (2008) Involvement of SDF1 alpha/CXCR4 axis in the 
enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer.122: 91-99. 
Kamimura D, Ishihara K, Hirano T. (2003). IL-6 signal transduction and its physiological roles: the signal orchestration 
model. Rev Physiol Biochem Pharmacol. 149: 1-38. 
Kanaan RA, Kanaan LA (2006) Transforming growth factor β1, bone connection. Med Sci Monit. 12(8): 164-169. 
Kapoun AM, Liang F, O’Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. (2004) B-
Type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac 
fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 94: 453-461. 
Karsenty G, Wagner EF. (2002) Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2: 389-
406. 
Kasper S. (2008) Stem cells: The root of prostate cancer? J Cell Physiol. 216: 332-336. 
Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell 
Biochem. 91: 718-729. 
Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. (2001) Prostate carcinoma skeletal 
metastases: Cross-talk between tumor and bone. Cancer Metastasis Rev. 20: 333-349. 
Kelly K, Yin JJ. (2008) Prostate cancer and metastasis initiating stem cells. Cell Res. 18: 528-537. 
Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, Roy-Burman P. (2006) Increased 
expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 66: 883-888. 
Kido J, Yamauchi N, Ohishi K, Kataoka M, Nishikawa S, Nakamura T, Kadono H, Ikedo D, Ueno A, Nonomura N, 
Okuyama A, Nagata T. (2007) Inhibition of osteoblastic cell differentiation by conditioned medium derived from the human 
prostatic cancer cell line PC-3 in vitro. J Cell Biochem. 67: 248-256. 
Kiefer JA, Farach-Carson MC (2001) Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: 
implications for enhanced growth in the bone microenvironment. Matrix Biol. 20: 429-437. 
_______________________________________________________References 
 132 
Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C. (1996) Genetic change in transforming growth 
factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta1 in human prostate cancer cells. Cancer 
Res. 56: 44-48. 
Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C. (1996) Modulation of sensitivity to transforming growth 
factor-beta1 (TGF-beta1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res. 222: 
103-110. 
Kinder M, Chislock E, Bussard KM, Shuman L, Mastro AM. (2007) Metastatic breast cancer induces an osteoblast 
inflammatory response. Exp Cell Res. 314: 173-183. 
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. (2007) Molecular biology of bone metastasis. Mol Cancer Ther. 6: 
2609-2617. 
Kirkland SC. (2009) Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal 
carcinoma cells. Br J Cancer. Jun 30 [Epub ahead of print]. 
Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL. (2009) Invasive prostate 
cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 26: 433-446. 
Knerr K, Ackermann K, Neidhart T, Pyerin W. (2004) Bone metastasis: Osteoblasts affect growth and adhesion regulons in 
prostate tumor cells and provoke osteomimicry. Int J Cancer. 111(1): 152-159. 
Kobayashi T, Kronenberg H. (2005) Minireview: Transcriptional regulation in development of bone. Endocrinology. 146: 
1012-1017. 
Koeneman KS, Yeung F, Chung LW. (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the 
predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 39(4): 246-261. 
Konstantinova IM, Tsimokha AS, Mittenberg AG. (2008) Role of proteasomes in cellular regulation. Int Rev Cell Mol Biol. 
267: 59-124. 
Kowanetz M, Loenn P, Vanlandewijck M, Kowanetz K, Heldin Ch, Moustakas A. (2008) TGFbeta induces SIK to negatively 
regulate type I receptor kinase signaling. J Cell Biol. 182: 655-62. 
Kozawa O, Suzuki A, Uematsu T. (1997) Basic fibroblast growth factor induces interleukin-6 synthesis in osteoblasts: 
autoregulation by protein kinase C. Cell Signal. 9: 463-468. 
Kozlow W, Guise TA. (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J 
Mammary Gland Biol Neoplasia. 10: 169-180. 
Krishnan V, Bryant HU, MacDougal OA. (2006) Regulation of bone mass by Wnt signaling. J Clin Invest. 116: 1202-1209.  
Kwabi-Addo B, Ozen M, Ittmann M. (2004) The role of fibroblast growth factors and their receptors in prostate cancer. 
Endocr Rel Cancer. 11: 709-724. 
Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 
227(5259): 680-685. 
Lai TH, Fong YC, Fu WM, Yang RS, Tang CH. (2008) Osteoblast-derived BMP-2 enhances the motility of prostate cancer 
cells via activation of integrins. Prostate. 68: 1341-1353. 
Lang SH, Frame FM, Collins AT. (2009) Prostate cancer stem cells. J Pathol. 217: 299-306. 
Lang SH, Miller WR, Habib FK. (1995) Stimulation of human prostate cancer cell lines by factors present in human 
osteoblast-like cells but not in bone marrow. Prostate. 7(5): 287-293. 
Le Bitoux MA, Stamenkovic I. (2008) Tumor-host interactions: the role of inflammation. Histochem Cell Biol. 130: 1079-
1090. 
Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC (2007) Interleukin-6 undergoes transition from growth inhibitor 
associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP 
prostate cancer cell progression. Prostate. 67: 764-773. 
Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. (2008) PC3 human prostate carcinoma cell holoclones contain self-
renewing tumor-initiating cells. Cancer Res. 68: 1820-1825. 
Li L, Neaves WB. (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66: 4553-4557. 
Li Y, Backesjo CM, Haldosen LA, Lindgren U. (2008) IL-6 receptor expression and IL-6 effects change during osteoblast 
differentiation. Cytokine. 43: 165-173. 
Lian JB, Stein GS, Javed A, van Wijnen AJ, Stein JL, Montecino M, Hassan MQ, Gaur T, Lengner CJ, Yound DW. (2006) 
Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord. 7: 1-16. 
Lian JB, Stein GS. (1995) Development of the osteoblast phenotype: molecular mechanisms mediating osteoblast growth and 
differentiation. Iowa Orthop J. 15: 118-140. 
Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. (2001) Bone metastatic LNCaP-derivative 
C4-2B prostate cancer cell line mineralizes in vitro. Prostate. 473: 212-221. 
Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, Shi Y, Chen YG, Meng 
A, Feng XH. (2006) PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 125: 915-928. 
Lindemann RK, Ballschmieter P, Nordheim A, Dittmer J. (2001) Transforming growth factor-beta regulates parathyroid 
hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem. 
276: 46661-46670. 
Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, Himeno M, Narai S, Yamaguchi T, Komori J. (2001) 
Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol. 
155: 157-166. 
Lobo NA, Shimono Y, Qian D, Clarke MF. (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol. 23: 675-699. 
Logothetis CJ, Lin SH.(2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 5(1): 21-28.  
Lorenzo J, Horowitz M, Choi Y. (2008) Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 29: 
403-440. 
_______________________________________________________References 
 133 
Lou W, Zuyao N, Dyer K, Tweardy DJ, Gao AC. (2000) Interleukin-6 induces prostate cancer cell growth accompanied by 
activation of Stat3 signaling pathway. Prostate. 42: 239-242. 
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951) Protein measurement with the Folin phenol reagent. J Biol 
Chem.193: 265-275. 
Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV. (2004) Secreted transforming growth 
factor beta-2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. PNAS 101: 7112-
7117. 
Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. (2004) Osteoblasts induce prostate cancer proliferation 
and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis. 21(5): 399-408. 
Mackie EJ. (2003) Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol. 35: 1301-1305. 
Manolagas SC. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and 
treatment of osteoporosis. Endocr Rev. 21: 115-137. 
Marie PJ. (2003) Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 316: 23-32. 
Marie PJ. (2008) Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys. 473: 98-105. 
Massard C, Deutsch E, Soria JC. (2006) Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol. 17: 
1620-1624. 
Mastro AM, Gay CV, Welch DR, Donahue HJ, Jewell J, Mercer R, DiGirolamo D, Chislock EM, Guttridge K. (2004) Breast 
cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. J Cell Biochem. 91: 265-276.  
Mercer RR, Miyasaka C, Mastro AM. (2004) Metastatic breast cancer cells suppress osteoblast adhesion and 
differentiation. Clin Exp Metastasis. 21: 427-435. 
Milat F, Ng KW. (2009) Is Wnt signalling the final common pathway leading to bone formation? Mol Cell Endocrinol. 
doi:10.1016/j.mce.2009.06.002 (article in press). 
Mori S, Murakami-Mori K, Bonavida B. (1999) Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-
dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun. 
257(2): 609-614. 
Morinaga T, Nakagawa N, Yasuda H, Tsuda E, Higashio K. (1998) Cloning and characterization of the gene encoding 
human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur. J. Biochem. 254: 685-691. 
Moustakas A, Souchelnytskyi S, Heldin CH. (2001) Smad regulation in TGF-β signal transduction. J Cell Sci. 114: 4359-
4369. 
Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2: 584-593. 
Neiva K, Sun YX, Taichman RS. (2005) The role of osteoblasts in regulating hematopoietic stem cell activity and tumor 
metastasis. Braz J Med Biol Res. 38: 1449-1454. 
Nemeth JA, Harb JF, Barroso U, He Z, Grignon DJ, ML (1999)  Severe combined immunodeficient-hu model of human 
prostate cancer metastasis to human bone. Cancer Res. 59: 1987-1993. 
Nichols WW, Murphy DG, Cristofalo VJ, Toji LH, Greene AE, Dwight SA. (1977) Characterization of a new human diploid 
cell strain, IMR-90. Science. 196: 60-63. 
Nilsson SK, Johnston HM, Whitty GA, Williams M, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ, 
Haylock DN. (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic 
progenitor cells. Blood. 106: 1232-1239. 
Noble BS. (2008) The osteocyte lineage. Arch Biochem Biophys. 473: 106-11. 
Noda M, Yoon K, Prince CW, Butler WT, Rodan GA. (1988) Transcriptional regulation of osteopontin production in rat 
osteosarcoma cells by type beta transforming growth factor. J Biol Chem. 263: 13916-13921. 
Okamoto M, Lee C, Oyasu R. (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic 
carcinoma cells in vitro. Cancer Res. 57: 141-146. 
Okamoto M, Ono M, Uchiumi T, Ueno H, Kohno K, Sugimachi K, Kuwano M. (2002) Up-regulation of thrombospondin-1 
gene by epidermal growth factor and transforming growth factor β in human cancer cells -  transcriptional activation and 
messenger RNA stabilization. Biochim Biophys Acta. 1574: 24-34. 
Ortiz CO, Chen BK, Bale LK, Overgaard MT, Oxvig C, Conover Ca. (2003) Transforming growth factor-beta regulation of 
the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts. J Bone Miner Res. 18: 1066-
1072. 
Palmqvist P, Persson E, Conaway HH, Lerner UH. (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone 
resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of 
NF-kappa B in mouse calvariae. J Immunol. 169(6): 3353-3362. 
Pantel K, Brakenhoff RH. (2004) Dissecting the metastatic cascade. Nat Rev Cancer. 4: 448-456. 
Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT. (2006) BMP signaling is required for RUNX2-dependent 
induction of the osteoblast phenotype. J Bone Miner Res. 21: 637-646. 
Pinski J, Parikh A, Bova GS, Isaacs JT. (2001) Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced 
by coculture of prostate cancer cells with osteoblasts. Cancer Res. 61(17): 6372-6376. 
Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD. (2008) The role of Dickkopf-1 in bone 
development, homeostasis and disease. Blood. 113: 517-525. 
Prunier C, Howe PH. (2005) Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to 
mesenchymal transition (EMT). J Biol Chem. 280: 17540-17548. 
Pyerin W, Ackermann K. (2003) Genes encoding human protein kinase CK2 and their functional links. Prog Nucl Acid Res 
Mol Biol. 74: 239-269. 
Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD. (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast 
differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone. 42: 669-680. 
_______________________________________________________References 
 134 
Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD. (2008) Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast 
cancer cells via depression of Wnt signalling. Cancer Lett. 269: 67-77. 
Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D (1990) An amino-terminal fragment of 
urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun. 
173: 1058–1064. 
Rabinovich GA, Gabrilovich D, Sotomayor EM. (2007) Immunosuppressive strategies that are mediated by tumor cells. 
Annu Rev Immunol. 25: 267-296. 
Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD. (2007) Adrenomedullin is expressed 
in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, 
ADMR. Cancer Res. 67: 2666-2675. 
Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 
16: 79-87. 
Rentsch CA, Cecchini MG, Thalmann GN. (2009) Loss of inhibition over master pathways of bone mass regulation results 
in osteosclerotic bone metastases in prostate cancer. Swiss Med Wkly. 139: 220-225. 
Reya T, Morrison SJ, Clarke MF, Weissman IL. (2001) Stem cells, cancer, and cancer stem cells. Nature. 414: 105-111. 
Ritchie CK, Andrews LR, Thomas K, Tindall DJ, Fitzpatrick L (1997) The effects of growth factors associated with 
osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. 
Endocrinology. 138: 1145-1150. 
Roato I, D’Amelio P, Gorassini E, Grimaldi A, Bonello L, Fiori C, Delsedime L, Tizzani A, De Libero A, Isaia G, Ferracini 
R. (2008) Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE. 3: e3627. 
Roberts AB, Russo A, Felici A, Flanders KC. (2003) Smad3: a key player in pathogenetic mechanisms dependent on TGF-
beta. Ann NY Acad Sci. 995: 1-10. 
Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, Wilson EL. (2005) TGF-beta maintains dormancy of prostatic stem 
cells in the proximal region of ducts. J Cell Biol. 170: 81-90. 
Sato S, Futakuchi M, Ogawa K, Asamoto, Kimihisa N, Asai K, Shirai T. (2008) Transforming growth factor β derived from 
bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone 
microenvironment. Cancer Sci 99: 316-323. 
Schroeder TM, Jensen ED, Westendorf JJ. (2005) Runx2: a master organizer of gene transcription in developing and 
maturing osteoblasts. Birth Defects Res C Embryo Today. 75: 213-225. 
Schuurmans AL, Bolt J, Veldscholte J, Mulder E. (1991) Regulation of growth of LNCaP human prostate tumor cells by 
growth factors and steroid hormones. J Steroid Biochem Mol Biol. 40: 193-197. 
Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, van der Plujim G, Loewik CW, Ackermann 
K, Pyerin W, Hamdy FC, Thalmann GN, Cecchini MG. (2007) Lack of noggin expression by cancer cells is a determinant of the 
osteoblast response in bone metastases. Am J Pathol. 170: 160-175. 
Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. (2001) Plasma levels of interleukin-6 and its soluble 
receptor are associated with prostate cancer progression and metastasis. Urology. 58: 1008-1015.  
Shi Y, Massague J. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113: 685-700. 
Shipman CM, Croucher PI. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-
inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63: 912-916. 
Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. (2004) CX3CR1-fractalkine expression regulates cellular 
mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64(14): 4693-4698. 
Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I. (1990) Expression of the interleukin 6 receptor and interleukin 6 
in prostate carcinoma cells. Cancer Res. 50: 7786-7788. 
Sims NA, Gooi JH. (2008) Bone remodeling: Multiple cellular interactions required for coupling of bone formation and 
resorption. Sem Cell Dev Biol. 19: 444-451. 
Soos G, Jones RF, Haas GP, Wang CY. (1997) Comparative intraosseal growth of human prostate cancer cell lines LNCaP 
and PC3 in the nude mouse. Anticancer Res. 17: 4253-4258. 
Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. (2002) Smad3 promotes alkaline phosphatase activity and 
mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res. 17: 1190-1199. 
Stier S, Forkert R, Lutz C, Neuhaus T, Gruenewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR, Scadden DT. 
(2005) Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 201: 
1781-1791. 
Suda M, Tanaka K, Fukushima M, Natsui K, Yasoda A, Komatsu Y, Ogawa Y, Itoh H, Nakao K. (1996) C-type natriuretic 
peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. 
Biochem Biophys Res Commun. 223: 1-6. 
Suda T, Arai F, Hirao A. (2005) Hematopoietic stem cells and their niche. Trends Immunol. 26: 426-433. 
Suh JH, Lee HW, Lee JW, Kim JB. (2008) Hes1 stimulates transcriptional activity of Runx2 by increasing protein 
stabilization during osteoblast differentiation. Biochem Biophys Res Commun. 367: 97-102. 
Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, 
Lee JK, Amin M, Lyles P, Johnstone PA, Marshall FF, Chung LW. (2008) Coevolution of prostate cancer and bone stroma in 
three-dimensional coculture: Implications for cancer growth and metastasis. Cancer Res. 68: 9996-10003. 
Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H, DeTogni P, Nakayama N, Boyce BF, Abe E, Manolagas SC. 
(1998) Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc 
Assoc Am Physicians. 110(6): 559-574. 
Takayanagi H, Kim S, Koga T, Taniguchi T. (2005) Stat1-mediated cytoplasmic attenuation in osteoimmunology. J Cell 
Biochem. 94: 232-240. 
_______________________________________________________References 
 135 
Tan AR, Alexe G, Reiss M. (2009) Transforming growth factor-beta signaling: emerging stem cell target in metastatic 
breast cancer? Breast Cancer Res Treat. 115: 453-495. 
ten Dijke P, Hill CS. (2004) New insights into TGF-β-Smad signalling. Trends Biochem Sci. 29: 265-273. 
Tenta R, Sotiriou E, Pitulis N, Thyphronitis G, Koutsilieris M. (2005) Prostate cancer cell survival pathways activated by 
bone metastasis microenvironment. J Musculoskelet Neuronal Interact. 5: 135-144. 
Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LWK 
(1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 5: 2271-2277. 
Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. (2000) LNCaP progression 
model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate. 44: 91-103. 
Thirunavukkarasu K, Miles RR, Halladay DL, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE. (2001) 
Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG 
promoter region that  mediates TGF-beta effects. J Biol Chem. 276(39): 36241-36250. 
Tian E, Zhan F, Walker R, Rasmussen E, Yupo M, Barlogie B, Shaughnessy J. (2003) The role of the Wnt-signaling 
antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 349: 2483-2494. 
Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. (1998) SARA, a FYVE domain protein that recruits Smad2 to 
the TGFbeta receptor. Cell. 95: 779-791. 
Utsugi M, Dobashi K, Ishizuka T, Masubuchi K, Shimizu Y, Nakazawa T, Mori M. (2003) C-Jun-NH2-terminal kinase 
mediates expression of connective tissue growth factor induced by transforming growth factor-beta1 in human lung fibroblasts. 
Am J Respir Cell Mol Biol. 28: 754-761. 
Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. (1988) Transforming growth factor β1 
positively regulates its own expression in normal and transformed cells. J Biol Chem. 263: 7741-7746. 
Verrecchia F, Chu ML, Mauviel A. (2001) Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a 
combined cDNA microarray/promoter transactivation approach. J Biol Chem. 276: 17058-17062. 
Virk MS, Lieberman JR. (2007) Tumor metastasis to bone. Arthr Res Ther. 9 (Suppl 1): S5 (doi:10.1186/ar2169). 
Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S. (2002) Guidelines for human gene nomenclature. 
Genomics. 79: 464-470. 
Wan M, Cao X. (2005) BMP signaling in skeletal development. Biochem Biophys Res Commun. 328: 651-657. 
Wang Y. (2001) The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer 
invasion and metastasis. Med Res Rev. 21: 146-170. 
Waschek JA. (2004) Developmental actions of natriuretic peptides in the brain and skeleton. Cell Mol Life Sci. 61: 2332-
2342. 
Watabe T, Miyazono K. (2009) Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res. 19: 
103-115. 
Wegiel B, Bjartel A, Culig Z, Persson JL. (2008) Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to 
promote prostate cancer cell survival. Int J Cancer. 122: 1521-1529. 
Weidemann A, Klanke B, Wagner M, Volk T, Willam C, Wiesener MS, Eckardt KU, Warnecke C. (2008) Hypoxia, via 
stabilization of the hypoxia-inducible factor HIF-1a, is a direct and sufficient stimulus for brain-type natriuretic peptide 
induction. Biochem J. 409: 233-242. 
Wikstrom P, Damber JE, Bergh A (2001) Role of transforming growth factor-β1 in prostate cancer. Microsc Res Tech. 52: 
411-419. 
Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A (1998) Transforming growth factor β1 is associated with 
angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 37: 19-29. 
Wilson A, Trumpp A. (2006) Bone-marrow haematopoietic stem-cell niches. Nat Rev Immunol. 6: 93-106. 
Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F (2004) RANKL/RANK/OPG: new 
therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 1704: 49-57. 
Woodard GE, Rosado JA. (2007) Recent advances in natriuretic peptide research. J Cell Mol Med. 11: 1263-1271. 
Wooten MW, Geetha T, Seibenhener ML, Babu JR, Diaz-Meco MT, Moscat J. (2005) The p62 scaffold regulates nerve 
growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem. 280: 35625-35629. 
Wrana JL, Kubota T, Zhang Q, Overall CM, Aubin JM, Butler WT, Sodek J. (1991) Regulation of transformation-sensitive 
secreted phosphoprotein (SPPI/osteopontin) expression by transforming growth factor-beta. Comparisons with expression of 
SPARC (secreted acidic cysteine-rich protein). Biochem. J. 273: 523-531. 
Yamaguchi A, Komori T, Suda T. (2000) Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, 
hedgehogs, and Cbfa1. Endocr Rev. 21: 393-411. 
Yang F, Strand DW, Rowley DR. (2008) Fibroblast growth factor-2 mediates transforming growth factor-beta action in 
prostate cancer reactive stroma. Oncogene. 27: 450-459. 
Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetic CJ, 
Karsenty G, Navone NM. (2001) Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. 
Cancer Res. 61: 5652-5659. 
Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, Pavlidis P, Kucherlapati R, Roberts AB, Boettinger EP (2003) 
Hierarchical model of gene regulation by transforming growth factor β. PNAS 100: 10269-10274. 
Yavropoulou MP, Yovos JG. (2007) The role of the Wnt signaling pathway in osteoblast commitment and differentiation. 
Hormones. 6: 279-294. 
Yeh LC, Zavala MC, Lee JC. (2002) Osteogenic protein-1 and interleukin-6 with its soluble receptor synergistically 
stimulate rat osteoblastic cell differentiation. J Cell Physiol. 190(3): 322-31. 
Yin JJ, Pollock CB, Kelly K. (2005) Mechanisms of cancer metastasis to the bone. Cell Res. 15: 57-62. 
Yin T, Li L. (2006) The stem cell niches in bone. J Clin Invest. 116: 1195-201. 
_______________________________________________________References 
 136 
Yoshiko Y, Aubin JE, Maeda N. (2002) Stanniocalcin 1 (STC1) protein and mRNA are developmentally regulated during 
embryonic mouse osteogenesis: the potential of STC1 as an autocrine/paracrine factor for osteoblast development and bone 
formation. J Histochem Cytochem. 50: 483-491. 
Yoshiko Y, Maeda N, Aubin JE. (2003) Stanniocalcin 1 stimulates osteoblast differentiation in rat calvaria cell cultures. 
Endocrinology 144: 4134–4143. 
Zayzafoon M, Abdulkadir SA, McDonald JM. (2004) Notch signaling and ERK activation are important for the 
osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem. 279(5): 3662-3670.  
Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. (2005) Blockade of transforming growth factor-beta signaling suppresses 
progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res. 11: 4512-4520. 
Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. (2001) Osteoprotegerin 
inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107: 1235-
1244. 
Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross H, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina 
Y, Li L. (2003) Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 425: 836-841. 
Zhang Q, Rubenstein JN, Jang TL, Pins M, Javonovic B, Yang X, Kim SJ, Park I, Lee C. (2005) Insensitivity to transforming 
growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol 
Endocrinol. 19: 2390-2399. 
Zhang S, Fei T, Zhang L, Zhang R, Chen R, Chen F, Ning Y, Han Y, Feng XH, Meng A, Chen YG. (2007) Smad7 
antagonizes transforming growth factor-beta signaling in the nucleus by interfering with functional Smad-DNA complex 
formation. Mol Cell Biol. 27: 4488-4499. 
Zhang YQ, Kanzaki M, Shibata H, Kojima I. (1997) Regulation of the expression of follistatin in rat hepatocytes. Biochim 
Biophys Acta. 1354: 204-210. 
Zheng Y, Zhou H, Fong-Yee C, Modzelewski JR, Seibel MJ, Dunstan CR. (2008) Bone resorption increases tumour growth 
in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis. 25: 559-567. 
Zhu HJ, Burgess AW. (2001) Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun. 4: 321-
330. 
Zhu J, Emerson SG. (2004) A new bone to pick: osteoblasts and the haematopoietic stem-cell niche. BioEssays 26: 595-599. 
Zhu Y, Sun Z, Han Q, Liao L, Wang J, Bian C, Li J, Yan X, Liu Y, Shao C, Zhao RC. (2009) Human mesenchymal stem 
cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia. 23: 925-33. 
Zunich SM, Douglas T, Valdovinos M, Chang T, Bushman W, Walterhouse D, Iannaccone P, Lamm ML. (2009) Paracrine 
sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiation. Mol Cancer. 8: 12 (doi: 10.1186/1476-
4598-8-12). 
 
  137 
Supplementary data 
 
Tab. 1 Genes significantly (≥ 2-fold) UPREGULATED in all three coculture combinations. 
Genes were divided into functional groups on the basis of information from the Entrez Gene and PubMed databases (www.ncbi.nlm.nih.gov). 
For experimental details see Results, the legend to Fig. 19. 
 
Entrez 
GeneID 
Gene 
symbol Gene product Function 
Enzymes (metabolism) 
272 AMPD3 adenosine monophosphate deaminase (isoform E) enzyme; metabolism 
55768 NGLY1 N-glycanase 1 enzyme; metabolism 
80055 PGAP1 GPI deacylase enzyme; metabolism 
25976 TIPARP TCDD-inducible poly(ADP-ribose) polymerase enzyme; metabolism 
Cell signaling 
1437 CSF2 colony stimulating factor 2 (granulocyte-macrophage) cytokine 
1848 DUSP6 dual specificity phosphatase 6 signal transduction 
2260 FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) signal transduction 
3556 IL1RAP interleukin 1 receptor accessory protein signal transduction 
8660 IRS2 insulin receptor substrate 2 signal transduction 
64840 PORCN porcupine homolog (Drosophila) 
endoplasmic reticulum; protein processing; processing of Wnt signaling 
components 
6236 RRAD Ras-related associated with diabetes signal transduction 
Membrane proteins 
9635 CLCA2 chloride channel, calcium activated, family member 2 ion channel, adhesion molecule 
9976 CLEC2B C-type lectin domain family 2, member B adhesion molecule 
667 DST dystonin adhesion molecule 
1837 DTNA dystrobrevin, alpha membrane protein 
4311 MME membrane metallo-endopeptidase surface marker; peptidase; inactivates hormones 
8496 PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1) plasma membrane, protein interactions 
7037 TFRC transferrin receptor (p90, CD71) membrane receptor 
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Transcription regulation 
3638 INSIG1 insulin induced gene 1 lipid metabolism; regulatory protein; endoplasmic reticulum 
80853 JHDM1D jumonji C domain-containing histone demethylase 1 homolog D (S. cerevisiae) transcription regulation 
9734 HDAC9 histone deacetylase 9 transcription regulation 
3280 HES1 hairy and enhancer of split 1, (Drosophila) transcription factor; osteoblast differentiation 
4783 NFIL3 nuclear factor, interleukin 3 regulated transcription factor 
Transport 
2017 CTTN cortactin cytoskeleton/vesicle transport 
2803 GOLGA4 golgi autoantigen, golgin subfamily a, 4 Golgi apparatus (vesicle transport) 
9818 NUPL1 nucleoporin like 1 nuclear pore complex (transport) 
10802 SEC24A SEC24 related gene family, member A (S. cerevisiae) vesicle transport 
9871 SEC24D SEC24 related gene family, member D (S. cerevisiae) vesicle transport 
55186 SLC25A36 solute carrier family 25, member 36 solute carrier  
Stress response 
597 BCL2A1 BCL2-related protein A1 stress response; antiapoptotic protein 
5494 PPM1A protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform negative regulator of stress response; cell cycle control; terminates TGFβ signaling 
23645 PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A stress response 
6095 RORA RAR-related orphan receptor A stress response 
51616 TAF9B 
TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
31kDa transcription initiation 
7272 TTK TTK protein kinase required for progression of mitosis (cell proliferation) 
Other 
27065 D4S234E DNA segment on chromosome 4 (unique) 234 expressed sequence other 
10144 FAM13A1 family with sequence similarity 13, member A1 other 
55785 FGD6 FYVE, RhoGEF and PH domain containing 6 other 
54985 HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent) other 
652526 /// 
727927 /// 
9659 
 
LOC727927 
/// PDE4DIP 
phosphodiesterase 4D interacting protein (myomegalin) /// similar to 
phosphodiesterase 4D interacting protein isoform 2 other 
654342 LOC654342 Similar to lymphocyte-specific protein 1 other 
375449 MAST4 Microtubule associated serine/threonine kinase family member 4 other 
4884 NPTX1 neuronal pentraxin I other 
8731 RNMT RNA (guanine-7-) methyltransferase other 
51750 
RTEL1 /// 
TNFRSF6B 
tumor necrosis factor receptor superfamily, member 6b, decoy /// regulator of 
telomere elongation helicase 1 telomere maintenance 
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23429 RYBP RING1 and YY1 binding protein other 
25907 TMEM158 transmembrane protein 158 other 
7267 TTC3 tetratricopeptide repeat domain 3 other 
 
 
 
 
Tab. 2 Genes significantly (≥ 2-fold) DOWNREGULATED in all three coculture combinations. 
For details see the legend to Tab. 1. 
 
 
Entrez 
GeneID 
Gene 
symbol Gene product Function 
Enzymes 
31 ACACA acetyl-Coenzyme A carboxylase alpha fatty acid synthesis (lipid metabolism) 
18 ABAT 4-aminobutyrate aminotransferase enzyme 
875 CBS cystathionine-beta-synthase enzyme; metabolism 
8560 DEGS1 degenerative spermatocyte homolog 1, lipid desaturase (Drosophila) lipid metabolism 
1718 DHCR24 24-dehydrocholesterol reductase cholesterol biosynthesis (lipid metabolism) 
1719 DHFR dihydrofolate reductase enzyme; nucleotide synthesis 
3295 HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 enzyme; fatty acid catabolism (lipid metabolism) 
3417 IDH1 isocitrate dehydrogenase 1 (NADP+), soluble enzyme; metabolism 
51056 LAP3 leucine aminopeptidase 3 aminopeptidase 
4247 MGAT2 mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase Golgi enzyme 
11098 PRSS23 protease, serine, 23 serine protease 
7296 TXNRD1 thioredoxin reductase 1 enzyme; protection against oxidative stress 
10269 ZMPSTE24 zinc metallopeptidase (STE24 homolog, S. cerevisiae) protease 
Cell signaling 
2247 FGF2 fibroblast growth factor 2 (basic) cytokine 
22943 DKK1 dickkopf homolog 1 (Xenopus laevis) secreted protein 
10468 FST follistatin cytokine 
4739 NEDD9 neural precursor cell expressed, developmentally down-regulated 9 signal transduction 
8829 NRP1 neuropilin 1 membrane coreceptor to tyrosine kinase receptor 
60676 PAPPA pregnancy-associated plasma protein A, pappalysin 1 metalloproteinase; regulates growth factor availability 
5999 RGS4 regulator of G-protein signaling 4 G-protein signaling 
7048 TGFBR2 transforming growth factor, beta receptor II (70/80kDa) growth factor receptor 
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ECM, adhesion, cytoskeleton 
347902 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion molecule 
1009 CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) adhesion molecule 
1277 COL1A1 collagen, type I, alpha 1 ECM component 
1278 COL1A2 collagen, type I, alpha 2 ECM component 
4771 NF2 neurofibromin 2 (bilateral acoustic neuroma) cytoskeleton 
7057 THBS1 thrombospondin 1 adhesion molecule 
10330 TMEM4 transmembrane protein 4 interacts with cytoskeleton 
DNA, RNA and protein synthesis 
11056 DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 proliferation-associated nuclear antigen; splicing, translation 
1153 CIRBP cold inducible RNA binding protein cell proliferation 
90993 CREB3L1 cAMP responsive element binding protein 3-like 1 transcription factor 
4173 MCM4 minichromosome maintenance complex component 4 initiation of replication 
10605 PAIP1 poly(A) binding protein interacting protein 1 translation initiation, protein biosynthesis 
6421 SFPQ 
splicing factor proline/glutamine-rich (polypyrimidine tract binding protein 
associated) multifunctional nuclear protein 
Immune response 
9510 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 inflammatory processes, matrix remodeling 
6347 CCL2 chemokine (C-C motif) ligand 2 cytokine; inflammatory response 
4599 MX1 
myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 
(mouse) immune response 
5806 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta marker of inflammation 
6772 STAT1 signal transducer and activator of transcription 1, 91kDa transcription factor; immune response 
Other 
 
  
4591 TRIM37 tripartite motif-containing 37 unknown 
25972 UNC50 unc-50 homolog (C. elegans) fibroblast differentiation 
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Tab. 3 Significant transcription alterations selective for hfOBPC3, hfOBLNCaP or hfOBC4-2B4.  
Genes were divided into functional groups on the basis of information from the Entrez Gene and PubMed databases (www.ncbi.nlm.nih.gov). 
For experimental details see Results, the legend to Fig. 19. Transcription alterations observed in only one coculture combination on the array, but 
confirmed by qRT-PCR as present in two or three coculture combinations have been included in Results, Tab. 9. 
hfOBX, X-cocultured hfOB; , ≥ 2-fold elevation; , ≥ 1,5-fold elevation; , ≥ 2-fold repression; , ≥ 1,5-fold repression;  
nc, no change; * ,verified by qRT-PCR; #, transcript upregulated by TGFβ; I , immune response; ** , change seen only in qRT-PCR 
  
 
Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBLNCaP  
48 h 
hfOBC4-2B4  
48 h 
 
Stress response; modulation of pro- and antiapoptotic mechanisms 
3708 ITPR1 inositol 1,4,5-triphosphate receptor, type 1 Calcium channel required for apoptotic cell death.  nc nc 
9467 SH3BP5 SH3-domain binding protein 5 (BTK-associated) Mitochondrial protein, phosphorylated by stress-activated protein kinase 3.  nc nc 
7133 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B Suppressor of death receptor-mediated apoptosis.  nc nc 
 
8793 TNFRSF10D 
tumor necrosis factor receptor superfamily, member 10d, 
decoy with truncated death domain Inhibitory role in TRAIL-induced cell apoptosis. nc  nc 
 
 
23300 ASCIZ ATM/ATR-Substrate Chk2-Interacting Zn2+-finger protein DNA repair, depletion increases apoptosis after DNA damage. nc  nc 
 
 
10628 TXNIP thioredoxin interacting protein 
Glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-
induced apoptosis. nc nc  
 
Decreased DNA and RNA synthesis, suppressed proliferation 
1028 CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) Negative regulator of cell proliferation - strong inhibitor of G1 cyclin/Cdk complexes.  nc nc 
 
5586 PKN2 protein kinase N2 
Ser/Thr kinase and Rho/Rac effector protein, essential regulator of both entry into mitosis 
and exit from cytokinesis nc  nc 
22936 ELL2 elongation factor, RNA polymerase II, 2 Component of transcriptional machinery. nc  nc 
 
1020 CDK5 cyclin-dependent kinase 5 Cell cycle control.  nc nc 
11052 CPSF6 cleavage and polyadenylation specific factor 6, 68kDa Subunit of a cleavage factor required for 3' RNA cleavage and polyadenylation processing.  nc nc 
1503 CTPS CTP synthase Nucleotide synthesis.  nc nc 
2071 ERCC3 
excision repair cross-complementing rodent repair deficiency, 
complementation group 3 (xeroderma pigmentosum group B 
complementing) 
ATP-dependent DNA helicase, functions in nucleotide excision repair. Also functions in 
class II transcription (as a subunit of TFIIH).  nc nc 
64785 GINS3 GINS complex subunit 3 (Psf3 homolog) Essential for the initiation of DNA replication.  nc nc 
2958 GTF2A2 general transcription factor IIA, 2, 12kDa Regulates transcription initiation.  nc nc 
8520 HAT1 histone acetyltransferase 1 
Acetylation of newly synthesized cytoplasmic histones, which plays an important role in 
replication-dependent chromatin assembly.  nc nc 
3182 HNRPAB heterogeneous nuclear ribonucleoprotein A/B RNA binding protein, associates with pre-mRNA in the nucleus.  nc nc 
5654 HTRA1 HtrA serine peptidase 1 Regulates availability of insulin-like growth factors and possibly cell growth.  nc nc 
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Entrez 
GeneID 
Gene 
Symbol 
Gene Product Description 
 
hfOBPC3  
48 h 
hfOBLNCaP  
48 h 
hfOBC4-2B4  
48 h 
3609 ILF3 interleukin enhancer binding factor 3, 90kDa 
Complexes with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate 
gene expression and stabilize mRNAs.  nc nc 
4331 MNAT1 
menage a trois homolog 1, cyclin H assembly factor (Xenopus 
laevis) 
Involved in the assembly of the kinase complex that activates cyclin-dependent kinases, 
which participate in cell cycle control.  nc nc 
51728 POLR3K 
polymerase (RNA) III (DNA directed) polypeptide K, 12.3 
kDa 
Small essential subunit of RNA polymerase III, the polymerase responsible for 
synthesizing transfer and small ribosomal RNAs in eukaryotes.  nc nc 
80324 PUS1 pseudouridylate synthase 1 
Converts uridine into pseudouridine after the nucleotide has been incorporated into RNA. 
Pseudouridine may have a functional role in tRNAs and may assist in the peptidyl transfer 
reaction of rRNAs.  nc nc 
3431 SP110 SP110 nuclear body protein 
Component of the nuclear body, a multiprotein complex that may participate in the 
regulation of transcription.. May play a role in transcription activation and in ribosome 
biogenesis.  nc nc 
54962 TIPIN TIMELESS interacting protein 
Nuclear protein. Depletion of endogenous tipin results in reduced growth rate, which may 
be due in part to inefficient progression of S phase and DNA synthesis.  nc nc 
8295 TRRAP transformation/transcription domain-associated protein 
 
Recruitment of histone acetyltransferase complexes to chromatin during transcription, 
replication and DNA repair.  nc nc 
79084 WDR77 WD repeat domain 77 Component of methyltransferase complex that modifies spliceosomal proteins.  nc nc 
 
 
4609 MYC v-myc myelocytomatosis viral oncogene homolog (avian) 
Multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, 
apoptosis and cellular transformation. Transcription factor. nc  nc 
4999 ORC2L origin recognition complex, subunit 2-like (yeast) Essential for initiation of DNA replication. nc  nc 
 
8317 CDC7 cell division cycle 7 homolog (S. cerevisiae) Cell division cycle protein with kinase activity that is critical for the G1/S transition. nc nc  
2965 GTF2H1 general transcription factor IIH, polypeptide 1, 62kDa Transcription initiation. nc nc  
 
10614 HEXIM1 hexamethylene bis-acetamide inducible 1 
Suppresses transcription elongation. Directly associates with glucocorticoid receptor to 
suppress glucocorticoid-inducible gene activation. nc nc  
 
Gene-specific regulation of transcription 
23253 ANKRD12 Ankyrin repeat domain 12 Transcriptional coregulator.  nc nc 
1195 CLK1 CDC-like kinase 1 Kinase indirectly involved in pre-mRNA processing, may influence splice site selection.  nc nc 
4601 MXI1 MAX interactor 1 Transcriptional repressor.  nc nc 
864 RUNX3 runt-related transcription factor 3 Transcription factor.  nc nc 
 
604 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) Transcriptional repressor. nc  nc 
81606 LBH limb bud and heart development homolog (mouse) Putative transcriptional activator. nc  nc 
10308 ZNF267 zinc finger protein 267 Transcriptional repressor. nc  nc 
 
8091 HMGA2 high mobility group AT-hook 2 Transcriptional regulator.  nc nc 
4150 MAZ 
MYC-associated zinc finger protein (purine-binding 
transcription factor) Transcription factor, inflammation-responsive.  nc nc 
9111 NMI 
 I
 N-myc (and STAT) interactor 
Interacts with transcription factors, augments STAT-mediated transcription in response to 
interferon.  nc nc 
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1997 ELF1 E74-like factor 1 (ets domain transcription factor) Transcription factor. nc nc  
 
Protein synthesis, modification and degradation 
1917 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 Component of translational machinery.  nc nc 
 
9958 USP15 ubiquitin specific peptidase 15 Dissassembly of polyubiquitin chains on degraded proteins. nc  nc 
 
29071 C1GALT1C1 C1GALT1-specific chaperone 1 Molecular chaperone.  nc nc 
54431 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 Putative co-chaperone in the endoplasmic reticulum.  nc nc 
60681 FKBP10 FK506 binding protein 10, 65 kDa Molecular chaperone localized in the ER.  nc nc 
23463 ICMT isoprenylcysteine carboxyl methyltransferase Posttranslational protein modification in the ER.  nc nc 
5696 PSMB8 I 
proteasome (prosome, macropain) subunit, beta type, 8 (large 
multifunctional peptidase 7) Protein degradation (proteasome subunit). Interferon-induced.  nc nc 
871 SERPINH1 
serpin peptidase inhibitor, clade H (heat shock protein 47), 
member 1, (collagen binding protein 1) 
Putative molecular chaperone involved in the maturation of collagen molecules. Localizes 
to the ER.  nc nc 
 
908 CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) Molecular chaperone (protein folding). nc  nc 
51809 GALNT7 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 7 (GalNAc-T7) Protein glycosylation. nc  nc 
 
54982 CLN6 ceroid-lipofuscinosis, neuronal 6, late infantile, variant Possibly involved in the degradation of posttranslationally modified proteins in lysosomes. nc nc  
9997 SCO2 SCO cytochrome oxidase deficient homolog 2 (yeast) 
The yeast gene enables assembly of the cytochrome c oxidase complex, which catalyzes 
the transfer of reducing equivalents from cytochrome c to molecular oxygen and pumps 
protons across the inner mitochondrial membrane. nc nc  
 
Cytokines, cell  surface receptors and cell signaling 
394 ARHGAP5 Rho GTPase activating protein 5 Negatively regulates Rho GTPases.  nc nc 
960 CD44 CD44 molecule (Indian blood group) Cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration.  nc nc 
7852 CXCR4 chemokine (C-X-C motif) receptor 4 Cell surface chemokine receptor.  nc nc 
9289 GPR56 G protein-coupled receptor 56 Cell signaling.  nc nc 
2872 MKNK2 MAP kinase interacting serine/threonine kinase 2 Cell signaling.  nc nc 
5801 PTPRR protein tyrosine phosphatase, receptor type, R Regulator of cell signaling cascades.  nc nc 
5979 RET ret proto-oncogene Cell surface receptor tyrosine kinase.  nc nc 
58528 RRAGD Ras-related GTP binding D G protein. Cell signaling.  nc nc 
 
7189 TRAF6 TNF receptor-associated factor 6 Signal transducer in the NF-kB pathway acting in response to proinflammatory cytokines. nc  nc 
 
57124 CD248 CD248 molecule, endosialin Cell surface adhesion molecule.  nc nc 
8760 CDS2 
CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 2 Cell signaling - regulates the amount of phosphatidylinositol available for signaling.  nc nc 
91851 CHRDL1 chordin-like 1 Antagonist of bone morphogenetic protein-4.  nc nc 
2919 CXCL1
 I
 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) Proinflammatory chemokine.  nc nc 
1825 DSC3 desmocollin 3 
Calcium-dependent adhesive glycoprotein, component of  the desmosome cell-cell 
junction.  nc nc 
1906 EDN1# endothelin 1 
Osteoblast mitogen, pro-osteoblastic factor in osteoblastic prostate cancer metastasis. 
TGFβ target.  nc nc 
2150 F2RL1 coagulation factor II (thrombin) receptor-like 1 Cell signaling - transmembrane receptor., couples to G proteins.  nc nc 
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166647 GPR125 G protein-coupled receptor 125 Initiates signaling via G proteins.  nc nc 
3434 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Interferon-induced negative-feedback regulator of virus-triggered signaling.  nc nc 
9562 MINPP1 multiple inositol polyphosphate histidine phosphatase, 1 Cell signaling - hydrolyzes inositol phosphate  metabolites.  nc nc 
56106 
 
PCDHGA10 /// 
PCDHGA11 /// 
PCDHGA12 /// 
PCDHGA3 /// 
PCDHGA5 /// 
PCDHGA6 
protocadherin gamma subfamily A, 12 /// protocadherin 
gamma subfamily A, 11 /// protocadherin gamma subfamily A, 
10 /// protocadherin gamma subfamily A, 6 /// protocadherin 
gamma subfamily A, 5 /// protocadherin gamma subfamily A, 
3 Cell-cell adhesion protein.  nc nc 
8434 RECK reversion-inducing-cysteine-rich protein with kazal motifs Membrane glycoprotein.  nc nc 
7424 VEGFC vascular endothelial growth factor C Cytokine, mediator of angiogenesis.  nc nc 
 
3676 ITGA4 
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 
receptor) Cell adhesion (integrin family). nc  nc 
 
NF-kB pathway components and target genes 
54101 RIPK4 receptor-interacting serine-threonine kinase 4 Ser/Thr protein kinase, can activate NF-kB.  nc nc 
6648 SOD2 superoxide dismutase 2, mitochondrial Upregulated by NF-kB.  nc nc 
 
Transport 
4864 NPC1 Niemann-Pick disease, type C1 Membrane protein, intracellular cholesterol transport.  nc nc 
5172 SLC26A4 solute carrier family 26, member 4 Transport across membranes.  nc nc 
51312 SLC25A37 solute carrier family 25, member 37 Transport across membranes.  nc nc 
 
28231 SLCO4A1 solute carrier organic anion transporter family, member 4A1 Transport across membranes. nc  nc 
 
1174 AP1S1 adaptor-related protein complex 1, sigma 1 subunit 
Part of the clathrin coat assembly complex which links clathrin to receptors in coated 
vesicles. These vesicles are involved in endocytosis and Golgi processing.  nc nc 
3839 KPNA3 karyopherin alpha 3 (importin alpha 4) Involved in nuclear protein import.  nc nc 
9688 NUP93 nucleoporin 93kDa Component of nuclear pore complex.  nc nc 
6522 SLC4A2 
solute carrier family 4, anion exchanger, member 2 
(erythrocyte membrane protein band 3-like 1) Membrane-bound protein, mediates anion exchange.   nc nc 
6747 SSR3 
signal sequence receptor, gamma (translocon-associated 
protein gamma) 
Glycosylated ER membrane receptor associated with protein translocation across the ER 
membrane.  nc nc 
 
9114 ATP6V0D1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 
Component of vacuolar ATPase, which mediates acidification of eukaryotic intracellular 
organelles, necessary e.g. for protein sorting and zymogen activation. nc  nc 
5527 CCDC91 coiled-coil domain containing 91 Promotes movement of clathrin-coated vesicles and lysosomal enzyme sorting. nc  nc 
3838 KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) Nuclear transport of proteins. nc  nc 
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51393 TRPV2 
transient receptor potential cation channel, subfamily V, 
member 2 Ion channel, may be involved in nociception. nc  nc 
 
23404 EXOSC2 exosome component 2 Exosome component (cellular transport). nc nc  
8675 STX16 syntaxin 16 Found on cell membranes, permits specific synaptic vesicle docking and fusion. nc nc  
 
Metabolism  
10840 ALDH1L1 aldehyde dehydrogenase 1 family, member L1 Metabolic enzyme.  nc nc 
3099 HK2 hexokinase 2 Metabolic enzyme.  nc nc 
5209 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Metabolic enzyme.  nc nc 
 
1743/ 
1744 
DLST /// 
DLSTP 
dihydrolipoamide S-succinyltransferase (E2 component of 2-
oxo-glutarate complex) /// dihydrolipoamide S-
succinyltransferase pseudogene (E2 component of 2-oxo-
glutarate complex) Metabolic enzyme.  nc nc 
55568 GALNT10 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) Synthesis of mucin-type oligosaccharides.  nc nc 
3052 HCCS holocytochrome c synthase (cytochrome c heme-lyase) Metabolic enzyme.  nc nc 
 
34 ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain Metabolic enzyme (mitochondrial fatty acid beta-oxidation). nc  nc 
5019 OXCT1 3-oxoacid CoA transferase 1 Metabolic enzyme (mitochondrial ketone body catabolism). nc  nc 
641371 
ACOT1 /// 
ACOT2 acyl-CoA thioesterase 2 /// acyl-CoA thioesterase 1 Metabolic enzyme. nc  nc 
2530 FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) Synthesis of complex glycopeptides. nc  nc 
3954 LETM1 Leucine zipper-EF-hand containing transmembrane protein 1 Regulation of mitochondrial biogenesis and ATP production. nc  nc 
 
262 AMD1 adenosylmethionine decarboxylase 1 Intermediate enzyme in polyamine biosynthesis. nc nc  
9517 SPTLC2 serine palmitoyltransferase, long chain base subunit 2 Key enzyme in sphingolipid biosynthesis. nc nc  
 
Structural proteins 
2201 FBN2 fibrillin 2 (congenital contractural arachnodactyly) Component of connective tissue microfibrils.  nc nc 
3017 HIST1H2BD histone cluster 1, H2bd Chromatin component (histone).  nc nc 
 
72 ACTG2 actin, gamma 2, smooth muscle, enteric Cytoskeleton component.  nc nc 
 ACTR2 ARP2 actin-related protein 2 homolog (yeast) Involved in cytoskeletal dynamics.  nc nc 
1634 DCN decorin Binds to collagen fibrils, plays a role in matrix assembly.  nc nc 
4281 MID1 midline 1 (Opitz/BBB syndrome) 
Associates with microtubules in the cytoplasm, likely involved in the formation of 
multiprotein structures acting as anchor points to microtubules.  nc nc 
3916 LAMP1 lysosomal-associated membrane protein 1 Membrane glycoprotein.  nc nc 
 
8365 HIST1H4H histone cluster 1, H4h Chromatin component (histone). nc  nc 
 
81493 SYNC1 syncoilin, intermediate filament 1 Member of the intermediate filament family. nc nc  
7094 TLN1 talin 1 
Cytoskeletal protein, concentrated in areas of cell-substratum and cell-cell contacts. Plays 
a role in the assembly of actin filaments, in cell attachment to the ECM and cell migration. nc nc  
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Other 
55917 CTTNBP2NL CTTNBP2 N-terminal like Function unknown.  nc nc 
54629 FAM63B family with sequence similarity 63, member B Function unknown.  nc nc 
9788 MTSS1 metastasis suppressor 1 Function unknown.  nc nc 
22990 PCNX pecanex homolog (Drosophila) Function unknown.  nc nc 
5187 PER1 period homolog 1 (Drosophila) Involved in regulation of circadian rhytms in the brain.  nc nc 
83937 RASSF4 Ras association (RalGDS/AF-6) domain family 4 Function unknown.  nc nc 
728695 
SPANXB1 /// 
SPANXB2 SPANX family, member B2 /// SPANX family, member B1 Functions in spermatogenesis.  nc nc 
7163 TPD52 tumor protein D52 Function unknown.  nc nc 
9960 USP3 ubiquitin specific peptidase 3 Deubiquitinates histones. Role in preventing chromatin damage.  nc nc 
 
81553 FAM49A family with sequence similarity 49, member A Function unknown. nc  nc 
221037 JMJD1C jumonji domain containing 1C Function unknown. nc  nc 
54469 ZFAND6 Zinc finger, AN1-type domain 6 Function unknown. nc  nc 
 
399491 LOC399491 LOC399491 protein Function unknown. nc nc  
 
29 ABR active BCR-related gene Function unknown.  nc nc 
208 AKT2 v-akt murine thymoma viral oncogene homolog 2 Ser/Thr kinase.  nc nc 
9532 BAG2 BCL2-associated athanogene 2 Inhibits chaperone activity of Hsc70.  nc nc 
51200 CPA4 carboxypeptidase A4 Zinc-containing endopeptidase.  nc nc 
2633 GBP1 
I
 guanylate binding protein 1, interferon-inducible, 67kDa Binds guanine nucleotides. Induced by interferon.  nc nc 
10964 IFI44L 
I
 interferon-induced protein 44-like Function unknown.  nc nc 
3430 IFI35 
I
 interferon-induced protein 35 Interferon-induced., relocalizes in apoptotic cells.  nc nc 
4323 MMP14 matrix metallopeptidase 14 (membrane-inserted) ECM remodeling.  nc nc 
4600 MX2 
I
 myxovirus (influenza virus) resistance 2 (mouse) Nuclear and cytoplasmic localization. Upregulated by interferon-alpha.  nc nc 
4938 OAS1 
I
 2',5'-oligoadenylate synthetase 1, 40/46kDa Interferon-induced protein, involved in the innate immune response to viral infection.  nc nc 
55714 ODZ3 odz, odd Oz/ten-m homolog 3 (Drosophila) Function unknown.  nc nc 
10745 PHTF1 putative homeodomain transcription factor 1 Function unknown.  nc nc 
23753 SDF2L1 stromal cell-derived factor 2-like 1 Function unknown.  nc nc 
60559 SPCS3 signal peptidase complex subunit 3 homolog (S. cerevisiae) Function unknown.  nc nc 
23424 TDRD7 tudor domain containing 7 Function unknown.  nc nc 
57215 THAP11 THAP domain containing 11 Contains a DNA-binding domain.  nc nc 
23670 TMEM2 transmembrane protein 2 Function unknown.  nc nc 
85453 TSPYL5 TSPY-like 5 Function unknown.  nc nc 
10190 TXNDC9 thioredoxin domain containing 9 Function unknown  nc nc 
81839 VANGL1 vang-like 1 (van gogh, Drosophila) Function unknown.  nc nc 
90233 ZNF551 zinc finger protein 551 Function unknown.  nc nc 
  147 
 
 
 
 
 
221154 EFHA1 EF-hand domain family, member A1 Function unknown. nc  nc 
24147 FJX1 four jointed box 1 (Drosophila) Function unknown. nc  nc 
81887 LAS1L LAS1-like (S. cerevisiae) Function unknown. nc  nc 
83752 LONP2 Lon peptidase 2, peroxisomal Proteolysis of mitochondrial substrates. nc  nc 
84939 MUM1 melanoma associated antigen (mutated) 1 Function unknown. nc  nc 
 
1809 DPYSL3 dihydropyrimidinase-like 3 Function unknown. nc nc  
54737 HSMPP8 M-phase phosphoprotein, mpp8 Function unknown. nc nc  
6428 SFRS3 splicing factor, arginine/serine-rich 3 Target gene of beta-catenin/TCF4 signaling. nc nc  
_________________________________________________Curriculum vitae 
 148 
Curriculum vitae 
 
 
Personal information 
 
Name: 
  Agnieszka Anna Halas 
 
Address: Tulipanowa 68 
20-827 Lublin 
Poland 
 
Phone number: (48 81) 746 67 84 
Date of birth: 31.12.1980 in Lublin 
Nationality: Polish 
Family: single, no children 
 
 
Education 
 
1987-1995 Elementary School No. 9, Lublin 
 
 
1995 - 1999 
 
Stanisław Staszic High School No.1, Lublin 
 
1999 Maturity exams 
 
1999 - 2002 Vocational undergraduate studies at the Maria Curie-Skłodowska University in 
Lublin, Department of Biology and Earth Sciences, major in biotechnology 
 
01.07.2002 Bachelor's thesis defence 
(Advances in the research on bioartificial liver devices) 
 
2002 - 2004 
 
 
Graduate studies at the Maria Curie-Skłodowska University in Lublin, Faculty of 
Biology and Earth Sciences, major in biotechnology 
01.09 - 30.09.2003 Internship at the Institute of Immunology and Experimental Therapy,  
Polish Academy of Arts and Sciences, Wrocław, Poland 
 
31.05.2004 Master's thesis defence 
(An evaluation of the antineoplastic properties of quinaldic acid in cell cultures) 
 
05.06 - 30.09.2004 Internship at the University of Idaho (Moscow, Idaho, USA) - Department of 
Microbiology, Molecular Biology and Biochemistry 
 
24.05 - 22.07.2005 Internship at the German Cancer Research Center, Heidelberg, Germany - Department of 
Biochemical Cell Physiology (A135/PROMET) 
 
2006-2009 Doctoral studies at the German Cancer Research Center, Heidelberg - Department of 
Biochemical Cell Physiology 
12.2009 Doctoral thesis defence - Technical University in Kaiserslautern, Germany 
(Crosstalk of cells in bone metastasis: Molecular and cellular analysis 
of the mutual effects of prostate cancer cells and osteoblasts) 
 
 
 
______________________________________________________Erklärung 
 149 
 
Erklärung 
 
Hiermit versichere ich ausdrücklich, dass ich die vorliegende Arbeit 
selbständig und ohne fremde Hilfe verfasst habe. Andere als die von mir 
angegebenen Quellen und Hilfsmittel wurden nicht benutzt und die aus den 
verwendeten Werken wörtlich oder inhaltlich entnommenen Stellen sind einzeln, 
nach Autor, Jahr der Erscheinens, Titel, Journal, Band und Seite kenntlich 
gemacht. Die Dissertation wurde keinem Fachvertreter einer anderen Hochschule 
zur Überprüfung vorgelegt und ich habe mich nicht anderweitig um Zulassung zur 
Promotion beworben. 
 
 
Heidelberg, im November 2009 
 
 
Agnieszka Halas 
 
 
 
Translation: 
I hereby declare that I have written this dissertation independently and with 
no assistance from other persons. No other sources than those listed by me were 
used. All content that has been derived from outside sources (either as literal 
quotation or as paraphrasis) has been clearly indicated by bibliographical entries, 
listing the author(s), year of publication, title, journal, volume and page(s). 
The dissertation has not been submitted for review to a representative of 
another university, nor have I applied for a doctoral promotion elsewhere. 
 
